

Gut

Journal of the British Society of Gastroenterology
which is a registered charity

Editor: Michael J G Farthing

Associate Editors: Michael J P Arthur, John Calam, Roger Chapman, Ian Forgacs (reviews, editorials)
Michael A Kamm, Thomas T MacDonald

Managing Editor: Andrea Horgan

Editorial Assistants: Michelle Dimler
Julia Neary

EDITORIAL BOARD

D Adams (UK)

D Alderson (UK)

C Arvanitakis (Greece)

G Bianchi Porro (Italy)

I Booth (UK)

M Buchler (Switzerland)

E Butruk (Poland)

J Dent (Australia)

G Dockray (UK)

J Galmiche (France)

J Heathcote (Canada)

S Hubscher (UK)

P Jansen (The Netherlands)

J Jass (New Zealand)

G Krejs (Austria)

S K Lam (Hong Kong)

N Lemoine (UK)

M M Levine (USA)

O Lundgren (Sweden)

P Malfertheiner (Germany)

J Neoptolemos (UK)

D Rachmilewitz (Israel)

D S Rampton (UK)

J Rask-Madsen (Denmark)

P Rutgeerts (Belgium)

G Sandle (UK)

C Scarpignato (Italy)

E Schrumpf (Norway)

P Shorvon (UK)

D Thompson (UK)

G Tytgat (The Netherlands)

B J R Whittle (UK)

T Wright (UK)

Shu-Dong Xiao (China)

R G Newcombe
(Statistical adviser)

Editor
British Medical Journal

familial breast and colorectal cancer, with a speculative and unsatisfactory review of the role of radiotherapy in this context, and closes with a chapter on the molecular therapy and prevention of hepatitis B infection, this being of more relevance to sporadic than to familial cancers.

In conclusion, this staccato collection of contributions on aspects of familial cancer is of some value, its main strengths being reports of small genotype/phenotype correlation studies, but there is little emphasis on the clinical surveillance and management of patients and their relatives, and the book is far from comprehensive, of necessity becoming out of date, and frustrating because of the brevity of each topic and the lack of continuity.

SHIRLEY V HODGSON

NOTE

Penang International Teaching Course in Gastroenterology

The Penang International Teaching Course in Gastroenterology will be held on 23–26 July 1997 in Penang, Malaysia. This is a joint meeting between the Penang Medical Practitioner's Society, Malaysian Society of Gastroenterology and Hepatology and the British Society of Gastroenterology. The Scientific programme comprises symposia on acid related disease, malignant oesophageal

obstruction, dyspepsia, biliary obstruction, and colorectal carcinoma. State of the art lectures will be given on broad range of topics including liver failure, minimally invasive surgery, inflammatory bowel disease, irritable bowel syndrome, viral hepatitis, endoscopic management of chronic pancreatitis, oesophageal cancer, and management of upper gastrointestinal disease. The course will also include a live endoscopy workshop and gastrointestinal assistant and nurses education program. An international faculty includes J Dent, N Soehendra, J Wong, ATR Axon, D Campbell, K Huibregtse, JM Rhodes, SG Lim, F Konishi, H Dowling, M McMahon, D Kelleher, J Neuberger, T Poynard, J Lambert, SK Lam, ST Kew, S Samad, and SB Chua.

VOLUME 40: AUTHOR INDEX – MAIN HEADINGS

KEY: (C) = Correspondence; (E) = Editorial; (LA) = Leading Article

- Aadland E, 313, 328
 Abergel A, 575
 Acalovschi M, 412
 Adamek HE, 678
 Adams S, 710
 Adler G, 531
 Aeed H, 133
 Akamatsu T, 782
 Akkermans LMA, 641, 704
 Al-Awadi FM, 307
 Albert E, 623
 Aida JO, 175
 Alderson D, 565 (LA)
 Alexander GA, 695 (C)
 Andrews JM, 234
 Andreyev HJN, 555
 Angermüller S, 720
 Anggiansah A, 182
 Armitage NC, 110
 Autherton JC, 701 (LA)
 Aufenanger J, 386
 Azuma T, 726
- Baczako K, 73
 Baigrie RJ, 381
 Baird AW, 634
 Bakewell M, 370
 Bardhan KD, 31
 Baron JH, 155 (C), 156 (C)
 Barthet M, 262
 Basile G, 188
 Bassendine MF, 277
 Bauditz J, 470
 Bauerfeind P, 25
 Baumann R, 475
 Beales ILP, 14, 155 (C)
 Beauchamp N, 798
 Belai A, 767
 Bell JL, 572 (LA)
 Bemelmans M, 560 (C)
 Benda N, 406
 Benjamin N, 211
 Benyedder Y, 167
 Benz C, 678
 Bernades P, 262
 Berstad AE, 196
 Bianchi MB, 102
 Bianchi PA, 188
 Bianchi Porro G, 560 (C)
 Biemond I, 267, 591
 Bijl H, 320
 Bilenker M, 333
 Bischoff SC, 745
 Bjarnason I, 228, 608
 Blackman G, 362
 Blendis L, 151
 Bloemena E, 113
 Blomberg B, 431 (C)
 Blum AL, 36
 Bobrzyński AJ, 463
 Bodger K, 739
 Bodmer WF, 654
 Boissier B, 356
 Bommelaer G, 575
 Bonucci A, 215
 Booker SV, 521
 Borch K, 536
 Börsch G, 36
 Boruchowicz A, 262
 Bostock K, 110
 Bouchier IAD, 139
 Boulant J, 575
 Boulos PB, 767
 Bovee-Oudenhoven IMJ, 497
 Bower M, 289 (C)
 Bown SG, 362
 Brada M, 801
 Bramble MG, 192
 Brandtzaeg P, 196
 Bray MJ, 393
 Breuer RI, 485
 Brignola C, 102
 Britton KE, 790
 Brotodiharjo A, 492
 Brough JL, 204
 Brown CM, 693
 Brown NJ, 31
 Brownlee A, 105
 Bruck R, 133
 Bruhat A, 167
 Bryan R, 9
 Büchler MW, 73, 386
- Buckley C, 805
 Buhr HJ, 526
 Bukhave K, 582
 Bülow S, 716
 Burke CM, 687
 Burnham WR, 9
 Burnstock G, 767
 Buskens E, 716
 Buurman WA, 560 (C)
 Buxton-Thomas M, 228
- Cadiot G, 167
 Calabresi C, 102
 Calam J, 14
 Camby I, 253
 Campbell A, 234
 Campieri M, 102
 Cao Q-X, 683
 Carballo F, 794
 Carr-Locke DL, 697 (LA)
 Catassi C, 215
 Cetin Y, 745
 Challacombe DN, 57
 Chan WC, 161 (LA)
 Chapman P, 105
 Chaumette M-T, 356
 Chmiela M, 20
 Christ ML, 485
 Chu M, 536
 Chua E, 435 (LA)
 Clausen MR, 400
 Clyne M, 731
 Coleman S, 683
 Collins JK, 512
 Collins JSA, 697 (LA)
 Colon C, 695 (C)
 Compston JE, 695 (C)
 Cook GC, 428
 Coppa GV, 215
 Coste T, 167
 Csakany I, 412
 Cuckow PM, 689
 Cunningham D, 555
 Czernichow B, 67
 Czkwianianc E, 20
- Daerr W, 761
 D'Amato M, 575
 Danguy A, 253
 Danielsson D, 431 (C)
 Dapoigny M, 575
 Davidson G, 370
 Dawodu JB, 431 (C)
 de Calan L, 262
 De Decker R, 253
 De Franchis R, 102
 de Ruiter P, 716
 Dejong CHC, 418
 Delcenserie R, 262
 Delchier J-C, 356
 Demeester TR, 804
 Dent J, 370, 449
 Desjeux JF, 333
 Deutz NEP, 418
 Diamond AG, 277
 Dickneite G, 531
 Dickson A, 302
 Dillon JF, 664
 Dominguez-Muñoz JE, 459
 Domschke W, 86
 Dorandeu A, 350
 Dotti M, 215
 Dowling D, 560 (C)
 Doyle JS, 687
 Droy-Lefaix MT, 333
 Drumm B, 731
 Drummond RS, 211
 Duckworth C, 253
 Duclos B, 475
 Duggan JM, 492
 Dumitrascu DL, 412
 Dumont S, 475
 Duncan CW, 211
 Duncan HD, 393
 Dunn BE, 25
- Ebert EC, 333
 Eigler A, 623
 Ekblom A, 328
 El-Nujumi A, 302
- El-Omar E, 302
 Elias E, 798
 Elliott TSJ, 454
 Emery PW, 393
 Endo M, 123
 Endres S, 623
 Engel G, 720
 England RE, 272
 English JSC, 289 (C)
 Ernst H, 463
 Esumi H, 660
 Evans DF, 614
 Evans JMM, 619
- Fabiani E, 215
 Falch JA, 313
 Faller G, 463
 Farbstein M, 754
 Farrant JM, 695 (C)
 Farrell RJ, 561 (C)
 Farthing MJG, 563 (E)
 Fasano A, 505
 Fausa O, 328
 Ferretti M, 102
 Filipowicz B, 204
 Fitzke G, 406
 Flemal KL, 485
 Floren I, 797 (suppl 1 abstract)
 Foitzik Th, 526
 Folwaczny C, 623
 Foo AY, 689
 Forgacs I, 228
 Forrest EH, 139, 664
 Foulkes R, 628
 Franken HCM, 61
 Fraser R, 370
 Fredlund H, 431 (C)
 Fricke H, 623
 Friedman GD, 297
 Friess H, 73
 Fujii T, 660
 Fukumoto M, 647
 Fukushima S, 660
 Fukushima Y, 344
- Gabryelewicz A, 86
 Gale L, 492
 Galluser M, 67
 Garden OJ, 128
 Gardiner KR, 560 (C)
 Garner R, 25
 Garred P, 544
 Gebel M, 745
 Gemmell CG, 431 (C)
 Geoghegan JG, 164 (LA)
 George EK, 61
 Gerbes AL, 145
 Giardiello FM, 521
 Gilat T, 754
 Gillen D, 302
 Gionchetti P, 102
 Giorgi PL, 215
 Gleeson FV, 695 (C)
 Glover JR, 362
 Gold LI, 73
 Goldberg PA, 790
 Golden M, 211
 Goldsworthy W, 370
 Gomolka M, 623
 González-Calero G, 49
 Görlach E, 720
 Gossé F, 67
 Gosselin M, 350
 Götz JM, 591
 Gouma DJ, 560 (C)
 Graudal N, 544
 Greve JW, 560 (C)
 Griffin SM, 671
 Griffioen G, 716
 Grönroos JM, 95
 Grool TA, 241
 Gruber SB, 521
- Haapamäki MM, 95
 Haber HP, 406
 Hacker UT, 623
 Haemling J, 470
 Hahn EG, 463
 Hahn SA, 120
 Hallak A, 754
- Halliday MI, 560 (C)
 Halpern Z, 133
 Halstensen TS, 196
 Hamilton MI, 105
 Hamilton SR, 521
 Hämling J, 761
 Hammel P, 356
 Hanauer SB, 485
 Hanby A, 654
 Hardcastle JD, 110
 Harig JM, 485
 Harris AW, 155 (C), 156 (C)
 Harrison DJ, 128
 Hart A, 554
 Hasebe T, 660
 Haslam R, 370
 Havranek EG, 92
 Hawkey CJ, 204, 797 (suppl 1 abstract)
 Hayashi S, 123
 Hayden GH, 128
 Hayes PC, 128, 139, 664
 Heading RC, 541
 Heathcote J, 440 (LA)
 Heatley RV, 739
 Heidt PJ, 497
 Heinisch A, 80
 Heinrichs C, 550
 Hellström PM, 376
 Hengst K, 86
 Heresbach D, 262
 Hershkoviz R, 133
 Heyman M, 333
 Hilditch TE, 302
 Hillingso J, 582
 Hirai M, 726
 Hirasing RA, 61
 Hobsley M, 155 (C)
 Höglason K, 544
 Holloway RH, 449
 Holst JJ, 597
 Holstege A, 80
 Holzhüter C, 481
 Homann C, 544
 Honda T, 123
 Hoque ATMS, 120
 Hotz HG, 526
 Houwen RHJ, 61
 Howaldt S, 761
 Hull MA, 204
 Hunt LM, 110
 Hussaini SH, 695 (C)
- Ilyas M, 654
 Imamura M, 647
 Imamura T, 647
 Imbesi V, 560 (C)
 Inoue H, 123
 Ireland A, 449, 804
 Irvine EJ, 775
 Irving MH, 218
 Ito S, 726
 Ito Y, 726
- Jackson N, 805
 Jacob S, 31
 Jacobs M, 608
 Jahnsen J, 313
 Jakobs R, 678
 Jalkan R, 664
 Jamal A, 689
 Jamieson GG, 381
 Janowitz HD, 289 (C)
 Järnerot G, 431 (C)
 Jarvis LM, 128
 Jebbink RJA, 641
 Jewell DP, 234, 572 (LA), 695 (C)
 Johnston BT, 587
 Jones DEJ, 277
 Jones PW, 289 (C)
 Jorgensen JR, 400
- Kalia N, 31
 Kallajoki M, 95
 Kamm MA, 9, 157 (C), 790
 Kando F, 123
 Kapp A, 745
 Karayiannis P, 294 (LA)
 Katsuyama T, 782
 Kedingger M, 475

- Keele AM, 393
 Keeling PWN, 561 (C)
 Kelleher D, 634
 Keller E, 623
 Kelly J, 512
 Kelman A, 302
 Kenet G, 133
 Kenney JS, 475
 Kern SE, 120
 Keshavarzian A, 485
 Khan I, 307
 Kiessling R, 153
 Kingsnorth A, 1 (LA)
 Kinzig M, 526
 Kinzler KW, 521
 Kiss R, 253
 Klein I, 754
 Klingler C, 463
 Knifton A, 204
 Kohli Y, 726
 Konturek JW, 86
 Konturek PCh, 463
 Konturek SJ, 86, 463
 Korc M, 73
 Korn A, 49
 Kouyoumdjian J-C, 356
 Krömer M, 678
 Kruis W, 761
 Krush AJ, 521
 Kulesza E, 86
 Kullman E, 536
 Kummer JA, 113
 Kuriyama M, 726
 Kusterer K, 720
- Labenz J, 36
 Laken SJ, 521
 Lamers CBHW, 267, 591
 Lanas A, 175
 Lanas AI, 42
 Lang A, 406
 Langenberg M, 406
 Langman MJS, 516
 Längström G, 797 (suppl 1 abstract)
 Lashner BA, 485
 Launois B, 350
 Le Bodic L, 262
 Le Guludec D, 167
 Lear JT, 289 (C)
 Leclercq-Rioux N, 350
 Lennard-Jones JE, 157 (C)
 Lenzing T, 49
 Leodolter A, 459
 Leon MP, 277
 Leonard C, 687
 Lerch MM, 531
 Leser HG, 80
 Leusing C, 36
 Levine MM, 505
 Lévy P, 262
 Liao FM, 505
 Lider O, 133
 Lim SH, 683
 Liras G, 794
 Lochs H, 470
 Lock G, 80
 Lockwood CM, 105
 Loeschke K, 623
 Lombard M, 435 (LA)
 Lorente S, 42
 Losowsky MS, 695 (C)
 Lubin F, 754
 Lubin R, 356
 Luce MC, 521
 Lührs H, 531
 Luman W, 541
 Lygren I, 328
 Lyrenas E, 449
- McColl KEL, 302
 McCutcheon AD, 561 (C)
 McDevitt DG, 619
 Macdonald CE, 157 (C)
 MacDonald TM, 619
 MacDonald TT, 559
 McDougall NI, 587
 McIntyre A, 223
 Mackintosh C, 228
 McKnight GM, 211
 McMahon AD, 619
 Macpherson A, 228, 608
 Madden M, 512
 Mahida YR, 161 (LA)
 Mahmoud AEA, 798
 Mahmud T, 608
 Mahraoui L, 333
 Maier M, 678
 Malferteiner P, 459
 Manns MP, 745
 Mansfield JC, 671
 Marshall JK, 775
 Marshall REK, 182
- Martin CJ, 710
 Martin DF, 156 (C), 272
 Martin ED, 350
 Martin WR, 678
 Mary JY, 284
 Matas Z, 133
 Mathieu S, 575
 Mathus-Vliegen L, 716
 Matsuhashi N, 344
 Matsuo K, 782
 Matthewson K, 671
 Mayberry J, 554
 Mayberry M, 554
 Mayer J, 745
 Mearin ML, 61
 Mee AS, 289 (C)
 Meenan J, 241
 Meier PN, 745
 Meisner S, 597
 Mertz-Nielsen A, 582
 Messmann H, 80
 Miglioli M, 102
 Mignon M, 167
 Miki K, 370
 Millat B, 262
 Milton JD, 234
 Misiewicz JJ, 155 (C), 156 (C)
 Miyaji H, 726
 Mobley HLT, 25
 Mokhashi MS, 431 (C)
 Mollnes TE, 544
 Molloy RM, 247
 Moniz C, 228
 Mora A, 794
 Moreau J, 262
 Morgan J, 512
 Mörk H, 481
 Morris G, 790
 Mortensen N, 695 (C)
 Mortensen PB, 400
 Moum B, 328
 Mowinckel P, 313
 Mukai K, 660
 Mulder WMC, 113
 Müller A, 481
 Müller C, 425
 Muller CD, 475
 Muro K, 521
 Murphy A, 634
 Murray FE, 619
 Murray L, 302
 Myers JC, 381
 Myrholm T, 716
- Nagengast F, 716
 Nakajima A, 344
 Nakshabendi IM, 431 (C)
 Nandurkar S, 710
 Naya MJ, 175
 Nevalainen TJ, 95, 386
 Newcombe RG, 563 (E)
 Newton M, 9
 Ng THK, 710
 Nicholls RJ, 790
 Nightingale JMD, 157 (C)
 Noriega FR, 505
 Nsi-Emvo E, 67
 Nurmi H, 95
- Oda Y, 660
 Offerhaus GJA, 521, 591
 Ohshio G, 647
 Ohtaki Y, 726
 Oka T, 344
 Okada N, 647
 O'Keane C, 687
 Olde Damink SWM, 418
 Oldenburg A, 720
 Omari TI, 370
 Orentreich N, 297
 Ortego J, 175
 Ortner M, 470
 Oshowo O, 155 (C)
 O'Sullivan GCO, 512
 Ota H, 782
 O'Toole P, 435 (LA)
 Otori K, 660
 Owen WA, 182
 Owen WJ, 182
- Palmer JM, 277
 Palmer KR, 541
 Pals ST, 241
 Pappas TN, 164 (LA)
 Parente F, 560 (C)
 Pariente EA, 262
 Parks RW, 560 (C)
 Parsonnet J, 297
 Pasteels J-L, 253
 Paumgartner G, 145
 Peitz U, 36
 Pereboom D, 175
- Pérez-Mateo M, 794
 Perkins AC, 223
 Petermann D, 425
 Petersen GM, 521
 Piantadosi S, 521
 Piedbois P, 356
 Pigott R, 234
 Playford RJ, 157 (C), 286
 Plique O, 333
 Pohl T, 720
 Poindron P, 475
 Poulson R, 516
 Pounder RE, 105
 Poxon V, 454
 Price AB, 608
 Pryde A, 541
- Radema S, 320
 Rademaker AW, 485
 Raedler A, 470, 761
 Rafi S, 608
 Ramée M-P, 350
 Raoul J-L, 350
 Rask-Madsen J, 582
 Rättsch IM, 215
 Raul F, 67
 Rautelin H, 431 (C)
 Redhead DN, 664
 Reed MWR, 31
 Rees WDW, 693
 Rehfeld JF, 536
 Reif S, 754
 Reilly TG, 454
 Reimund JM, 475
 Rhodes JM, 431 (C), 807
 Richards DM, 218
 Riemann JF, 678
 Riemer H, 425
 Riepl RL, 49
 Riese E, 73
 Riethmüller J, 406
 Rigaud D, 167
 Rizzello F, 102
 Roberts AI, 333
 Robinson M, 485
 Robinson MHE, 110
 Robson T, 767
 Rooney PS, 110
 Rose F, 161 (LA)
 Rotman N, 356
 Rowlands BJ, 560 (C)
 Rudnicka W, 20
 Russell RI, 431 (C)
- Saeiki I, 123
 Sahnoud T, 284
 Saidel L, 133
 Sainz R, 42
 Saito N, 123
 Salmon I, 253
 Sampson SA, 801
 Samsom M, 641
 Sánchez-Paya J, 794
 Sanders DSA, 454, 695 (C)
 Sargeant IR, 362
 Sato F, 726
 Satsangi J, 572 (LA)
 Sauar J, 328
 Sauerbruch T, 459
 Sauvagnet A, 262
 Scheiman JM, 720
 Scheper RJ, 113
 Scheurlein M, 481
 Schmitter N, 386
 Schnider P, 425
 Schölmerich J, 80
 Schrag H-J, 386
 Schreiber S, 470, 761
 Schulz T, 328
 Schutte M, 120
 Scott D, 608
 Scott-Coombes DM, 92
 Seeger W, 550
 Seibold F, 481
 Sellin JH, 485
 Serrano MT, 42
 Shanahan F, 512, 557
 Shaw-Smith CJ, 5 (LA)
 Sheppard MC, 516
 Sherwood R, 608
 Shirin H, 133
 Sighorsson G, 608
 Silcock JG, 192
 Silk DBA, 393
 Simmonds P, 128, 291 (LA)
 Singer MV, 49
 Singh S, 516
 Sinico RA, 102
 Siriser F, 350
 Slors JFM, 716
 Smith LM, 211
 Smithson JE, 234
 Smout AJPM, 641
- Soergel KH, 485
 Soeters PB, 418
 Somasundaram S, 608
 Sonnenberg A, 247
 Sörgel F, 526
 Soussi T, 356
 Spaans J, 241
 Spiller RC, 223
 Stadil F, 597
 Stain C, 425
 Stam R, 704
 Stave R, 196
 Stephens P, 683
 Stephens S, 628
 Stern M, 406
 Stray N, 328
 Stringer MD, 689
 Stronkhorst A, 320
 Stukart MJ, 113
 Sugiyama A, 782
 Sugiyama K, 660
 Suwa H, 647
 Svensson TH, 376
 Szalay A, 550
- Taal BG, 716
 Tajiri H, 660
 Takeshita K, 123
 Talbot IC, 654
 Talley NJ, 710
 Tang C, 267
 Tani M, 123
 Tanza S, 481
 Taylor CT, 634
 Taylor-Robinson SD, 805
 Teichberg S, 602
 Temmesfeld-Wollbrueck B, 550
 ten Berge IJM, 320
 Termond DSML, 497
 Terrault NA, 568 (LA)
 Teysse S, 49
 Tham TCK, 587, 697 (LA)
 Thio JL, 591
 Thollander M, 376
 Thomas DW, 683
 Thomas HC, 294 (LA)
 Thomas J, 731
 Thompson JN, 92
 Thomsen AC, 544
 Thorpe S, 362
 Tillenburg B, 36
 Tillner A, 720
 Tobias JS, 362
 Toghiani PJ, 431 (C)
 Tomlinson IPM, 654
 Traboulsi EI, 521
 Traill Z, 695 (C)
 Tutt ANJ, 801
 Tytgat GNJ, 241, 320
- Uhl W, 73, 386
 Usadel KH, 720
- v Schönfeld J, 614
 Vallance P, 288
 Vallance R, 156 (C)
 Vallot T, 167
 Van der Meer R, 497
 van Deventer SJH, 241, 320, 443
 van Isselt H, 641
 Vanaganas A, 485
 vanBerge-Henegouwen GP, 641
 Vandembroucke JP, 61
 Varming K, 544
 Vasen HFA, 716
 Vatn MH, 328
 Vautier G, 204
 Vecchi M, 102
 Veenendaal RA, 591
 Velio P, 188
 Venturi A, 102
 Verspaget HW, 591
 Vidican DE, 485
 Viedma JA, 794
 Vincent RM, 223
 Vogelman H, 297
 Vogelshang H, 425
 Vogelstein B, 521
 Vogt W, 80
 Vollmar AM, 145
 von Fürstenberg A, 80
 Vuagnat A, 167
- Wadehra V, 671
 Wadstrom T, 20
 Wagner M, 73
 Wagstaff J, 113
 Wakefield AJ, 105
 Walan A, 797 (suppl 1 abstract)
 Walmsley RS, 105
 Walt RP, 454

Walters JRF, 5 (LA)
Wang W, 505
Wang Z, 647
Wapnir RA, 602
Ward P, 628
Warren B, 695 (C)
Warren BF, 628
Watkins PE, 628
Watson DI, 381
Watson RGP, 587
Weaver L, 731
Weber P, 481
Wedemeyer J, 745
Wedi B, 745

Weidenbach H, 531
Weinberg D, 485
Welbourn CRB, 565 (LA)
Wettergren A, 597
Whawell SA, 92
Wheatley AM, 386
Wheeler EE, 57
Wiegant VM, 704
Wilde JT, 798
Williams CB, 430
Williams GT, 691
Wimalaratna H, 492
Wingate DL, 614
Wingertzahn MA, 602

Wojdemann M, 597
Wong F, 151
Woodward JM, 695 (C)
Wrba F, 425
Wrigglesworth JM, 608
Wright NA, 516
Wright TL, 568 (LA)
Wyatt JI, 739

Yamaguchi H, 531
Yamazaki Y, 726
Yazaki Y, 344
Yeaman SJ, 277

Yeaton P, 253
Yeomans ND, 797 (suppl 1
abstract)
Yong S-L, 320
Yoshida S, 660

Zeck-Kapp G, 745
Zehnter E, 761
Zeiler K, 425
Zhang QB, 431 (C)
Zhao L, 73
Zhao MH, 105
Zirngibl H, 80

VOLUME 40: SUBJECT INDEX – MAIN HEADINGS

- Absorption**, Regional expression of intestinal genes for nutrient absorption: *leading article*, 5
- Acetic acid**, Colonic muscle enhances the production of interleukin-1 β messenger RNA in experimental colitis, 307
- Acid reflux**
Relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease, 182
Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, 175
- Acid secretion**
Effect of N α -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for *Helicobacter pylori* associated gastritis and gastric physiology, 14
Multivariate analysis of pathophysiological factors in reflux oesophagitis, 167
- Activated complement**, Epithelium related deposition of activated complement in *Helicobacter pylori* associated gastritis, 196
- Adenoma**
High frequency of K-*ras* mutations in human colorectal hyperplastic polyps, 660: *commentary*, 691
Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all?, 691
- Adenosine**, Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis, 139
- Adherence**, In vitro evaluation of the role of antibodies against *Helicobacter pylori* in inhibiting adherence of the organism to gastric cells, 731
- Agent orange**, "Golf ball liver": agent orange hepatitis, 687
- Alcoholic beverages**, Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans, 49
- Aminosalicic acid**, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicilate, 761
- Ammonia**, Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, 726: *commentary*, 805
- Ampulla of Vater carcinoma**, Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases, 350
- Amylase**, Familial hyperamylasaemia, 689
- Antibiotic therapy**, Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis, 526
- Antibody**, Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha, 628
- Antigliadin antibodies**, Down's syndrome is strongly associated with coeliac disease, 492
- Antimicrobial peptides**, Antimicrobial peptides in the gastrointestinal tract: *leading article*, 161
- Antineutrophil antibodies**, Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies, 550
- Antineutrophil cytoplasm autoantibodies**, Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease, 105
- Antineutrophil cytoplasmic antibodies**, Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils, 102
- Antioxidants**, Treatment of *Helicobacter pylori* infection favourably affects gastric mucosal superoxide dismutases, 591
- Antithrombin III**, Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis, 531
- APC gene mutation**, APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis, 521
- Arg-Gly-Asp acid**, Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice, 133
- Atrial natriuretic peptide**, Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver, 145: *commentary*, 151
- Autoimmune cholangitis**, Autoimmune cholangitis: *leading article*, 440
- Autoimmunity**, T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function, 277
- Bactericidal/permeability-increasing protein**, Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease, 105
- Barrett's oesophagus**
Evaluation of *Helicobacter pylori* in reflux oesophagitis and Barrett's oesophagus, 9
Relation between gastric cancer and previous peptic ulcer disease, 247
Short segment Barrett's oesophagus: prevalence, diagnosis and associations, 710: *commentary*, 804
- Basic fibroblast growth factor**
Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration, 204: *commentary*, 286
Recombinant peptides for gastrointestinal ulceration: still early days, 286
- Bicarbonate secretion**
Human oesophageal bicarbonate secretion: a phenomenon waiting for a role, 693
Reappraisal of bicarbonate secretion by the human oesophagus, 582: *commentary*, 693
- Bile duct stones**, Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study, 678
- Bile reflux**, The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease, 182
- Biliary strictures**, A prospective evaluation of cytology from biliary strictures, 671
- Biliary tree**, Fibrinolysis and the biliary tree, 92
- Blood gavages**, Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats, 418
- Bone density, Reduced bone density in patients with inflammatory bowel disease**, 228
- Bone disease**, Bone disease after liver transplantation should not be underestimated: *correspondence*, 695
- Bone marrow micrometastases**, Micrometastases: marker of metastatic potential or evidence of residual disease? 512: *commentary*, 555
- Bone mineral density**, Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study, 313
- Book reviews**
Berci G, Cuschieri A. Bile ducts and bile duct stones, 696
Boyer Z, *editor*. Hepatology: a textbook of liver disease, volumes 1 and 2, 3rd edn., 562
Champion MC, Orr WC, *editors*. Evolving concepts in gastrointestinal motility, 809
Derveris CG, *editor*. Advances in pancreatic disease, molecular biology, diagnosis and treatment, 157
Farthing MJG, *editor*. Clinical guidelines in gastroenterology, 432
Hancock L. Physician's guide to the Internet, 433
Kagnoff MF, Kiyono H, *editors*. Essentials of mucosal immunology, 432
Kumar D, Christensen J, *editors*. A diagnostic guide to clinical gastroenterology, 290
MacFayden BV, Ponsky JL, *editors*. Operative laparoscopy and thoracoscopy, 562
Manns MP, *guest editor*. Baillière's clinical gastroenterology. Liver and gastrointestinal immunology, 432
Muller HJ, Scott RJ, Weber W, *editors*. Hereditary cancer, 809
Olden KW, *editor*. Handbook of functional gastrointestinal disorders. Medical Psychiatry series/14, 431
Pavone P, Passariello R, *editors*. MR cholangiopancreatography techniques. Results and clinical indications, 696
Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE. Textbook of gastroenterology, volumes 1 and 2, 561
- Bowel wall thickening**, Colonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls, 406
- Bran**, Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors, 223
- Branched chain amino acids**, Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats, 418
- Breath test**
A citric acid solution is an optimal test drink in the ¹³C-urea breath test for the diagnosis of *Helicobacter pylori* infection, 459
The *Helicobacter pylori* breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients, 302

- C1 esterase inhibitor**, Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis, 531
- C3 deficiency**, Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality, 544
- C reactive protein**, Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis, 80
- ¹³C-urea breath test**
A citric acid solution is an optimal test drink in the ¹³C-urea breath test for the diagnosis of *Helicobacter pylori* infection, 459
Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests, 454
- ¹⁴C urea breath test**, The *Helicobacter pylori* breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients, 302
- CagA**, Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection, 297
- Calcium**, Increasing the intestinal resistance of rats to the invasive pathogen *Salmonella enteritidis*: additive effects of dietary lactulose and calcium, 497
- Cancer**, Micrometastases: marker of metastatic potential or evidence of residual disease? 512: *commentary*, 555
- Capillary blood flow**, Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis, 526
- Carcinogenesis**, Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster, 536
- Catalase**, Synthesis and activity of *Helicobacter pylori* urease and catalase at low pH, 25
- CD4 antibody treatment**, CD4 antibody treatment in patients with active Crohn's disease: a phase I dose finding study, 320
- Cecropins**, Antimicrobial peptides in the gastrointestinal tract: *leading article*, 161
- Cefotaxime**, Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis, 526
- Cellular immunity**, Activation of cellular immune response in acute pancreatitis, 794
- Central peptidergic control**, Central peptidergic control of gastric acid secretion: *leading article*, 164
- Cerebral lymphoma**, Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder, 801
- Cerulein pancreatitis**, Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats, 386
- Cholangiocarcinoma**, A prospective evaluation of cytology from biliary strictures, 671
- Cholangitis**, Autoimmune cholangitis: *leading article*, 440
- Cholecystokinin**, Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans, 575
- Cholecystokinin-B-receptor antagonist**, Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster, 536
- Cimetidine**
Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration, 204: *commentary*, 286
Recombinant peptides for gastrointestinal ulceration: still early days, 286
- Cirrhosis**
Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality, 544
Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis, 139
Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, 726: *commentary*, 805
Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis – a simultaneous sonographic study, 412
Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? 664
- Citric acid solution**, A citric acid solution is an optimal test drink in the ¹³C-urea breath test for the diagnosis of *Helicobacter pylori* infection, 459
- Clinical trials**, Reporting of clinical trials in Gut: the CONSORT statement: *editorial*, 563
- CME**, CME – certification by the European Board of Gastroenterology: *correspondence*, 431
- Coagulation system**, Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis, 531
- Coccidian protozoan**, 'Tropical sprue': some early investigators favoured an infective cause, but was a coccidian protozoan involved? 428
- Coeliac disease**
Adult coeliac disease, dermatitis herpetiformis and smoking: *correspondence*, 289
Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells, 634
Down's syndrome is strongly associated with coeliac disease, 492
Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder, 801
Is the sugar intestinal permeability test a reliable investigation for coeliac disease screening?, 215
Twenty years of childhood coeliac disease in The Netherlands: a rapidly increasing incidence?, 61
- Colitis**
Colonic muscle enhances the production of interleukin-1 β messenger RNA in experimental colitis, 307
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease, 619
- Colitis-associated neoplasia**, *DPC4* gene mutation in colitis associated neoplasia, 120
- Collagen**, Increased expression of transforming growth factor β s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair, 73
- Colon**
High frequency of K-ras mutations in human colorectal hyperplastic polyps, 660: *commentary*, 691
Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all? 691
- Colon adenoma**, Histochemistry of the surface mucous gel layer of the human colon, 782: *commentary*, 807
- Colon cancer (carcinoma)**
Histochemistry of the surface mucous gel layer of the human colon, 782: *commentary*, 807
Signals from lymphocytes in colon cancer, 153
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma, 113: *commentary*, 153
- Colonic mucin**, Altered expression of mucins throughout the colon in ulcerative colitis, 234
- Colonic muscle**, Colonic muscle enhances the production of interleukin-1 β messenger RNA in experimental colitis, 307
- Colonic polyps**, Effects of sulindac on sporadic colorectal adenomatous polyps, 344: *commentary*, 430
- Colonic stricture**, Colonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls, 406
- Colonocyte oxidation**, Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes, 400
- Colonoscopic allergen provocation**, Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy, 745
- Colorectal cancer**
Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers, 654
Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer, 110
Detection and monitoring of serum p53 antibodies in patients with colorectal cancer, 356
DPC4 gene mutation in colitis associated neoplasia, 120
Effects of sulindac on sporadic colorectal adenomatous polyps, 344: *commentary*, 430
In vitro influence of *Phaseolus vulgaris*, *Griffonia simplicifolia*, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth, 253
- Colorectal carcinogenesis**
High frequency of K-ras mutations in human colorectal hyperplastic polyps, 660: *commentary*, 691
Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all? 691
- Complement**, Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality, 544
- Concanavalin A**, Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice, 133
- CONSORT statement**, Reporting of clinical trials in Gut: the CONSORT statement: *editorial*, 563
- Continuing medical education**, CME – certification by the European Board of Gastroenterology: *correspondence*, 431
- Corticosteroids**, Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis, 775

- Cottontop tamarin**, Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha, 628
- Crohn's colitis**, Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease, 619
- Crohn's disease**
- Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease, 105
 - Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study, 313
 - CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study, 320
 - DPC4* gene mutation in colitis associated neoplasia, 120
 - Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies, 550
 - Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway, 328
 - Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? 284
 - Neurochemical coding in the small intestine of patients with Crohn's disease, 767
 - Pancreatic autoantibodies in Crohn's disease: a family study, 481: *commentary*, 557
 - Pre-illness dietary factors in inflammatory bowel disease, 754
 - Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease, 470: *commentary*, 559
 - Tumour necrosis factor and Crohn's disease: review, 443: *commentary*, 559
- Cyclic nucleotide phosphodiesterase inhibitors**, In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease, 475: *commentary*, 559
- Cystic fibrosis**, Colonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls, 406
- Cytokines**
- Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice, 133
 - Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells, 634
 - Cytokine effects on pepsinogen secretion from human peptic cells, 42
 - In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease, 475: *commentary*, 559
 - Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis, 623
 - Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis, 80
 - Role of cytokines and their inhibitors in acute pancreatitis: *leading article*, 1
 - T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function, 277
- Cytology**, A prospective evaluation of cytology from biliary strictures, 671
- Cytotoxin**, Cytotoxin production and neutrophil activation by strains of *Helicobacter pylori* isolated from patients with peptic ulceration and chronic gastritis: *correspondence*, 431
- Decision analysis**, Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis, 716
- Defensins**, Antimicrobial peptides in the gastrointestinal tract: *leading article*, 161
- Dermatitis herpetiformis**, Adult coeliac disease, dermatitis herpetiformis and smoking: *correspondence*, 289
- Diabetes mellitus**, Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus, 641
- Diagnosis**
- A citric acid solution is an optimal test drink in the ¹³C-urea breath test for the diagnosis of *Helicobacter pylori* infection, 459
 - Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests, 454
- Diagnosis assurance**, Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway, 328
- Diarrhoea**, Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo, 505
- 2,4-Dichlorophenoxyacetic acid**, "Golf ball liver": agent orange hepatitis, 687
- Diet**, Pre-illness dietary factors in inflammatory bowel disease, 754
- Dietary nitrate**
- Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans, 211: *commentary*, 288
 - Dietary nitrate: poison or panacea? 288
- Diosmectite**, Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor- α , 339
- Distal ulcerative colitis**, Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial, 485
- Down's syndrome**, Down's syndrome is strongly associated with coeliac disease, 492
- DPC4 gene mutation**, *DPC4* gene mutation in colitis associated neoplasia, 120
- Duodenal cancer**, Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis, 716
- Duodenal ulcer**
- Helicobacter pylori* and duodenal ulcers, *correspondence*, 155
 - Helicobacter pylori* and ulcer healing: *correspondence*, 560
 - Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of *Helicobacter pylori*, 463
 - Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users – the OMNIUM Study, 797 (suppl 1 abstract)
 - Relation between gastric cancer and previous peptic ulcer disease, 247
- Dyspepsia**, The *Helicobacter pylori* breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients, 302
- Dysphagia**, Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study, 362
- E-cadherin expression**, Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers, 654
- Electrolyte homeostasis**, Peptide YY and electrolyte homeostasis: *correspondence*, 157
- ELISA serology**, Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests, 454
- Endocrine tumour**, Expression of peptide receptors in human endocrine tumours of the pancreas, 267
- Endoscopic management**, Endoscopic management of Mirizzi's syndrome, 272
- Endoscopic papillectomy**, Endoscopic papillectomy: *correspondence*, 561
- Endoscopic retrograde cholangiopancreatography**
- Endoscopic management of Mirizzi's syndrome, 272
 - Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study, 678
 - Risk factors for pancreatitis: *correspondence*, 289
- Endoscopic sphincterotomy**, Endoscopic sphincterotomy in the young patient: is there cause for concern? *leading article*, 697
- Endoscopic therapy**
- Endoscopic management of Mirizzi's syndrome, 272
 - Endoscopic treatment of early oesophageal or gastric cancer, 123
- Endoscopy**
- Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests, 454
 - Video education and evidence in endoscopy, 554
- Endothelial adhesion**, Studies on gastric mucosal microcirculation.
1. The nature of regional variations induced by ethanol injury, 31
- Enema**, Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis, 775
- Enteral**, Enteral supplementation with ornithine ketoglutarate improves the early adaptive response to resection, 67
- Enteric nerves**, Neurochemical coding in the small intestine of patients with Crohn's disease, 767
- Enteropathy associated T cell lymphoma**, Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder, 801
- Enzyme linked immunosorbent assay**, Clinical significance of serum p53 antigen in patients with pancreatic carcinomas, 647
- Epidermal growth factor**
- Cytokine effects on pepsinogen secretion from human peptic cells, 42
 - Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of *Helicobacter pylori*, 463

- Epithelial cells**, Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells, **634**
- Epithelial tumours**, Micrometastases: marker of metastatic potential or evidence of residual disease? **512: commentary, 555**
- Erosions**, Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users – the OMNIUM Study, **797** (suppl 1 abstract)
- Erratum**, **797**
- Ethanol injury**, Studies on gastric mucosal microcirculation. 1. The nature of regional variations induced by ethanol injury, **31**
- European Board of Gastroenterology**, CME – certification by the European Board of Gastroenterology: *correspondence*, **431**
- Extracorporeal shock wave lithotripsy**, Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study, **678**
- Extraintestinal lesions**, APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis, **521**
- Factor V Leiden**, Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis, **798**
- Faecal occult blood tests**, Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer, **110**
- Familial adenomatous polyposis**
APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis, **521**
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis, **716**
Effects of sulindac on sporadic colorectal adenomatous polyps, **344: commentary, 430**
- Family study**, Pancreatic autoantibodies in Crohn's disease: a family study, **481: commentary, 557**
- Fat**, Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux, **449**
- Fatty acid oxidation**, Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes, **400**
- Feeding**, Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients, **262**
- Fetuin**, Role of *Helicobacter pylori* surface structures in bacterial interaction with macrophages, **20**
- Fibrinolysis**, Fibrinolysis and the biliary tree, **92**
- Fibrosing colonopathy**, Colonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls, **406**
- Food allergy**, Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy, **745**
- Free radical**, Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, **175**
- Fundoplication**, Outcome of laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis, **381**
- Gall bladder emptying**, Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis - a simultaneous sonographic study, **412**
- Gall bladder stones**, Fibrinolysis and the biliary tree, **92**
- Gardner syndrome**, APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis, **521**
- Gastric acid output**, Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans, **49**
- Gastric acid secretion**
Central peptidergic control of gastric acid secretion: *leading article*, **164**
Gastric acid secretion: *correspondence*, **155**
Inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation, **597**
- Gastric cancer**
Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer, **516**
Endoscopic treatment of early oesophageal or gastric cancer, **123**
Relation between gastric cancer and previous peptic ulcer disease, **247**
Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection, **297**
- Gastric cells**, In vitro evaluation of the role of antibodies against *Helicobacter pylori* in inhibiting adherence of the organism to gastric cells, **731**
- Gastric emptying**
Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors, **223**
Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis – a simultaneous sonographic study, **412**
Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus, **641**
- Gastric microcirculation**, Studies on gastric mucosal microcirculation. 1. The nature of regional variations induced by ethanol injury, **31**
- Gastric mucosa**, Treatment of *Helicobacter pylori* infection favourably affects gastric mucosal superoxide dismutases, **591**
- Gastric ulcer**
Gastric ulcers: *correspondence*, **289**
Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration, **204: commentary, 286**
Helicobacter pylori and ulcer healing: *correspondence*, **560**
Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users – the OMNIUM Study, **797** (suppl 1 abstract)
Recombinant peptides for gastrointestinal ulceration: still early days, **286**
Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide, **720**
Relation between gastric cancer and previous peptic ulcer disease, **247**
- Gastrin**
Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans, **49**
Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster, **536**
Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of *Helicobacter pylori*, **463**
- Gastrin releasing peptide**
Gastric acid secretion: *correspondence*, **155**
Helicobacter pylori and duodenal ulcers, *correspondence*, **155**
- Gastritis**
Epithelium related deposition of activated complement in *Helicobacter pylori* associated gastritis, **196**
Treatment of *Helicobacter pylori* infection favourably affects gastric mucosal superoxide dismutases, **591**
- Gastro-oesophageal reflux**
Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans, **575**
Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the “sensitive oesophagus”, **587**
Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux, **449**
Evaluation of *Helicobacter pylori* in reflux oesophagitis and Barrett's oesophagus, **9**
Laparoscopic surgery for gastro-oesophageal reflux disease: *leading article*, **565**
Multivariate analysis of pathophysiological factors in reflux oesophagitis, **167**
Relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease, **182**
Short segment Barrett's oesophagus: prevalence, diagnosis and associations, **710: commentary, 804**
- Gastroenterologists**, Ultrasound for gastroenterologists: *correspondence*, **156**
- Gastrointestinal haemorrhage**, Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats, **418**
- Gene expression**
Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver, **145: commentary, 151**
Natriuretic peptides: are these new links in the hepatorenal connections? **151**
Regional expression of intestinal genes for nutrient absorption: *leading article*, **5**
- Genetics**
Genetics of inflammatory bowel disease: *leading article*, **572**
Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis, **623**
- Glucagon-like peptide-1 (7-36 amide)**, The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation, **597**
- Glyceril trinitrate**, Topical glyceril trinitrate relaxes the sphincter of Oddi, **541**
- Golf ball liver**, “Golf ball liver”: agent orange hepatitis, **687**
- Graft-versus-host disease**, Autoimmune cholangitis: *leading article*, **440**
- Granulomatous gastritis**, Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies, **550**

Granzyme B

Signals from lymphocytes in colon cancer, 153

T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma, 113: *commentary*, 153

Growth hormone, The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vivo, 57

Gut homing, Altered expression of $\alpha 4\beta 7$, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation, 241

Gut hormone receptor, Expression of peptide receptors in human endocrine tumours of the pancreas, 267

H2/H3 histamine receptors, Effect of N α -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for *Helicobacter pylori* associated gastritis and gastric physiology, 14

HCT-15, In vitro influence of *Phaseolus vulgaris*, *Griffonia simplicifolia*, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth, 253

HCV genotypes, Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population, 128

Helicobacter pylori

A citric acid solution is an optimal test drink in the ^{13}C -urea breath test for the diagnosis of *H. pylori* infection, 459

Clinical relevance of strain types of *H. pylori*: *leading article*, 701

Comparison of serum, salivary, and rapid whole blood diagnostic tests for *H. pylori* and their validation against endoscopy based tests, 454

Cytotoxin production and neutrophil activation by strains of *H. pylori* isolated from patients with peptic ulceration and chronic gastritis: *correspondence*, 431

Effect of N α -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for *H. pylori* associated gastritis and gastric physiology, 14

Effects of *H. pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, 726: *commentary*, 805

Epithelium related deposition of activated complement in *H. pylori* associated gastritis, 196

Evaluation of *H. pylori* in reflux oesophagitis and Barrett's oesophagus, 9

Gastric acid secretion: *correspondence*, 155

Gastric mucosal secretion of interleukin-10: relations to histopathology, *H. pylori* status, and tumour necrosis factor- α secretion, 739

H. pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients, 302

H. pylori and duodenal ulcers, *correspondence*, 155

H. pylori and ulcer healing: *correspondence*, 560

In vitro evaluation of the role of antibodies against *H. pylori* in inhibiting adherence of the organism to gastric cells, 731

Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of *H. pylori*, 463

Relation between gastric cancer and previous peptic ulcer disease, 247

Risk for gastric cancer in people with CagA positive or CagA negative *H. pylori* infection, 297

Role of *H. pylori* surface structures in bacterial interaction with macrophages, 20

Synthesis and activity of *H. pylori* urease and catalase at low pH, 25

Treatment of *H. pylori* infection favourably affects gastric mucosal superoxide dismutases, 591

Heparin, Role of *Helicobacter pylori* surface structures in bacterial interaction with macrophages, 20

Hepatic encephalopathy, Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, 726: *commentary*, 805

Hepatic vein, Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis, 798

Hepatitis

Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice, 133

"Golf ball liver": agent orange hepatitis, 687

Hepatitis B virus

Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population, 128

Hepatitis B virus infection and liver transplantation: *leading article*, 568

Hepatitis C virus

Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population, 128

Clinical relevance of hepatitis C virus genotypes: *leading article*, 291

Hepatitis G virus, Hepatitis G virus: identification, prevalence and unanswered questions: *leading article*, 294

Hepatocellular carcinoma, Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population, 128

Hepatorenal reflex, Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? 664

Hip bone density, Reduced bone density in patients with inflammatory bowel disease, 228

Histamine receptors, Effect of N α -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for *Helicobacter pylori* associated gastritis and gastric physiology, 14

Histochemistry, Histochemistry of the surface mucous gel layer of the human colon, 782: *commentary*, 807

Home parenteral nutrition, Assessing the quality of life of patients with intestinal failure on home parenteral nutrition, 218

HT29-19A cell line, Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor- α , 339

Human milk, In vitro evaluation of the role of antibodies against *Helicobacter pylori* in inhibiting adherence of the organism to gastric cells, 731

5-Hydroxytryptamine, Neurochemical coding in the small intestine of patients with Crohn's disease, 767

Hyperammonaemia, Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, 726: *commentary*, 805

Hyperamylasaemia, Familial hyperamylasaemia, 689

Hypergastrinaemia, Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster, 536

Hyperglycaemia, Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus, 641

Hyperplastic polyps

High frequency of K-ras mutations in human colorectal hyperplastic polyps, 660: *commentary*, 691

Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all? 691

Ileal brake, The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation, 597

Ileoanal pouch, Contribution of gastrointestinal transit and pouch characteristics in determining pouch function, 790

Imipenem, Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis, 526

Immunofluorescence, Epithelium related deposition of activated complement in *Helicobacter pylori* associated gastritis, 196

Immunohistochemistry, Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases, 350

In situ hybridisation, Gene expression of group II phospholipase A2 in intestine in ulcerative colitis, 95

Indomethacin

Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration, 204: *commentary*, 286

Recombinant peptides for gastrointestinal ulceration: still early days, 286

Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide, 720

Infection, Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality, 544

Inflammation, Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, 175

Inflammatory bowel disease

Altered expression of $\alpha 4\beta 7$, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation, 241

Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study, 313

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study, 320

Colonic muscle enhances the production of interleukin-1 β messenger RNA in experimental colitis, 307

Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy, 745

Gene expression of group II phospholipase A2 in intestine in ulcerative colitis, 95

Genetics of inflammatory bowel disease: *leading article*, 572

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease, 475: *commentary*, 559

- Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis, **623**
 Pre-illness dietary factors in inflammatory bowel disease, **754**
 Reduced bone density in patients with inflammatory bowel disease, **228**
 Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate, **761**
- Insulin**, Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans, **86**
- Insulin-like growth factor-I**, The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vivo, **57**
- Integrin**, Altered expression of $\alpha 4\beta 7$, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation, **241**
- Interleukin 1**, Cytokine effects on pepsinogen secretion from human peptic cells, **42**
- Interleukin-1 receptor antagonist**, Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis, **623**
- Interleukin-1 β** , Colonic muscle enhances the production of interleukin-1 β messenger RNA in experimental colitis, **307**
- Interleukin-6**, Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis, **80**
- Interleukin-8 receptor**, Intestinal intraepithelial lymphocytes have a promiscuous interleukin-8 receptor, **333**
- Interleukin-10**, Gastric mucosal secretion of interleukin-10: relations to histopathology, *Helicobacter pylori* status, and tumour necrosis factor- secretion, **739**
- Intestinal adaptation**, Enteral supplementation with ornithine α ketoglutarate improves the early adaptive response to resection, **67**
- Intestinal failure**, Assessing the quality of life of patients with intestinal failure on home parenteral nutrition, **218**
- Intestinal genes**, Regional expression of intestinal genes for nutrient absorption: *leading article*, **5**
- Intestinal immunity**, Treatment with tumour necrosis factor inhibitor oxforditylline does not improve corticosteroid dependent chronic active Crohn's disease, **470: commentary**, **559**
- Intestinal metaplasia**, Short segment Barrett's oesophagus: prevalence, diagnosis and associations, **710: commentary**, **804**
- Intestinal non-haem iron absorption**, Regulation of intestinal non-haem iron absorption: *leading article*, **435**
- Intestinal permeability**
 Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor- α , **339**
 Is the sugar intestinal permeability test a reliable investigation for coeliac disease screening?, **215**
- Intestinal tolerability**, Intestinal tolerability of nitroxybutyl-flurbi-profen in rats, **608**
- Intraduodenal fat**, Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux, **449**
- Intraepithelial lymphocytes**
 Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells, **634**
 Intestinal intraepithelial lymphocytes have a promiscuous interleukin-8 receptor, **333**
- Intragastric feeding**, Enteral supplementation with ornithine ketoglutarate improves the early adaptive response to resection, **67**
- Iron absorption**, Regulation of intestinal non-haem iron absorption: *leading article*, **435**
- Irritable bowel syndrome**, Trauma and the gut: interactions between stressful experience and intestinal function: *review*, **704**
- Isoleucine**, Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats, **418**
- Isoprenaline**, Stimulation of β -adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans, **376**
- Ispaghula**, Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors, **223**
- Jejunectomy**, Enteral supplementation with ornithine α ketoglutarate improves the early adaptive response to resection, **67**
- K-ras**
 High frequency of K-ras mutations in human colorectal hyperplastic polyps, **660: commentary**, **691**
 Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all? **691**
- Kallikrein-kinin system**, Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis, **531**
- L-arginine**, L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions, **602**
- L-NMMA**, Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans, **86**
- Lactulose**
 Increasing the intestinal resistance of rats to the invasive pathogen *Salmonella enteritidis*: additive effects of dietary lactulose and calcium, **497**
 Is the sugar intestinal permeability test a reliable investigation for coeliac disease screening? **215**
- Laparoscopic surgery**, Laparoscopic surgery for gastro-oesophageal reflux disease: *leading article*, **565**
- Laparoscopy**, Outcome of laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis, **381**
- Large bowel**
 High frequency of K-ras mutations in human colorectal hyperplastic polyps, **660: commentary**, **691**
 Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all? **691**
- Laser**, Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study, **362**
- Laser lithotripsy**, Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study, **678**
- Lectin**, In vitro influence of *Phaseolus vulgaris*, *Griffonia simplicifolia*, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth, **253**
- Leucocytes**, Studies on gastric mucosal microcirculation. 1. The nature of regional variations induced by ethanol injury, **31**
- Liver**
 Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver, **145: commentary**, **151**
 Natriuretic peptides: are these new links in the hepatorenal connections? **151**
- Liver cirrhosis**, Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, **726: commentary**, **568**
- Liver failure**, Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats, **418**
- Liver transplantation**
 Bone disease after liver transplantation should not be underestimated: *correspondence*, **695**
 Hepatitis B virus infection and liver transplantation: *leading article*, **568**
- Loss of heterozygosity (LOH)**, *DPC4* gene mutation in colitis associated neoplasia, **120**
- LoVo**, In vitro influence of *Phaseolus vulgaris*, *Griffonia simplicifolia*, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth, **253**
- Lower oesophageal sphincter**
 Characterisation of relaxation of the lower oesophageal sphincter in healthy premature infants, **370**
 Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans, **575**
 Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux, **449**
 Multivariate analysis of pathophysiological factors in reflux oesophagitis, **167** **Loxiglumide**, Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans, **575**
- Lymphocyte**
 Altered expression of $\alpha 4\beta 7$, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation, **241**
 Intestinal intraepithelial lymphocytes have a promiscuous interleukin-8 receptor, **333**
 Signals from lymphocytes in colon cancer, **153**
 T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma, **113: commentary**, **153**
- Macromolecular leakage**, Studies on gastric mucosal microcirculation. 1. The nature of regional variations induced by ethanol injury, **31**
- Macrophages**, Role of *Helicobacter pylori* surface structures in bacterial interaction with macrophages, **20**
- Magainins**, Antimicrobial peptides in the gastrointestinal tract: *leading article*, **161**

- Mannitol**, Is the sugar intestinal permeability test a reliable investigation for coeliac disease screening?, 215
- Mass screening**, Is the sugar intestinal permeability test a reliable investigation for coeliac disease screening? 215
- Megacolon**, Oesophageal manometry in the evaluation of megacolon with onset in adult life, 188
- Mesalazine**, Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? 284
- Metastases**, Micrometastases: marker of metastatic potential or evidence of residual disease? 512: *commentary*, 555
- Microcirculation**
Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis, 526
Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide, 720
- Micrometastases**, Micrometastases: marker of metastatic potential or evidence of residual disease? 512: *commentary*, 555
- Migrating motility complex (MMC)**, Trauma and the gut: interactions between stressful experience and intestinal function: *review*, 704
- Mirizzi's syndrome**, Endoscopic management of Mirizzi's syndrome, 272
- Misoprostol**, Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users – the OMNIUM Study, 797 (suppl 1 abstract)
- Monoclonal antibodies**, Altered expression of mucins throughout the colon in ulcerative colitis, 234
- Monoclonal antibody treatment**, CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study, 320
- Mortality**
Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality, 544
Soluble TNF receptors as prognostic factors for mortality: *correspondence*, 560
- Motility**
Daytime and night time motor activity of the small bowel after solid meals of different caloric value in humans, 614
Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors, 223
Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus, 641
Outcome of laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis, 381
Stimulation of β -adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans, 376
- Mucin**
Altered expression of mucins throughout the colon in ulcerative colitis, 234
Histochemistry of the surface mucous gel layer of the human colon, 782: *commentary*, 807
- Multivariate analysis**, Multivariate analysis of pathophysiological factors in reflux oesophagitis, 167
- N α -methyl-histamine**, Effect of N α -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for *Helicobacter pylori* associated gastritis and gastric physiology, 14
- Natriuretic peptides**
Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver, 145: *commentary*, 151
Natriuretic peptides: are these new links in the hepatorenal connections? 151
- Neopterin**, Activation of cellular immune response in acute pancreatitis, 794
- Nephrotoxicity**, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate, 761
- The Netherlands**, Twenty years of childhood coeliac disease in The Netherlands: a rapidly increasing incidence? 61
- Neurochemical coding**, Neurochemical coding in the small intestine of patients with Crohn's disease, 767
- Neutrophil activation**, Cytotoxin production and neutrophil activation by strains of *Helicobacter pylori* isolated from patients with peptic ulceration and chronic gastritis: *correspondence*, 431
- Nissen**, Outcome of laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis, 381
- Nitrate**
Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans, 211: *commentary*, 288
Dietary nitrate: poison or panacea? 288
- Nitric oxide**
Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans, 211: *commentary*, 288
- Dietary nitrate: poison or panacea? 288
- L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions, 602
- Neurochemical coding in the small intestine of patients with Crohn's disease, 767
- Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans, 86
- Nitroxybutyl-flurbiprofen**, Intestinal tolerability of nitroxybutyl-flurbiprofen in rats, 608
- Non-haem iron absorption**, Regulation of intestinal non-haem iron absorption: *leading article*, 435
- Non-steroidal anti-inflammatory drugs**
Effects of sulindac on sporadic colorectal adenomatous polyps, 344: *commentary*, 430
Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration, 204: *commentary*, 286
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease, 619
Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users – the OMNIUM Study, 797 (suppl 1 abstract)
Recombinant peptides for gastrointestinal ulceration: still early days, 286
Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide, 720
- Northern blotting**, Gene expression of group II phospholipase A2 in intestine in ulcerative colitis, 95
- Notes**, 157, 290, 433, 562, 810
- Nutrient absorption**, Regional expression of intestinal genes for nutrient absorption: *leading article*, 5
- Nutritional intake**, Two phase randomised controlled clinical trial of postoperative oral dietary supplements in surgical patients, 393
- Octreotide**, Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide, 720
- Oesophageal adenoma**, Relation between gastric cancer and previous peptic ulcer disease, 247
- Oesophageal cancer**
Endoscopic treatment of early oesophageal or gastric cancer, 123
Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study, 362
- Oesophageal motility**
Characterisation of relaxation of the lower oesophageal sphincter in healthy premature infants, 370
Oesophageal manometry in the evaluation of megacolon with onset in adult life, 188
- Oesophageal sensitivity**, Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the "sensitive oesophagus", 587
- Oesophagitis**, Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, 175
- Oesophagogastric junction**, Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux, 449
- Oesophagus**
Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux, 449
Human oesophageal bicarbonate secretion: a phenomenon waiting for a role, 693
Reappraisal of bicarbonate secretion by the human oesophagus, 582: *commentary*, 693
- Oestrogen**, Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer, 516
- Omeprazole**
Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the "sensitive oesophagus", 587
Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study, 36
Human oesophageal bicarbonate secretion: a phenomenon waiting for a role, 693
Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users – the OMNIUM Study, 797 (suppl 1 abstract)
Reappraisal of bicarbonate secretion by the human oesophagus, 582: *commentary*, 693
- Open access gastroscopy**, Open access gastroscopy: second survey of current practice in the United Kingdom, 192

- Oral dietary supplements**, Two phase randomised controlled clinical trial of postoperative oral dietary supplements in surgical patients, 393
- Oral rehydration solutions**, L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions, 602
- Ornithine decarboxylase**, Enteral supplementation with ornithine ketoglutarate improves the early adaptive response to resection, 67
- Orofacial granulomatosis**, Molecular analysis of T cell receptor β variability in a patient with orofacial granulomatosis, 683
- Osteopenia**, Bone disease after liver transplantation should not be underestimated: *correspondence*, 695
- Osteoporosis**
Bone disease after liver transplantation should not be underestimated: *correspondence*, 695
Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study, 313
- Oxpentifylline**
In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease, 475: *commentary*, 559
Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease, 470: *commentary*, 559
- p53**
Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases, 350
Clinical significance of serum p53 antigen in patients with pancreatic carcinomas, 647
Detection and monitoring of serum p53 antibodies in patients with colorectal cancer, 356
- Palliation**, Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study, 362
- Pancreas**
Expression of peptide receptors in human endocrine tumours of the pancreas, 267
Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans, 86
- Pancreatic antibodies**, Pancreatic autoantibodies in Crohn's disease: a family study, 481: *commentary*, 557
- Pancreatic cancer (carcinoma)**
Clinical significance of serum p53 antigen in patients with pancreatic carcinomas, 647
Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster, 536
Prospective evaluation of cytology from biliary strictures, 671
- Pancreatic polypeptide**, Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans, 86
- Pancreatic repair**, Increased expression of transforming growth factor β s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair, 73
- Pancreaticoduodenectomy**, Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis, 716
- Pancreatitis**
Activation of cellular immune response in acute pancreatitis, 794
Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis, 531
Familial hyperamylasaemia, 689
Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients, 262
Increased expression of transforming growth factor β s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair, 73
Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis, 526
Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats, 386
Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis, 80
Risk factors for pancreatitis: *correspondence*, 289
Role of cytokines and their inhibitors in acute pancreatitis: *leading article*, 1
- Papillectomy**, Endoscopic papillectomy: *correspondence*, 561
- Parenteral nutrition**, Assessing the quality of life of patients with intestinal failure on home parenteral nutrition, 218
- Parietal cell**, Effect of $N\alpha$ -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for *Helicobacter pylori* associated gastritis and gastric physiology, 14
- Pentagastrin**
Helicobacter pylori and duodenal ulcers, *correspondence*, 155
The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation, 597
- Pepsin**, Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, 175
- Pepsinogen**
Cytokine effects on pepsinogen secretion from human peptic cells, 42
Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection, 297
- Peptic ulcer**
Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients, 302
Relation between gastric cancer and previous peptic ulcer disease, 247
- Peptic ulcer bleeding**, Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study, 36
- Peptide receptors**, Expression of peptide receptors in human endocrine tumours of the pancreas, 267
- Peptide YY**, Peptide YY and electrolyte homeostasis: *correspondence*, 157
- Peptides**
Antimicrobial peptides in the gastrointestinal tract: *leading article*, 161
Neurochemical coding in the small intestine of patients with Crohn's disease, 767
- Peptides**, central control, Central peptidergic control of gastric acid secretion: *leading article*, 164
- Peristalsis**, Outcome of laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis, 381
- pH**
Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study, 36
Synthesis and activity of *Helicobacter pylori* urease and catalase at low pH, 25
- Phospholipase A2**
Gene expression of group II phospholipase A2 in intestine in ulcerative colitis, 95
Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats, 386
- Pigbel-like syndrome**, Pigbel-like syndrome in a vegetarian in Oxford: *correspondence*, 695
- Polymerase chain reaction**, Whipple's disease: comparison of histology with diagnosis based on polymerase chain reaction in four consecutive cases, 425
- Polymorphonuclear elastase**, Activation of cellular immune response in acute pancreatitis, 794
- Portal hypertension**, Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis, 139
- Portal pressure**, Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? 664
- Portal vein**, Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis, 798
- Post-traumatic stress disorder**, Trauma and the gut: interactions between stressful experience and intestinal function: *review*, 704
- Postoperative surgical patients**, Two phase randomised controlled clinical trial of postoperative oral dietary supplements in surgical patients, 393
- Postprandial activity**, Daytime and night time motor activity of the small bowel after solid meals of different caloric value in humans, 614
- Pouch function**, Contribution of gastrointestinal transit and pouch characteristics in determining pouch function, 790
- Preterm neonate**, Characterisation of relaxation of the lower oesophageal sphincter in healthy premature infants, 370
- Primary biliary cirrhosis**
Autoimmune cholangitis: *leading article*, 440
T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function, 277
- Primary cerebral lymphoma**, Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder, 801
- Primary sclerosing cholangitis**, Autoimmune cholangitis: *leading article*, 440
- Propranolol**, Stimulation of β -adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans, 376

Prostaglandins

Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration, **204: commentary, 286**

Recombinant peptides for gastrointestinal ulceration: still early days, **286**

Protein synthesis, Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells, **634**

Provocation test, Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy, **745**

Pseudo-obstruction, Oesophageal manometry in the evaluation of megacolon with onset in adult life, **188**

Putrescine, Enteral supplementation with ornithine α ketoglutarate improves the early adaptive response to resection, **67**

Quality of life

Assessing the quality of life of patients with intestinal failure on home parenteral nutrition, **218**

Endoscopic treatment of early oesophageal or gastric cancer, **123**

Radiotherapy, Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study, **362**

Ranitidine

Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study, **36**

Human oesophageal bicarbonate secretion: a phenomenon waiting for a role, **693**

Reappraisal of bicarbonate secretion by the human oesophagus, **582: commentary, 693**

Rapid whole blood test, Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests, **454**

Rectal preparations, Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis, **775**

Refeeding, Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients, **262**

Reflux oesophagitis

Multivariate analysis of pathophysiological factors in reflux oesophagitis, **167**

Relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease, **182**

Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, **175**

Renal blood flow, Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? **664**

Renal circulation, Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis, **139**

Renal tubular dysfunction, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate, **761**

Replication errors, Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers, **654**

Residual disease, Micrometastases: marker of metastatic potential or evidence of residual disease? **512: commentary, 555**

Respiratory burst, Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils, **102**

Retained bile duct stones, Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study, **678**

RGD mimetics, Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice, **133**

Salivary nitrate and nitrite

Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans, **211: commentary, 288**

Dietary nitrate: poison or panacea? **288**

Salivary tests, Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests, **454**

Salmonella enteritidis, Increasing the intestinal resistance of rats to the invasive pathogen *Salmonella enteritidis*: additive effects of dietary lactulose and calcium, **497**

Scintigraphy, Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus, **641**

Screening, Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer, **110**

Secretin, Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans, **86**

Secretory IgA, In vitro evaluation of the role of antibodies against *Helicobacter pylori* in inhibiting adherence of the organism to gastric cells, **731**

Sex hormones, Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer, **516**

Shigellosis, Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo, **505**

Short chain fatty acids

Oxidation of short and medium chain C2-C2 fatty acids in Sprague-Dawley rat colonocytes, **400**

Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial, **485**

Short segment Barrett's oesophagus, Short segment Barrett's oesophagus: prevalence, diagnosis and associations, **710: commentary, 804**

Small intestinal mucosa, The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vivo, **57**

Small intestine

Daytime and night time motor activity of the small bowel after solid meals of different caloric value in humans, **614**

Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors, **223**

Stimulation of β -adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans, **376**

Smoking

Adult coeliac disease, dermatitis herpetiformis and smoking: *correspondence*, **289**

Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection, **297**

Sodium absorption, L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions, **602**

Sodium taurocholate pancreatitis, Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats, **386**

Somatostatin analogue, Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide, **720**

Sphincter of Oddi, Topical glyceryl trinitrate relaxes the sphincter of Oddi, **541**

Sporadic colorectal adenomatous polyp, Effects of sulindac on sporadic colorectal adenomatous polyps, **344: commentary, 430**

Stomach neoplasms, Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer, **516**

Stress, Trauma and the gut: interactions between stressful experience and intestinal function: *review*, **704**

Sucrase, Enteral supplementation with ornithine α ketoglutarate improves the early adaptive response to resection, **67**

Sulindac, Effects of sulindac on sporadic colorectal adenomatous polyps, **344: commentary, 430**

Sulphasalazine, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate, **761**

Superoxide anion

Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils, **102**

Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, **175**

Superoxide dismutase, Treatment of *Helicobacter pylori* infection favourably affects gastric mucosal superoxide dismutases, **591**

Suppository, Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis, **775**

Surface mucous gel layer, Histochemistry of the surface mucous gel layer of the human colon, **782: commentary, 807**

Surgery, Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases, **350**

SW837, In vitro influence of *Phaseolus vulgaris*, *Griffonia simplicifolia*, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth, **253**

Symptom index, Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the "sensitive oesophagus", **587**

T cell receptor β , Molecular analysis of T cell receptor β variability in a patient with orofacial granulomatosis, **683**

T cell receptor-zeta

Signals from lymphocytes in colon cancer, 153

T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma, 113: *commentary*, 153

T cells

Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice, 133

T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function, 277

Theophylline, Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis, 139

Thrombosis, Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis, 798

TIPS, Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?, 664

Transforming growth factor- α , Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of *Helicobacter pylori*, 463

Transforming growth factor β , Increased expression of transforming growth factor β s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair, 73

Transient relaxations, Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans, 575

Transit time, Contribution of gastrointestinal transit and pouch characteristics in determining pouch function, 790

Transjugular intrahepatic portosystemic stent-shunt, Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? 664

Trauma, Trauma and the gut: interactions between stressful experience and intestinal function: *review*, 704

Trophic action, The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vivo, 57

'Tropical sprue', 'Tropical sprue': some early investigators favoured an infective cause, but was a coccidian protozoan involved? 428

Tumour necrosis factor

Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis, 80

Tumour necrosis factor and Crohn's disease: *review*, 443: *commentary*, 559

Tumour necrosis factor-alpha

Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha, 339

Gastric mucosal secretion of interleukin-10: relations to histopathology, *Helicobacter pylori* status, and tumour necrosis factor-alpha secretion, 739

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease, 470: *commentary*, 559

Tumour necrosis factor-alpha antibody, Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha, 628

Tumour necrosis factor receptors, Soluble TNF receptors as prognostic factors for mortality: *correspondence*, 560

Tyrosine hydroxylase, Neurochemical coding in the small intestine of patients with Crohn's disease, 767

Tyrosine-kinase, Cytokine effects on pepsinogen secretion from human peptic cells, 42

Ulcer bleeding, Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients

with peptic ulcer bleeding: a prospective randomised controlled study, 36

Ulcerative colitis

Altered expression of mucins throughout the colon in ulcerative colitis, 234

Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease, 105

Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study, 313

DPC4 gene mutation in colitis associated neoplasia, 120

Gene expression of group II phospholipase A2 in intestine in ulcerative colitis, 95

Histochemistry of the surface mucous gel layer of the human colon, 782: *commentary*, 807

Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway, 328

Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis, 623

Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils, 102

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease, 619

Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes, 400

Pre-illness dietary factors in inflammatory bowel disease, 754

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis, 775

Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial, 485

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha, 628

Ultrasound, Ultrasound for gastroenterologists: *correspondence*, 156

Urease

Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis, 726: *commentary*, 805

Synthesis and activity of *Helicobacter pylori* urease and catalase at low pH, 25

Ussing chambers

Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor- α , 339

Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo, 505

Vagal innervation, The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation, 597

V β gene usage, Molecular analysis of T cell receptor β variability in a patient with orofacial granulomatosis, 683

Vegetarian, Pigbel-like syndrome in a vegetarian in Oxford: *correspondence*, 695

Vertebral bone density, Reduced bone density in patients with inflammatory bowel disease, 228

Video education, Video education and evidence in endoscopy, 554

Vitronectin, Role of *Helicobacter pylori* surface structures in bacterial interaction with macrophages, 20

Wegener's granulomatosis, Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies, 550

Whipple's disease, Whipple's disease: comparison of histology with diagnosis based on polymerase chain reaction in four consecutive cases, 425

VOLUME 40: AUTHOR INDEX – SUPPLEMENT

- Aabakken L, Suppl. 1. A83
Aase S, Suppl. 1. A46
Abraha H, Suppl. 1. A13
Adams DH, Suppl. 1. A67
Adams WR, Suppl. 1. A73
Adenekan RO, Suppl. 1. A72
Ahmad F, Suppl. 1. A5
Ahmad SM, Suppl. 1. A53
Ahmed HA, Suppl. 1. A14
Ahmed R, Suppl. 1. A66
Ainley CA, Suppl. 1. A12
Ainley CC, Suppl. 1. A43
Ajjan R, Suppl. 1. A23, A28
Akslen LA, Suppl. 1. A48
Al-Mufti RAM, Suppl. 1. A47
AlAtia R, Suppl. 1. A33
Alderson D, Suppl. 1. A37, A41
Allan R, Suppl. 1. A77
Allan RN, Suppl. 1. A24
Allen-Mersh TG, Suppl. 1. A49
Allison MC, Suppl. 1. A32, A63
Almeida SM, Suppl. 1. A31
Alstead EM, Suppl. 1. A19, A57, A77
Altomare DF, Suppl. 1. A65
Ambrose NS, Suppl. 1. A41
Anderson JT, Suppl. 1. A77
Andreyev HJN, Suppl. 1. A19, A45, A49
Angel CA, Suppl. 1. A65
Anker P, Suppl. 1. A77
Anthony A, Suppl. 1. A24, A25, A71
Ardill JES, Suppl. 1. A3, A46
Ardizzone S, Suppl. 1. A26
Arends MJ, Suppl. 1. A46
Armonis A, Suppl. 1. A30
Armstrong P, Suppl. 1. A48
Armstrong-James D, Suppl. 1. A50
Arnott J, Suppl. 1. A23
Arrowsmith H, Suppl. 1. A64
Asante MA, Suppl. 1. A2, A14, A61
Ashton L, Suppl. 1. A6
Atherton JC, Suppl. 1. A1, A6
Atkin WS, Suppl. 1. A57
Axon ATR, Suppl. 1. A5, A22, A61, A68, A69, A70, A83
Ayres RCS, Suppl. 1. A24
Aziz Q, Suppl. 1. A42, A53
- Bailey TA, Suppl. 1. A76
Baker A, Suppl. 1. A18
Balan KK, Suppl. 1. A20
Balaratnam N, Suppl. 1. A63
Ball C, Suppl. 1. A18
Ballam L, Suppl. 1. A2
Ballinger A, Suppl. 1. A77
Ballinger AB, Suppl. 1. A19
Bansi D, Suppl. 1. A29
Bardhan KD, Suppl. 1. A30
Barker H, Suppl. 1. A37
Barr H, Suppl. 1. A76
Barrett DA, Suppl. 1. A6
Bartley B, Suppl. 1. A35
Bartolo DCC, Suppl. 1. A55
Barton JR, Suppl. 1. A59
Barton S, Suppl. 1. A62
Barton SGRG, Suppl. 1. A69
Bartram CI, Suppl. 1. A53
Bartsocas C, Suppl. 1. A43
Bassendine MF, Suppl. 1. A16
Bates J, Suppl. 1. A40
Bateson MC, Suppl. 1. A5, A14
Baxter JN, Suppl. 1. A36
Beales I, Suppl. 1. A69, A70, A80
Beales IP, Suppl. 1. A81
Begent RH, Suppl. 1. A47
Bell DG, Suppl. 1. A33, A40
Bell G, Suppl. 1. A35
Beltinger J, Suppl. 1. A80
Bennett J, Suppl. 1. A20
Bennett JR, Suppl. 1. A34
Benson M, Suppl. 1. A42, A52
Benson MF, Suppl. 1. A41
Berg DE, Suppl. 1. A69
Besherdas K, Suppl. 1. A42, A58
Besser GM, Suppl. 1. A49, A66
Besser R, Suppl. 1. A19
Bettica P, Suppl. 1. A26
Bettini L, Suppl. 1. A16
Betts A, Suppl. 1. A39
Beveridge I, Suppl. 1. A59
Bevilacqua M, Suppl. 1. A26
Bhattacharya S, Suppl. 1. A47
Bhatti MA, Suppl. 1. A24, A74
- Bianchi F, Suppl. 1. A15
Bianchi Porro G, Suppl. 1. A7, A26, A32
Biddlestone LR, Suppl. 1. A76
Biggin CS, Suppl. 1. A8
Bird N, Suppl. 1. A20, A32
Bird NC, Suppl. 1. A66
Bjarnason I, Suppl. 1. A10, A70, A71, A73, A75
Blair CS, Suppl. 1. A16
Blaser MJ, Suppl. 1. A1
Bliss P, Suppl. 1. A80
Bliss PW, Suppl. 1. A1
Bloom SR, Suppl. 1. A79
Bode J, Suppl. 1. A46
Bodger K, Suppl. 1. A56
Bodmer WF, Suppl. 1. A45
Bollani S, Suppl. 1. A26, A32
Bolton R, Suppl. 1. A23, A28
Booth L, Suppl. 1. A60
Borman RA, Suppl. 1. A26
Borriello SP, Suppl. 1. A75
Botha A, Suppl. 1. A6, A7
Bottrill P, Suppl. 1. A82
Bouchier IAD, Suppl. 1. A15
Boulos P, Suppl. 1. A6, A7
Boulos PB, Suppl. 1. A49
Boulton R, Suppl. 1. A72
Bovill JG, Suppl. 1. A41
Bowling TE, Suppl. 1. A66
Bowrey DJ, Suppl. 1. A57
Boyle N, Suppl. 1. A37
Bramble MG, Suppl. 1. A60
Bramley P, Suppl. 1. A8, A13
Braunholtz D, Suppl. 1. A61, A68, A69
Brettler RP, Suppl. 1. A16
Brian M, Suppl. 1. A66
British Acute Pancreatitis Study Group, Suppl. 1. A12
Brown RC, Suppl. 1. A13
Brown S, Suppl. 1. A19, A62
Bruce J, Suppl. 1. A28
Brunsdan A, Suppl. 1. A81
Buckley P, Suppl. 1. A70
Buckner L, Suppl. 1. A8
Bunyan DJ, Suppl. 1. A78
Burden AC, Suppl. 1. A11
Burnham WR, Suppl. 1. A60, A62
Burns SM, Suppl. 1. A16
Burrroughs AK, Suppl. 1. A17, A30
Bury RS, Suppl. 1. A22
Butler P, Suppl. 1. A17
Butterfield I, Suppl. 1. A79
Buxton-Thomas M, Suppl. 1. A13
Bygrave S, Suppl. 1. A50
Byrne D, Suppl. 1. A35
- Cade A, Suppl. 1. A20
Cairns A, Suppl. 1. A47
Calam J, Suppl. 1. A1, A46, A69, A70, A80, A81
Campbell BJ, Suppl. 1. A81
Campbell FC, Suppl. 1. A45
Campbell S, Suppl. 1. A16, A18, A26
Cançado E, Suppl. 1. A15
Cann PA, Suppl. 1. A56, A58
Carey PD, Suppl. 1. A57
Cariem AK, Suppl. 1. A4
Carpani de Kaski MS, Suppl. 1. A37
Carter CR, Suppl. 1. A7, A36
Carter R, Suppl. 1. A39, A83
Castillo FD, Suppl. 1. A41
Cawkwell L, Suppl. 1. A47
Caygill CPJ, Suppl. 1. A35
Chadwick N, Suppl. 1. A28
Chalmers DM, Suppl. 1. A5, A22
Chan D, Suppl. 1. A60
Chapman R, Suppl. 1. A29
Charampopoulos A, Suppl. 1. A53
Charnley R, Suppl. 1. A29
Chen X, Suppl. 1. A77
Chesner IM, Suppl. 1. A64
Chess-Williams R, Suppl. 1. A66
Chetter I, Suppl. 1. A35
Chiotakou-Faliakou E, Suppl. 1. A23, A51
Chlouverakis G, Suppl. 1. A48
Chokshi S, Suppl. 1. A30
Christie J, Suppl. 1. A29
Christopoulou K, Suppl. 1. A30
Clark GWB, Suppl. 1. A57
Clark SK, Suppl. 1. A48
Clarke P, Suppl. 1. A32
- Clarke PA, Suppl. 1. A45, A49
Clayman C, Suppl. 1. A42, A51
Cobden I, Suppl. 1. A59
Cochran K, Suppl. 1. A3
Cochran KM, Suppl. 1. A13
Cole AT, Suppl. 1. A23, A61, A73, A74
Coleman MG, Suppl. 1. A78
Collins JSA, Suppl. 1. A60
Cominotti A, Suppl. 1. A16
Cooper BT, Suppl. 1. A36
Corfield AP, Suppl. 1. A56
Cotton PB, Suppl. 1. A83
Coul D, Suppl. 1. A55
Coupand K, Suppl. 1. A80
Coutts I, Suppl. 1. A33
Cover TL, Suppl. 1. A1
Cox JGC, Suppl. 1. A34
Cox MA, Suppl. 1. A36
Crabtree JE, Suppl. 1. A46, A69, A70
Craig DJ, Suppl. 1. A8
Cramp ME, Suppl. 1. A30
Crane R, Suppl. 1. A10
Crawford DHC, Suppl. 1. A13
Critchley M, Suppl. 1. A20
Crofton RW, Suppl. 1. A13
Cross SS, Suppl. 1. A65
Cruickshank N, Suppl. 1. A77
Cucino C, Suppl. 1. A7
Cullen DE, Suppl. 1. A23
Cummings JH, Suppl. 1. A27
Cunningham D, Suppl. 1. A19, A45, A49
Curtis H, Suppl. 1. A33, A75
Cuzick JA, Suppl. 1. A57
- Dahill S, Suppl. 1. A4
Dakkak M, Suppl. 1. A34
Dalling R, Suppl. 1. A55
D'Amato M, Suppl. 1. A32
Danesh BJ, Suppl. 1. A18, A26
Daniels P, Suppl. 1. A39
Darekar B, Suppl. 1. A41
Davidson BR, Suppl. 1. A17
Davies A, Suppl. 1. A10
Davies ET, Suppl. 1. A17
Davies JE, Suppl. 1. A11
Davies M, Suppl. 1. A28
Davis T, Suppl. 1. A14
Dawodu JB, Suppl. 1. A69
De Silva HJ, Suppl. 1. A52
de Souza NM, Suppl. 1. A50
De Tavonatti M, Suppl. 1. A16
Deady P, Suppl. 1. A20
Deakin M, Suppl. 1. A66
Deen KI, Suppl. 1. A52
Dees J, Suppl. 1. A31, A38
Dembinski A, Suppl. 1. A6
Dennison A, Suppl. 1. A20
Dennison AR, Suppl. 1. A11
Dew MJ, Suppl. 1. A2
Dhillon AP, Suppl. 1. A24, A71
Dhiman A, Suppl. 1. A25
Di Ciaula A, Suppl. 1. A33
Dick R, Suppl. 1. A30
Dixon M, Suppl. 1. A47, A70
Dixon MF, Suppl. 1. A22
Dobbins BM, Suppl. 1. A20, A76
Docherty E, Suppl. 1. A18
Dodds S, Suppl. 1. A66
Dolan K, Suppl. 1. A37, A77
Dollinger MM, Suppl. 1. A17
Domschke W, Suppl. 1. A6, A72, A74
Donaldson PT, Suppl. 1. A18
Donnelly MT, Suppl. 1. A79
Dooley JS, Suppl. 1. A17
Doran J, Suppl. 1. A29
Dove-Edwin I, Suppl. 1. A59
Dowell AC, Suppl. 1. A61, A68, A69
Dowling RH, Suppl. 1. A49, A66, A67
Drinkwater F, Suppl. 1. A54
Drummond H, Suppl. 1. A23
Duffy JN, Suppl. 1. A65
Duggan AE, Suppl. 1. A58
Dunk AA, Suppl. 1. A61
Durley P, Suppl. 1. A56
Dzik-Jurasz A, Suppl. 1. A12
- Eaden JA, Suppl. 1. A22, A57
Eastwood MA, Suppl. 1. A46
Ebrahim S, Suppl. 1. A22, A25
- Ebringer A, Suppl. 1. A25
Eccersley AJ, Suppl. 1. A55
Edwards J, Suppl. 1. A70, A80
Edwards R, Suppl. 1. A57
Efstathiou J, Suppl. 1. A48
Ehsanullah RSB, Suppl. 1. A41
El Hasani S, Suppl. 1. A35, A50
El-Nujumi A, Suppl. 1. A83
El-Omar E, Suppl. 1. A3, A46, A83
Elbert J, Suppl. 1. A6
Elemenoglou I, Suppl. 1. A48
Elia G, Suppl. 1. A45
Elia M, Suppl. 1. A19
Emmanuel AV, Suppl. 1. A52
Enck P, Suppl. 1. A53
Epstein O, Suppl. 1. A42, A51, A58, A82
Erah PO, Suppl. 1. A6
Erdsieck RJ, Suppl. 1. A28
Etolhi G, Suppl. 1. A69
Evangelou H, Suppl. 1. A83
Evanoff H, Suppl. 1. A29
Evans D, Suppl. 1. A34
Evans DF, Suppl. 1. A31, A35, A41, A43
Everett S, Suppl. 1. A70
Everitt S, Suppl. 1. A4
Everitt SE, Suppl. 1. A23
Evgenikos N, Suppl. 1. A55
- Facchinetti D, Suppl. 1. A8
Fairclough PD, Suppl. 1. A26, A49, A57, A75
Farthing MJG, Suppl. 1. A9, A19, A26, A27, A57, A76, A77
Favret M, Suppl. 1. A16
Ferguson A, Suppl. 1. A23, A46, A51, A55
Field JK, Suppl. 1. A77
Finch AC, Suppl. 1. A81
Finlay IG, Suppl. 1. A55
Finlayson C, Suppl. 1. A43
Fisher NC, Suppl. 1. A67
Fitzsimmons D, Suppl. 1. A12
Flegg PJ, Suppl. 1. A16
Fleming K, Suppl. 1. A29
Floren I, journal 797
Floyd D, Suppl. 1. A30
Fonseka MMD, Suppl. 1. A52
Forbes A, Suppl. 1. A23, A77
Foster DR, Suppl. 1. A1
Foster JM, Suppl. 1. A31, A44
Foster R, Suppl. 1. A70, A71, A73
Fouweather M, Suppl. 1. A32, A63
Francis CY, Suppl. 1. A43, A65
Fraser A, Suppl. 1. A8
French GR, Suppl. 1. A67
Friedman T, Suppl. 1. A56
Frier M, Suppl. 1. A28
Fuchs W, Suppl. 1. A6
Fujii T, Suppl. 1. A83
Fullerton G, Suppl. 1. A68, A83
Fullerton G, Suppl. 1. A35
- Gäken J, Suppl. 1. A15
Galvin A, Suppl. 1. A73, A74
Gandhi P, Suppl. 1. A49
Ganesh S, Suppl. 1. A23
Garde J, Suppl. 1. A77
Gardiner KR, Suppl. 1. A54, A65
Garlick NM, Suppl. 1. A73, A74
Gathercole DJ, Suppl. 1. A49, A66
Gatzen G, Suppl. 1. A50
Gazzard BG, Suppl. 1. A44, A67
Gearty JC, Suppl. 1. A36
Gedling P, Suppl. 1. A14
Gee JM, Suppl. 1. A73
Gemmell CG, Suppl. 1. A69
George DK, Suppl. 1. A13
George S, Suppl. 1. A12
Gharraie S, Suppl. 1. A43
Ghatei MA, Suppl. 1. A79
Ghosal S, Suppl. 1. A21
Ghosh S, Suppl. 1. A23, A38, A47
Giaffier MH, Suppl. 1. A19
Giannikaki E, Suppl. 1. A48
Gibbs P, Suppl. 1. A18
Gilderdale DJ, Suppl. 1. A50
Gillam D, Suppl. 1. A6, A7
Gillanders I, Suppl. 1. A26
Gillen D, Suppl. 1. A1, A3, A46, A83
Gilliam A, Suppl. 1. A70
Gilliland R, Suppl. 1. A54, A65
Glass RC, Suppl. 1. A66

- Goddard AF, Suppl. 1. A6
 Goddard WP, Suppl. 1. A80
 Goggin P, Suppl. 1. A38
 Going J, Suppl. 1. A7, A36
 Gokhale J, Suppl. 1. A41
 Gold D, Suppl. 1. A37
 Gold DM, Suppl. 1. A50
 Golding J, Suppl. 1. A33
 Gong F, Suppl. 1. A34
 Goodlad RA, Suppl. 1. A45, A72, A79
 Gordon FH, Suppl. 1. A17, A21
 Gosney J, Suppl. 1. A77
 Gough AC, Suppl. 1. A78
 Graham A, Suppl. 1. A17
 Green CJ, Suppl. 1. A10
 Green JRB, Suppl. 1. A66
 Greenaway JR, Suppl. 1. A56, A58
 Greenslade L, Suppl. 1. A30
 Griffin S, Suppl. 1. A39
 Griffin SM, Suppl. 1. A8
 Griffiths AE, Suppl. 1. A3
 Griffiths L, Suppl. 1. A82
 Grimley CE, Suppl. 1. A2
 Grundman M, Suppl. 1. A23, A28
 Grundy A, Suppl. 1. A42
 Guillou PJ, Suppl. 1. A35, A50
- Hadzic N, Suppl. 1. A17
 Hagger R, Suppl. 1. A42, A43
 Haigh C, Suppl. 1. A12
 Hainsworth I, Suppl. 1. A62
 Hall C, Suppl. 1. A66
 Hall W, Suppl. 1. A31, A77
 Halbyburton EM, Suppl. 1. A19, A27
 Halvorsen JF, Suppl. 1. A48
 Hamdy S, Suppl. 1. A42, A53
 Hamer-Hodges DW, Suppl. 1. A55
 Hamilton MI, Suppl. 1. A21
 Hansen S, Suppl. 1. A46
 Hardcastle JD, Suppl. 1. A21
 Hardinge E, Suppl. 1. A75
 Hardwick R, Suppl. 1. A37
 Harris AW, Suppl. 1. A59
 Harrison DJ, Suppl. 1. A17
 Harrison P, Suppl. 1. A15
 Hart AR, Suppl. 1. A57
 Hartmans WR, Suppl. 1. A31
 Haskard DO, Suppl. 1. A74
 Haslam N, Suppl. 1. A64
 Hawes RH, Suppl. 1. A83
 Hawkes ND, Suppl. 1. A10, A62
 Hawkey CJ, Suppl. 1. A1, A4, A23, A58, A61, A73, A74, A79, A80, journal 797
 Hawkey GM, Suppl. 1. A4, A61
 Hawthorne AB, Suppl. 1. A57
 Haydon GH, Suppl. 1. A16
 Hayes PC, Suppl. 1. A15, A16, A17, A29
 Healey Z, Suppl. 1. A70, A80
 Healy JC, Suppl. 1. A48
 Heatley RV, Suppl. 1. A56
 Heaton KW, Suppl. 1. A44
 Heaton N, Suppl. 1. A18
 Heaton ND, Suppl. 1. A17, A18
 Hebden JM, Suppl. 1. A28
 Hendrikse M, Suppl. 1. A22
 Hepworth CC, Suppl. 1. A8, A62
 Hernandez V, Suppl. 1. A69
 Hewer A, Suppl. 1. A45
 Heymen S, Suppl. 1. A65
 Hickman JA, Suppl. 1. A78, A79
 Hiew LY, Suppl. 1. A35
 Higgs NB, Suppl. 1. A79
 Higham A, Suppl. 1. A79
 Hill MJ, Suppl. 1. A35
 Hill P, Suppl. 1. A33
 Hillel P, Suppl. 1. A21
 Hillier K, Suppl. 1. A26
 Hilton SR, Suppl. 1. A60
 Hislop WS, Suppl. 1. A13
 Ho J, Suppl. 1. A53
 Hobbs KEF, Suppl. 1. A47
 Hobsley M, Suppl. 1. A6, A7
 Hobson A, Suppl. 1. A53
 Hodgson H, Suppl. 1. A30
 Hodgson JHF, Suppl. 1. A24, A74
 Hodgson SV, Suppl. 1. A45
 Hoem D, Suppl. 1. A48
 Holmes G, Suppl. 1. A23
 Holmes GKT, Suppl. 1. A33
 Holton J, Suppl. 1. A6, A7
 Hopwood D, Suppl. 1. A5, A31, A36, A77
 Houghton LA, Suppl. 1. A31, A43, A44, A52
 Howard GCW, Suppl. 1. A51
 Howard L, Suppl. 1. A18
 Howarth GF, Suppl. 1. A21
 Howie SEM, Suppl. 1. A17
 Huang JKC, Suppl. 1. A63
 Hudson MJ, Suppl. 1. A25
 Hudson N, Suppl. 1. A4
- Hull MA, Suppl. 1. A79
 Hungin APS, Suppl. 1. A60
 Hunt N, Suppl. 1. A29
 Hunter JO, Suppl. 1. A19, A22, A27, A64, A75
 Hussain F, Suppl. 1. A23, A28
 Hyde J, Suppl. 1. A75
- Idle N, Suppl. 1. A60
 Idle NL, Suppl. 1. A56
 Ihmaidat H, Suppl. 1. A7, A36
 Imbesi V, Suppl. 1. A7
 Imrie CW, Suppl. 1. A39, A83
 Ingoe L, Suppl. 1. A59
 International MELISSA Study Group, Suppl. 1. A4
- Jackson NA, Suppl. 1. A52
 Jacob M, Suppl. 1. A70, A71
 James P, Suppl. 1. A13
 Jameson J, Suppl. 1. A20
 Jamieson CP, Suppl. 1. A21
 Jankowski J, Suppl. 1. A77
 Jankowski JAZ, Suppl. 1. A76
 Jawhari AU, Suppl. 1. A76
 Jayne D, Suppl. 1. A50
 Jazrawi RP, Suppl. 1. A14, A63
 Jellum E, Suppl. 1. A46
 Jenkins D, Suppl. 1. A21, A79
 Jenkins HR, Suppl. 1. A10
 Jenkins P, Suppl. 1. A49, A66
 Jenkinson MD, Suppl. 1. A81
 Jewell R, Suppl. 1. A26
 Jewkes R, Suppl. 1. A44
 Johnson A, Suppl. 1. A32
 Johnson AG, Suppl. 1. A66
 Johnson CD, Suppl. 1. A11, A12
 Johnson IT, Suppl. 1. A73
 Johnson PRV, Suppl. 1. A11
 Johnson W, Suppl. 1. A72
 Johnston BJ, Suppl. 1. A37
 Johnston DA, Suppl. 1. A36, A77
 Jonas SK, Suppl. 1. A49
 Jones I, Suppl. 1. A32
 Jones RH, Suppl. 1. A58
 Jordinson M, Suppl. 1. A46, A81
 Jowett S, Suppl. 1. A39
- Kadairkamanathan SS, Suppl. 1. A34
 Kadirkamanathan SS, Suppl. 1. A35
 Kahn MA, Suppl. 1. A54
 Kamm MA, Suppl. 1. A51, A52, A53
 Kanavaros P, Suppl. 1. A14
 Kane KF, Suppl. 1. A78
 Karamanolis DG, Suppl. 1. A48
 Karim QN, Suppl. 1. A6
 Kasem H, Suppl. 1. A7
 Kay CL, Suppl. 1. A83
 Keeling N, Suppl. 1. A81
 Keen J, Suppl. 1. A59
 Keighley MRB, Suppl. 1. A40, A54, A55
 Keith WN, Suppl. 1. A36
 Kelly D, Suppl. 1. A71
 Kelly P, Suppl. 1. A9
 Kelly SM, Suppl. 1. A60
 Kennedy A, Suppl. 1. A47
 Kerker N, Suppl. 1. A17
 Kersulyte D, Suppl. 1. A69
 Khan B, Suppl. 1. A35
 Khan S, Suppl. 1. A77
 Khoo UY, Suppl. 1. A75
 Kiely M, Suppl. 1. A57
 Kim YS, Suppl. 1. A77
 Kimble J, Suppl. 1. A38
 King A, Suppl. 1. A67
 King TS, Suppl. 1. A19, A64
 Kingham JGC, Suppl. 1. A62
 Kite P, Suppl. 1. A76
 Kitsiou E, Suppl. 1. A43
 Klokouzas A, Suppl. 1. A49
 Kmiot WA, Suppl. 1. A50
 Kolios G, Suppl. 1. A24
 Konturek JW, Suppl. 1. A6
 Konturek SJ, Suppl. 1. A6
 Koopman HM, Suppl. 1. A41
 Koornstra JJ, Suppl. 1. A48
 Kopiker NP, Suppl. 1. A11
 Kouroumalis E, Suppl. 1. A14
 Kraal KJCM, Suppl. 1. A41
 Kucharzik T, Suppl. 1. A72, A74
 Kulhalli V, Suppl. 1. A43
 Kumar D, Suppl. 1. A42, A43, A52, A53, A54
 Kunkel SL, Suppl. 1. A29
- Laban S, Suppl. 1. A32
 Lai CWY, Suppl. 1. A63
- Langman MJS, Suppl. 1. A27, A78
 Långström G, journal 797
 Langworthy H, Suppl. 1. A5
 Lanzini A, Suppl. 1. A8, A16
 Law N, Suppl. 1. A82
 Law R, Suppl. 1. A20
 Lawson A, Suppl. 1. A7
 Lazzari C, Suppl. 1. A16
 Leahy ACB, Suppl. 1. A42, A51, A58
 Lean MEJ, Suppl. 1. A18
 Leatham A, Suppl. 1. A49
 Lederry C, Suppl. 1. A77
 Lee CA, Suppl. 1. A17
 Lee D, Suppl. 1. A60
 Lee FD, Suppl. 1. A4
 Leeds HELP Study Group, Suppl. 1. A61, A68, A69
 Leicester RJ, Suppl. 1. A53
 Levi S, Suppl. 1. A37
 Levin RJ, Suppl. 1. A81
 Lewis SJ, Suppl. 1. A44
 Liang Q, Suppl. 1. A46
 Lim AG, Suppl. 1. A60
 Lindley IJD, Suppl. 1. A69
 Linehan JD, Suppl. 1. A24
 Lingam MK, Suppl. 1. A35
 Lloyd A, Suppl. 1. A33
 Lockwood CM, Suppl. 1. A72
 Loft DE, Suppl. 1. A2
 Logan RFA, Suppl. 1. A21, A58, A65
 Logan RPH, Suppl. 1. A6, A80
 London NJM, Suppl. 1. A11
 Long RG, Suppl. 1. A61, A80
 Lorini GP, Suppl. 1. A16
 Louw JA, Suppl. 1. A4
 Lucke W, Suppl. 1. A4
 Lügering N, Suppl. 1. A72, A74
 Lui KC, Suppl. 1. A45
 Lukacs NW, Suppl. 1. A29
 Luo N, Suppl. 1. A9
 Lyautey J, Suppl. 1. A77
 Lyburn I, Suppl. 1. A62
- Ma Y, Suppl. 1. A15
 McAlindon ME, Suppl. 1. A62
 McCarthy M, Suppl. 1. A18
 McCartney SA, Suppl. 1. A26, A27
 McCloskey P, Suppl. 1. A30
 McColl KEL, Suppl. 1. A1, A3, A46, A83
 McConnell N, Suppl. 1. A26
 McCormick PA, Suppl. 1. A30
 McCourtney JS, Suppl. 1. A55
 McCreagh PD, Suppl. 1. A76
 MacDonald J, Suppl. 1. A83
 MacDonald TM, Suppl. 1. A36
 Macfarlane B, Suppl. 1. A82
 MacFie J, Suppl. 1. A11, A67, A70
 McGregor C, Suppl. 1. A75
 McKaig B, Suppl. 1. A33
 MacKay CK, Suppl. 1. A7, A36
 Mackay EH, Suppl. 1. A57
 McKenzie C, Suppl. 1. A57
 MacKenzie JF, Suppl. 1. A7, A36
 Mackintosh C, Suppl. 1. A13
 McKnight G, Suppl. 1. A8
 McLintock T, Suppl. 1. A83
 McMahon MJ, Suppl. 1. A20, A76
 McNair A, Suppl. 1. A15
 Maconi G, Suppl. 1. A7
 Macpherson A, Suppl. 1. A70, A71, A75
 MacSween RNM, Suppl. 1. A13, A16
 McWhirter JP, Suppl. 1. A63
 Maden K, Suppl. 1. A20
 Magee EAM, Suppl. 1. A27
 Mahida YR, Suppl. 1. A73, A75
 Mahmud T, Suppl. 1. A70, A71
 Maisey M, Suppl. 1. A37
 Makhdoom Z, Suppl. 1. A23
 Malek M, Suppl. 1. A5
 Mallet A, Suppl. 1. A66
 Mancey-Jones JB, Suppl. 1. A67
 Mandir N, Suppl. 1. A45, Suppl. 1. A79
 Manifold D, Suppl. 1. A37
 Mant D, Suppl. 1. A39
 Manzonna G, Suppl. 1. A32
 Mapstone N, Suppl. 1. A5
 Mapstone NP, Suppl. 1. A83
 Marchbank T, Suppl. 1. A72, A79
 Marinone MG, Suppl. 1. A8
 Marks IN, Suppl. 1. A4
 Marshall D, Suppl. 1. A47
 Marshall WJ, Suppl. 1. A10
 Martin IG, Suppl. 1. A20, A76
 Martin RM, Suppl. 1. A60
 Martins P, Suppl. 1. A31
 Mason HJ, Suppl. 1. A51
 Mason I, Suppl. 1. A42, A51
 Mason R, Suppl. 1. A37
- Mason S, Suppl. 1. A61, A68, A69
 Masson J, Suppl. 1. A8
 Mathie RT, Suppl. 1. A14
 Matthewson K, Suppl. 1. A39
 Maughan TS, Suppl. 1. A57
 Maw A, Suppl. 1. A55
 Maxwell JD, Suppl. 1. A14, A25
 Maxwell P, Suppl. 1. A18
 May CE, Suppl. 1. A76
 Mayberry J, Suppl. 1. A56
 Mayberry JF, Suppl. 1. A22, A57, A82
 Mayer AD, Suppl. 1. A67
 Maynard N, Suppl. 1. A37
 Mearin ML, Suppl. 1. A41
 Meeran K, Suppl. 1. A79
 Melby K, Suppl. 1. A46
 Mendall M, Suppl. 1. A2
 Menezes N, Suppl. 1. A39, A83
 Menzies D, Suppl. 1. A8
 Meuwissen SGM, Suppl. 1. A48
 Middleton SJ, Suppl. 1. A22, A27, A75
 Mieli-Vergani G, Suppl. 1. A15, A17, A18
 Milla PJ, Suppl. 1. A42
 Miller GV, Suppl. 1. A20, A41, A76
 Miller R, Suppl. 1. A27
 Mills JG, Suppl. 1. A41
 Mills PR, Suppl. 1. A13, A68
 Mills TN, Suppl. 1. A33, SA40
 Millson CE, Suppl. 1. A11
 Misiewicz JJ, Suppl. 1. A59
 Mistry PK, Suppl. 1. A17
 Mitchell CJ, Suppl. 1. A11, A67, A70
 Mitchell RMS, Suppl. 1. A10, A60
 Mitchell SA, Suppl. 1. A29
 Moayyedi P, Suppl. 1. A5, A61, A68
 Modlin I, Suppl. 1. A2
 Molteni P, Suppl. 1. A26
 Moniz C, Suppl. 1. A13
 Montgomery S, Suppl. 1. A25
 Montgomery SM, Suppl. 1. A21, A22
 Moody GA, Suppl. 1. A22
 Morgan K, Suppl. 1. A27
 Morgan R, Suppl. 1. A37
 Morran C, Suppl. 1. A4
 Morris AG, Suppl. 1. A2
 Morris AJ, Suppl. 1. A16
 Morris D, Suppl. 1. A22
 Morris J, Suppl. 1. A65
 Morton D, Suppl. 1. A40, A54
 Moshakis V, Suppl. 1. A38
 Moss S, Suppl. 1. A50
 Moss CA, Suppl. 1. A33, A40
 Motson RW, Suppl. 1. A8, A81
 Muiesan P, Suppl. 1. A18
 Mulcahy HE, Suppl. 1. A57, A77
 Mumtaz H, Suppl. 1. A6
 Murchan PM, Suppl. 1. A35, A50
 Murphy GM, Suppl. 1. A49, A66, A67
 Murray FE, Suppl. 1. A5, A23
 Murray IA, Suppl. 1. A80
 Murray L, Suppl. 1. A2, A46
 Mutch AF, Suppl. 1. A68
 Muthusami J, Suppl. 1. A8
 Mynott T, Suppl. 1. A75
- Nagral A, Suppl. 1. A17
 Naoumov NV, Suppl. 1. A30
 Naylor S, Suppl. 1. A22
 Nayyar AK, Suppl. 1. A30
 Negrini R, Suppl. 1. A8
 Neild PJ, Suppl. 1. A44, A67
 Newbould HE, Suppl. 1. A22
 Newcomb P, Suppl. 1. A37
 Newton M, Suppl. 1. A62
 Nicholls RJ, Suppl. 1. A53
 Noda M, Suppl. 1. A48
 Noguera JJ, Suppl. 1. A54
 Nomura T, Suppl. 1. A41
 Norman AR, Suppl. 1. A19, A49
 Northfield TC, Suppl. 1. A2, A14, A61, A63
 Northover JMA, Suppl. 1. A57
 Norton B, Suppl. 1. A33
 Norton SA, Suppl. 1. A41
 Novelli MR, Suppl. 1. A45
 Nugent KP, Suppl. 1. A39
 Nwokolo CU, Suppl. 1. A2
- Oates J, Suppl. 1. A19, A49
 Obeid OA, Suppl. 1. A21
 O'Boyle CJ, Suppl. 1. A70
 O'Donohue J, Suppl. 1. A13, A29
 O'Donohue JW, Suppl. 1. A12, A13, A68
 Ogreid D, Suppl. 1. A48
 Ogunbiyi OA, Suppl. 1. A54, A55

- Oien K, Suppl.1. A13, A83
 Olliff SP, Suppl.1. A67
 Oppong K, Suppl.1. A39
 Osborne JS, Suppl.1. A59
 Oshome A, Suppl.1. A6, A7
 Osler W, Suppl.1. A4
 Owen RJ, Suppl.1. A7
- Pace F, Suppl.1. A32
 Padley S, Suppl.1. A67
 Pagtel HRH, Suppl.1. A45
 Palasciano G, Suppl.1. A33
 Palmer K-J, Suppl.1. A78
 Palmer KR, Suppl.1. A38
 Papachryostomou M, Suppl.1. A47, A51
 Papadimitriou A, Suppl.1. A43
 Papadopoulou A, Suppl.1. A43
 Papakyriakou P, Suppl.1. A14
 Parente F, Suppl.1. A7
 Park HS, Suppl.1. A45
 Park R, Suppl.1. A13
 Paspatis GA, Suppl.1. A48
 Patch D, Suppl.1. A30
 Patchett SE, Suppl.1. A27
 Patel P, Suppl.1. A38, A60, Suppl.1. A2
 Payne S, Suppl.1. A12
 Pearson GM, Suppl.1. A4
 Pedley B, Suppl.1. A47
 Peek RM, Suppl.1. A1
 Pelli N, Suppl.1. A15
 Penman ID, Suppl.1. A46
 Pennington CR, Suppl.1. A63
 Penny C, Suppl.1. A83
 Pereira S, Suppl.1. A15
 Percira SP, Suppl.1. A13, A18, A29
 Perkins AC, Suppl.1. A28
 Phillips DH, Suppl.1. A45
 Phillips RKS, Suppl.1. A48
 Phillips S, Suppl.1. A11
 Piasecki C, Suppl.1. A71
 Pictor R, Suppl.1. A27
 Pignatelli M, Suppl.1. A46, A48, A50, A76
 Pigozzi MG, Suppl.1. A16
 Pilling J, Suppl.1. A73
 Piotrowicz AJK, Suppl.1. A12, A43
 Playford RJ, Suppl.1. A72, A79
 Plevris JN, Suppl.1. A17
 Podas T, Suppl.1. A56, A82
 Poon P, Suppl.1. A67
 Portincasa P, Suppl.1. A33
 Portmann B, Suppl.1. A17
 Poschet JF, Suppl.1. A75
 Potten CS, Suppl.1. A78, A79
 Pounder R, Suppl.1. A25, A28
 Pounder RE, Suppl.1. A5, A7, A21, A22, A24, A25, A59, A71, A72
 Powell LW, Suppl.1. A13
 Powell-Tuck J, Suppl.1. A21
 Prach AT, Suppl.1. A36, Suppl.1. A5
 Premaratna R, Suppl.1. A52
 Preston SR, Suppl.1. A41
 Price AB, Suppl.1. A10
 Primrose JN, Suppl.1. A39, A41, A78
 Prince MI, Suppl.1. A59
 Pritchard DM, Suppl.1. A78, A79
 Probert C, Suppl.1. A64
 Pryce D, Suppl.1. A3
 Puntis JWL, Suppl.1. A20
- Quirke P, Suppl.1. A47
- Rabie S, Suppl.1. A66
 Rafi S, Suppl.1. A70, A71
 Rahman MZ, Suppl.1. A18
 Raimes SA, Suppl.1. A8
 Rampton DS, Suppl.1. A69
 Rankin S, Suppl.1. A37
 Rashid NM, Suppl.1. A2
 Record CO, Suppl.1. A39
 Redhead DN, Suppl.1. A15
 Reed PI, Suppl.1. A35, A37
 Reggiani A, Suppl.1. A16
 Rela M, Suppl.1. A17, A18
 Rembacken B, Suppl.1. A47
 Rembacken BJ, Suppl.1. A22, A83
 Reuters RA, Suppl.1. A38
 Reznick RH, Suppl.1. A48
 Rhodes J, Suppl.1. A10
 Rhodes JM, Suppl.1. A81
 Rhodes M, Suppl.1. A68
- Richards ID, Suppl.1. A69
 Richards IDG, Suppl.1. A61, A68
 Riches A, Suppl.1. A57
 Riley S, Suppl.1. A23, A28, A32
 Ringler DJ, Suppl.1. A25
 Roberts E, Suppl.1. A30
 Roberts PJ, Suppl.1. A22, A27, A75
 Roberts SA, Suppl.1. A57
 Robertson DAF, Suppl.1. A24
 Robins A, Suppl.1. A73
 Robins RA, Suppl.1. A73, A74
 Robinson GJ, Suppl.1. A67
 Robinson MHE, Suppl.1. A21
 Robinson R, Suppl.1. A56
 Robinson RJ, Suppl.1. A82
 Robinson TJ, Suppl.1. A10
 Rogers J, Suppl.1. A35
 Rokke O, Suppl.1. A48
 Rolles K, Suppl.1. A17
 Rolton H, Suppl.1. A26
 Roseth A, Suppl.1. A70, A71, A73
 Roseveare C, Suppl.1. A38
 Ross PE, Suppl.1. A31, A77
 Ross PJ, Suppl.1. A45
 Rothwell JC, Suppl.1. A42
 Roy AJ, Suppl.1. A51
 Royston C, Suppl.1. A30
 Ruban RC, Suppl.1. A38
 Russell RI, Suppl.1. A4, A13, A69
 Ryder S, Suppl.1. A13, A29, A62
 Ryder SD, Suppl.1. A62
- Sabin C, Suppl.1. A30
 Sabin CA, Suppl.1. A17
 Sagabraten SO, Suppl.1. A48
 Sams V, Suppl.1. A49
 Sanchez M, Suppl.1. A31
 Sanders DSA, Suppl.1. A77
 Sanderson JD, Suppl.1. A39
 Sandhu BK, Suppl.1. A33
 Sandle GI, Suppl.1. A79
 Sangaletti O, Suppl.1. A7
 Sansom H, Suppl.1. A67
 Santoe MFM, Suppl.1. A28
 Sapelli P, Suppl.1. A8
 Sarela AI, Suppl.1. A14
 Sasieni P, Suppl.1. A45
 Saunders BP, Suppl.1. A39
 Savoldi E, Suppl.1. A8
 Schmid KW, Suppl.1. A72
 Schmidt MA, Suppl.1. A72
 Scott SM, Suppl.1. A35
 Segal I, Suppl.1. A9
 Segwagwe M, Suppl.1. A61
 Selden C, Suppl.1. A30
 Senior BW, Suppl.1. A5
 Sercombe J, Suppl.1. A5
 Serrano-Ikkos E, Suppl.1. A51
 Sewell HF, Suppl.1. A73
 Shafee Sami A, Suppl.1. A49
 Shah KA, Suppl.1. A10
 Shaw PN, Suppl.1. A6
 Shears J, Suppl.1. A82
 Shepherd H, Suppl.1. A38
 Shepherd HA, Suppl.1. A60
 Shepherd NA, Suppl.1. A76
 Sherwood P, Suppl.1. A62
 Shimoyama T, Suppl.1. A70
 Shorthouse M, Suppl.1. A22, A27, A75
 Shurey S, Suppl.1. A10
 Sidebotham RL, Suppl.1. A6
 Siersema PD, Suppl.1. A31, A38
 Sigthorsson G, Suppl.1. A70, A71, A73
 Silk DBA, Suppl.1. A59
 Sim R, Suppl.1. A25
 Simmonds N, Suppl.1. A38
 Simpson KJ, Suppl.1. A29
 Singh S, Suppl.1. A27
 Sinha A, Suppl.1. A2
 Skarstein A, Suppl.1. A48
 Slade D, Suppl.1. A11
 Slater E, Suppl.1. A7
 Smith A, Suppl.1. A3
 Smith CAD, Suppl.1. A78
 Smith GD, Suppl.1. A38
 Smith H, Suppl.1. A39, A57
 Smith JA, Suppl.1. A80
 Smith MSH, Suppl.1. A66
 Smith PM, Suppl.1. A10
 Smith VV, Suppl.1. A42
 Smith WC, Suppl.1. A8
 Smythe A, Suppl.1. A32
 Somasundaram S, Suppl.1. A70, A71
 Somers SS, Suppl.1. A35
 Sorbara R, Suppl.1. A16
- Sorg C, Suppl.1. A72
 Sosta S, Suppl.1. A16
 Sowdi R, Suppl.1. A70
 Spies SK, Suppl.1. A9
 Spiller RC, Suppl.1. A28, Suppl.1. A6
 Srivastava ED, Suppl.1. A32, A63
 Stack WA, Suppl.1. A4, A23, A65, A80
 Standen G, Suppl.1. A64
 Stanley AJ, Suppl.1. A15
 Stanton SL, Suppl.1. A54
 Stewart CJR, Suppl.1. A68
 Stewart JCM, Suppl.1. A23
 Stoll R, Suppl.1. A72, A74
 Stoner EA, Suppl.1. A12, A43
 Storrie JB, Suppl.1. A51
 Strickland N, Suppl.1. A50
 Strieter RM, Suppl.1. A29
 Stroun M, Suppl.1. A77
 Struthers AJ, Suppl.1. A83
 Stuart RC, Suppl.1. A36, Suppl.1. A7
 Sturrock RD, Suppl.1. A4
 Subhani J, Suppl.1. A22, A25
 Sue-Ling HM, Suppl.1. A83
 Suri D, Suppl.1. A39
 Sussman L, Suppl.1. A68
 Sutton R, Suppl.1. A37, A77
 Swain CP, Suppl.1. A33, A34, A40
 Swan CHJ, Suppl.1. A66
 Swift A, Suppl.1. A77
 Swift GL, Suppl.1. A10
 Swift S, Suppl.1. A11
 Sylvester PA, Suppl.1. A56
- Taha AS, Suppl.1. A61, Suppl.1. A4
 Tait CL, Suppl.1. A58
 Tait J, Suppl.1. A63
 Talbot IC, Suppl.1. A45
 Tang L, Suppl.1. A23
 Tavares I, Suppl.1. A70, A71
 Taylor CJ, Suppl.1. A21
 Taylor H, Suppl.1. A37
 Taylor HW, Suppl.1. A63
 Taylor JSW, Suppl.1. A62
 Teahon K, Suppl.1. A73
 Thadani H, Suppl.1. A10
 Tham TCK, Suppl.1. A60
 Thomas LA, Suppl.1. A49, A67
 Thomas MG, Suppl.1. A56
 Thomas R, Suppl.1. A77
 Thompson DG, Suppl.1. A42, A53
 Thompson L, Suppl.1. A10
 Thompson MR, Suppl.1. A50, A66
 Thompson N, Suppl.1. A22
 Thursz MR, Suppl.1. A3
 Tidmarsh C, Suppl.1. A82
 Tighe MJ, Suppl.1. A20, A76
 Timms PM, Suppl.1. A16, A18
 Tiwana H, Suppl.1. A25
 Todi D, Suppl.1. A11
 Toh SKC, Suppl.1. A11, A12
 Tolley K, Suppl.1. A58
 Tomlinson IPM, Suppl.1. A45
 Tompkins DS, Suppl.1. A5
 Tooze JA, Suppl.1. A25
 Torre F, Suppl.1. A30
 Tracey M, Suppl.1. A64
 Treharne C, Suppl.1. A2
 Trudgill N, Suppl.1. A32
 Tsai HH, Suppl.1. A11
 Tzardi M, Suppl.1. A14
 Tuffnell Q, Suppl.1. A64
 Turano A, Suppl.1. A8
 Turner IC, Suppl.1. A51, A53
 Turvill JL, Suppl.1. A9
 Twells RJ, Suppl.1. A1
 Tzampouras N, Suppl.1. A30
- Ubhi SS, Suppl.1. A11
 Ulvik A, Suppl.1. A48
 Ungorgil S, Suppl.1. A53
- v Kleef JW, Suppl.1. A41
 Vaizey CJ, Suppl.1. A53
 van Blankenstein M, Suppl.1. A28, A31, A38
 van Dam M, Suppl.1. A18
 vanBerge-Henegouwen GP, Suppl.1. A33
 Vasilakaki T, Suppl.1. A48
 Vautier G, Suppl.1. A13
 Vazeou A, Suppl.1. A43
 Veitch AM, Suppl.1. A9
- Vergani D, Suppl.1. A15, A17
 Verma A, Suppl.1. A14, A61, A63
 Verma S, Suppl.1. A19
 Veysey MJ, Suppl.1. A49, A66, A67
 Vickers D, Suppl.1. A65
 Vilca-Melendez H, Suppl.1. A18
 Vinjamuri S, Suppl.1. A20
 Vollset SE, Suppl.1. A46
- Wakefield A, Suppl.1. A25, A28
 Wakefield AJ, Suppl.1. A22, A24, A25, A71, A72
 Walan A, journal 797
 Walker EA, Suppl.1. A78
 Walker MM, Suppl.1. A3
 Walker SJ, Suppl.1. A37, A77
 Walmsley RS, Suppl.1. A24, A25, A72
 Walsh CJ, Suppl.1. A81
 Walsh KM, Suppl.1. A16
 Walters M, Suppl.1. A20
 Ward B, Suppl.1. A57
 Ward MR, Suppl.1. A36
 Ward UM, Suppl.1. A41
 Wardle J, Suppl.1. A57
 Warhurst G, Suppl.1. A79
 Warner PJ, Suppl.1. A76
 Warner TD, Suppl.1. A26
 Warren BF, Suppl.1. A56
 Wasan HS, Suppl.1. A45
 Wass JAH, Suppl.1. A49, A66
 Wassef WS, Suppl.1. A10
 Watson A, Suppl.1. A35
 Watson AJM, Suppl.1. A78, A79
 Watson JP, Suppl.1. A39
 Watson RGP, Suppl.1. A60
 Watters C, Suppl.1. A56
 Wayman J, Suppl.1. A8
 Weldon MJ, Suppl.1. A25
 Welsh M, Suppl.1. A38
 Wendon J, Suppl.1. A29
 Westaby D, Suppl.1. A67
 Westwick J, Suppl.1. A24
 Wexner SD, Suppl.1. A54, A65
 Wharton RQ, Suppl.1. A49
 White M, Suppl.1. A41
 White SA, Suppl.1. A11
 Whitehead MW, Suppl.1. A62
 Whorwell PJ, Suppl.1. A31, A43, A44, A52, A65
 Wicks ACB, Suppl.1. A11, A57
 Wicks C, Suppl.1. A10
 Wight N, Suppl.1. A75
 Wilkinson K, Suppl.1. A23
 Williams DW, Suppl.1. A2
 Williams EMI, Suppl.1. A37
 Williams M, Suppl.1. A5, A7, A59
 Williams NS, Suppl.1. A55
 Williams R, Suppl.1. A12, A13, A18, A29, A30
 Williamson JA, Suppl.1. A45
 Williamson RCN, Suppl.1. A14
 Wilson C, Suppl.1. A25
 Wilson CG, Suppl.1. A28
 Wilson JW, Suppl.1. A78
 Windsor ACJ, Suppl.1. A35, A50
 Wingate DL, Suppl.1. A31, A41
 Winn G, Suppl.1. A5
 Winnett A, Suppl.1. A45
 Winrow VR, Suppl.1. A69
 Winslet MC, Suppl.1. A47
 Winter TA, Suppl.1. A4
 Wirtz A, Suppl.1. A1, A3, A83
 Woitulewski J, Suppl.1. A61
 Woloszko J, Suppl.1. A53
 Wong T, Suppl.1. A15
 Woods M, Suppl.1. A26
 Woolner JT, Suppl.1. A22
 Worku M, Suppl.1. A6
 Wright NA, Suppl.1. A45, Suppl.1. A2
 Wright S, Suppl.1. A56
- Yeomans ND, journal 797
 Yorkshire GI Tumour Group, Suppl.1. A41
 Yoshioka K, Suppl.1. A40, A54, A55
 Young JWR, Suppl.1. A83
 Yu L-G, Suppl.1. A81
- Zappala F, Suppl.1. A16
 Zbar AP, Suppl.1. A50
 Zhang OB, Suppl.1. A69
 Zhao MH, Suppl.1. A72
 Zizi A, Suppl.1. A48

VOLUME 40: SUBJECT INDEX – SUPPLEMENT

- Accident & Emergency**, How are patients presenting to Accident & Emergency with upper gastrointestinal bleeding managed? Suppl.1.A61
- Acetic acid**, Concentrated (80%) acetic acid ingestion: systemic and gastrointestinal effects, Suppl.1.A31
- Achalasia**
Gastro-oesophageal reflux as a complication of achalasia therapy, Suppl.1.A34
Ten-year follow up after forceful balloon dilatation of achalasia, Suppl.1.A34
- Acid suppressants**, An audit of the use of long-term acid suppressants in general practice: potential for large savings, Suppl.1.A60
- Acromegaly**, In acromegalics with colorectal adenomas or carcinomas, serum deoxycholic acid is increased, Suppl.1.A49
- Adenocarcinoma**, Altered cadherins and catenins expressed in the Barrett's oesophagus, dysplasia, adenocarcinoma sequence, Suppl.1.A76
- Adenomatous polyposis coli**, Intestinal trefoil factor regulates the expression of E-cadherin, catenins and the adenomatous polyposis coli tumour suppressor protein, Suppl.1.A48
- Adenomatous polyposis coli gene**, APC in the regulation of intestinal crypt fission, Suppl.1.A45
- Africa**
Natural history of non-NSAID gastric ulcer disease following *H. pylori* eradication: a one year follow-up study in the African setting, Suppl.1.A4
Small intestinal crypt hyperplasia in African tropical enteropathy, Suppl.1.A9
- AIDS**, Biliary manometry in AIDS related cholangitis: relationship to symptoms and radiological findings, Suppl.1.A67
- Alcohol withdrawal**, Effect of abrupt alcohol withdrawal on liver transaminases and markers of liver fibrosis, Suppl.1.A18
- Alcoholic liver disease**, Long-term survival and alcohol relapse after liver transplantation for alcoholic liver disease, Suppl.1.A18
- Alginates**, Alginates alter oesophageal cell function in an animal model, Suppl.1.A31
- Alosetron**, Alosetron slows colonic transit in patients with irritable bowel syndrome, Suppl.1.A44
- Aminosalicilate levels**, Mucosal aminosalicilate levels correlate with clinical activity in patients with ulcerative colitis, Suppl.1.A23
- Anal fissure**, Do the old firm still stretch? Suppl.1.A55
- Anal sphincter**
Accuracy of digital examination, endoanal ultrasound and concentric needle electromyography in detecting anal sphincter, Suppl.1.A54
Randomized trial of faecal diversion in sphincter repair, Suppl.1.A55
- Anal sphincter degeneration**, Primary internal anal sphincter degeneration – a newly recognised cause of passive faecal incontinence, Suppl.1.A53
- Anal sphincter stretch**, Do the old firm still stretch? Suppl.1.A55
- Ankylosing spondylitis**, The immune response to *Klebsiella pneumoniae* in inflammatory bowel disease and ankylosing spondylitis, Suppl.1.A25
- Anorexia**, Serum leptin in inflammatory bowel disease: implications for the pathogenesis of anorexia and weight loss, Suppl.1.A19
- Anoxia**, Effect of *H. pylori*, aspirin and anoxia on antibiotic permeability in the rat stomach, Suppl.1.A6
- Anti-secretory drugs**, Audit of the use of anti-secretory drugs, Suppl.1.A59
- Antibiotic permeability**, Effect of *H. pylori*, aspirin and anoxia on antibiotic permeability in the rat stomach, Suppl.1.A6
- Antibiotics**, *Clostridium difficile*-associated diarrhoea: antibiotic usage, delay in detection of cytotoxin and failure of protection by metronidazole, Suppl.1.A75
- Antisense therapy**, Effective targeting of colorectal cancer *Kirsten ras* point mutations with antisense therapy *in vitro*, Suppl.1.A45
- Aphthous ulceration**, Aphthous ulceration in the terminal ileum: what is the significance? Suppl.1.A39
- Apoptosis**
Dietary calcium supplementation and apoptosis in murine colonic epithelium, Suppl.1.A46
Importance of apoptosis in the gastrointestinal toxicity induced by 5-fluorouracil: rescue from toxicity in p53^{-/-} mice, Suppl.1.A79
Ischaemia-reperfusion injury following syngeneic small bowel transplantation induces apoptosis, Suppl.1.A10
- Appendectomy**, Smoking and appendectomy in twins discordant for inflammatory bowel disease, Suppl.1.A25
- Argon plasma coagulation**, Colonoscopic argon plasma coagulation for benign and malignant rectal tumours, Suppl.1.A39
- Ascites**, Sapheno-peritoneal shunting for diuretic resistant ascites, Suppl.1.A29
- Aspirin**
Effect of *H. pylori*, aspirin and anoxia on antibiotic permeability in the rat stomach, Suppl.1.A6
Long-term survival, symptoms and drug use after peptic ulcer haemorrhage, Suppl.1.A8
Role of *Helicobacter pylori* in gastric adaptation to repeated aspirin administration in man, Suppl.1.A6
- Atopy**, The impact of breast feeding, atopy and other factors on the prevalence of gastro-oesophageal reflux, Suppl.1.A33
- ATP sensitive potassium channels**, ATP sensitive potassium channels in human gallbladder smooth muscle, Suppl.1.A66
- Audit**, Suppl.1.A57-66
Prospective audit of thoracoscopic splanchnicectomy in the management of intractable upper abdominal pain, Suppl.1.A39
- Augmentin**, Jaundice associated with augmentin: the tip of the iceberg? Suppl.1.A13
- Autoimmune liver disease**
Detection of anti conformational CYP2D6 antibodies in patients with autoimmune liver disease and HCV infection using a novel radioligand assay, Suppl.1.A15
New autoantigen in autoimmune liver disease: argininosuccinate lyase, Suppl.1.A15
- Autoimmunity**
Graft dysfunction associated with autoimmunity in paediatric liver transplantation, Suppl.1.A17
Lower prevalence of markers of autoimmunity in chronic hepatitis C in north-east of England, Suppl.1.A16
- Bacterial enzyme activity**, Bile acid metabolising intestinal bacterial enzyme activity: a novel factor in cholesterol gallstone pathogenesis, Suppl.1.A67
- Bacterial overgrowth**, Postoperative septic morbidity is related to severity of illness at presentation and to preoperative colonisation of the proximal gastrointestinal tract, Suppl.1.A70
- Bacterial translocation**, Obstructive jaundice does not promote bacterial translocation in man, Suppl.1.A67
- Bactericidal/permeability-increasing protein**, Bactericidal/permeability-increasing protein blocks lipopolysaccharide-induced procoagulant activity of endothelial cells, Suppl.1.A72
- Balloon dilatation**
Technique, and long term outcome of endoscopic balloon dilatation for pyloric stenosis, Suppl.1.A40
Ten-year follow up after forceful balloon dilatation of achalasia, Suppl.1.A34
- Barrett's adenocarcinoma**, Allelotype of Barrett's adenocarcinoma, Suppl.1.A77
- Barrett's oesophageal tumorigenesis**, Cell survival during Barrett's oesophageal tumorigenesis, Suppl.1.A76
- Barrett's oesophagus**
Acid and bile reflux in short segment Barrett's oesophagus, Suppl.1.A36
Altered cadherins and catenins expressed in the Barrett's oesophagus, dysplasia, adenocarcinoma sequence, Suppl.1.A76
Increasing incidence of Barrett's oesophagus: diagnostic zeal or genuine observation? Suppl.1.A36
Pattern of early chromosomal alterations in Barrett's oesophagus, Suppl.1.A36
Prevalence of specialised columnar epithelium at the cardia of patients with gastro-oesophageal reflux without obvious Barrett's oesophagus: comparison with normal, Suppl.1.A36
The UK National Barrett's Oesophagus Registry, Suppl.1.A35
- Basolateral K⁺ channels**, Nicardipine directly inhibits basolateral K⁺ channels involved in Cl secretion in human colon, Suppl.1.A79
- Bcl-2**, Bcl-2 and waf protein expression in chronic liver disease, Suppl.1.A14
- BDF1**, Immunohistochemical localisation of p21WAF1/CIP1 in the small intestine of BDF1 and p53^{-/-} (null) mice following gamma-irradiation, Suppl.1.A78
- Ben's endoscopy**, Ben's endoscopy, Suppl.1.A82
- Beta3-adrenoceptor agonist**, Reversal of and protection against indomethacin-induced blood stasis and mucosal damage by a β_3 -agonist in rat villi, Suppl.1.A71
- Bile reflux**, Acid and bile reflux in short segment Barrett's oesophagus, Suppl.1.A36

- Biliary manometry**, Biliary manometry in AIDS related cholangitis: relationship to symptoms and radiological findings, Suppl.1.A67
- Biliary strictures**, Brush cytology in the investigation of biliary strictures: a prospective study, Suppl.1.A68
- Birth cohort**, Inflammatory bowel disease in a national birth cohort, Suppl.1.A22
- Bleeding duodenal ulcer**, Improving the long term management of bleeding duodenal ulcer, Suppl.1.A62
- Bone mass**, Loss of bone mass in inflammatory bowel disease patients on long term steroids. Is there a safe limit? Suppl.1.A28
- Bone mineral density**, Low bone mineral density is related to disease duration in Crohn's disease and to glucocorticoid treatment and male gender in ulcerative colitis, Suppl.1.A26
- Bone turnover**, The effect of hormone replacement therapy on serum and urinary markers of bone turnover in primary biliary cirrhosis, Suppl.1.A13
- Bovine colostrum**, Bovine colostrum is prophylactic against indomethacin-induced intestinal injury, Suppl.1.A72
- Breast feeding**, The impact of breast feeding, atopy and other factors on the prevalence of gastro-oesophageal reflux, Suppl.1.A33
- Bromelain**, Effect of bromelain on *Salmonella typhimurium* invasion in cultured human intestinal cells, Suppl.1.A75
- Brush cytology**, Brush cytology in the investigation of biliary strictures: a prospective study, Suppl.1.A68
- Caco2 cells**, CD10 expression on human neutrophils and colonic epithelial cells (Caco2) after short-term incubation with various chemokines and growth factors, Suppl.1.A74
- Cadherins**
Altered cadherins and catenins expressed in the Barrett's oesophagus, dysplasia, adenocarcinoma sequence, Suppl.1.A76
Classical cadherins as morphoregulators in human colitis: in vivo and in vitro, Suppl.1.A77
Intestinal trefoil factor regulates the expression of E-cadherin, catenins and the adenomatous polyposis coli tumour suppressor protein, Suppl.1.A48
Transforming growth factor- α increases E-cadherin and β -catenin binding to the actin-bundling protein fascin, Suppl.1.A76
- cag pathogenicity island**, *Helicobacter pylori* induction of IL-8 synthesis in gastric epithelial cells depends on genes throughout the cag pathogenicity island, Suppl.1.A69
- CagA status**
Bacterial CagA status is unrelated to gastric function indexes or to the type either severity of symptoms in patients with *H. pylori*-positive non-ulcer dyspepsia, Suppl.1.A7
CagA status is associated with serum IgA antibodies to 60kDa heat shock proteins in *H. pylori*-associated gastric atrophy, Suppl.1.A69
H. pylori-induced hypergastrinaemia is related to bacterial CagA status, Suppl.1.A46
- Calcium channels**, Soybean lectin stimulates cholecystokinin release through calcium influx via L-type calcium channels, Suppl.1.A81
- Calcium supplementation**, Dietary calcium supplementation and apoptosis in murine colonic epithelium, Suppl.1.A46
- Calprotectin**, Faecal calprotectin: a suitable, sensitive, alternative to 111 indium labelled white cells for assessing intestinal inflammation in man, Suppl.1.A73
- Campylobacter jejuni**, Profound depression of carbachol stimulated secretion in colonic epithelial cells during invasion by *Campylobacter jejuni*, Suppl.1.A80
- Carbachol**, Profound depression of carbachol stimulated secretion in colonic epithelial cells during invasion by *Campylobacter jejuni*, Suppl.1.A80
- Carcinoembryonic antigen**, Multiple blood sampling increases the probability of identifying circulating tumour cells, Suppl.1.A49
- Carcinogenesis**, Mechanisms of carcinogenesis associated with intestinal epithelial regeneration, Suppl.1.A45
- Cardia**, carcinoma, Adenocarcinoma of the lower oesophagus and cardia are similar both epidemiologically and clinically: a population based study from 1974 to 1993, Suppl.1.A37
- Catenins**
Altered cadherins and catenins expressed in the Barrett's oesophagus, dysplasia, adenocarcinoma sequence, Suppl.1.A76
Intestinal trefoil factor regulates the expression of E-cadherin, catenins and the adenomatous polyposis coli tumour suppressor protein, Suppl.1.A48
Transforming growth factor- α increases E-cadherin and β -catenin binding to the actin-bundling protein fascin, Suppl.1.A76
- Catheter related sepsis**, A rapid qualitative technique for the in situ diagnosis of catheter related sepsis, Suppl.1.A76
- Catheter survival**, Optimising catheter survival in peripheral parenteral nutrition: a randomised control trial, Suppl.1.A20
- CD4+ T cells**, CD4+ T cell downregulation in the intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens, Suppl.1.A75
- CD10 expression**, CD10 expression on human neutrophils and colonic epithelial cells (Caco2) after short-term incubation with various chemokines and growth factors, Suppl.1.A74
- Chagas' disease**, Oesophageal motor dysfunction in patients with the indeterminate form of Chagas' disease, Suppl.1.A31
- Chemokine mRNA expression**, Semi-quantitative analysis of chemokine mRNA expression in gastric mucosa and its relation to the severity of gastritis, Suppl.1.A70
- Chemokines**, Production of angiogenic and chemoattractant chemokines during monocyte-hepatoma cell adhesion, Suppl.1.A29
- Chest pain**, Further evidence that sumatriptan induced chest pain is oesophageal in origin: effect on oesophageal visceral sensation, Suppl.1.A31
- Children**
Ben's endoscopy, Suppl.1.A82
Gastric emptying and gastrointestinal regulatory peptides in children with recurrent epigastric pain, Suppl.1.A43
Influence of siblings on risk of *Helicobacter pylori* infection, Suppl.1.A68
Social implications of childhood Crohn's disease, Suppl.1.A22
Total intravenous anaesthesia in paediatric gastrointestinal endoscopy, Suppl.1.A41
- Cholangitis**, Biliary manometry in AIDS related cholangitis: relationship to symptoms and radiological findings, Suppl.1.A67
- Cholecystokinin**, Soybean lectin stimulates cholecystokinin release through calcium influx via L-type calcium channels, Suppl.1.A81
- Cholera**
Inhibition of cholera toxin but not *E. coli* enterotoxin-induced secretion by substance P antagonist, Suppl.1.A9
Paroxetine inhibits cholera toxin induced secretion by depleting neuronal but not enterochromaffin cell 5-HT, Suppl.1.A9
- Cholestasis**, Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial, Suppl.1.A12
- Chromosomal alterations**, Pattern of early chromosomal alterations in Barrett's oesophagus, Suppl.1.A36
- Chronic idiopathic intestinal pseudo-obstruction**, Histological phenotyping of enteric smooth muscle disease causing functional intestinal obstruction in childhood, Suppl.1.A42
- Chronic liver disease**, Bcl-2 and waf protein expression in chronic liver disease, Suppl.1.A14
- Cimetidine**, An audit of the use of long-term acid suppressants in general practice: potential for large savings, Suppl.1.A60
- Cirrhosis of the liver**
Effect of TIPSS on renal blood flow in cirrhotic patients, Suppl.1.A15
Nitric oxide release in the splanchnic circulation of cirrhotic rats, Suppl.1.A14
Prognostic significance of hepatic venous pressure measurements in cirrhosis, Suppl.1.A30
- Cl- secretion**, Synergism between mediators of Cl- secretion in native rat colon: comparisons with colonic cell lines and implications for diarrhoea, Suppl.1.A81
- Clarithromycin**, Ranitidine bismuth citrate plus clarithromycin and tetracycline: a seven-day *Helicobacter pylori* eradication regimen, Suppl.1.A5
- CLO-testing**
CLO-testing for *H. pylori*: are we missing positive results? Suppl.1.A59
Does acid suppression affect the results of CLO tests? Suppl.1.A59
- Clostridium difficile**, *Clostridium difficile*-associated diarrhoea: antibiotic usage, delay in detection of cytotoxin and failure of protection by metronidazole, Suppl.1.A75
- Coeliac disease**
Atypical presentation of coeliac disease: a retrospective review of one institution's experience, Suppl.1.A10
Coeliac disease is associated with non-smoking and cessation of smoking, Suppl.1.A11
Elevated nitric oxide synthase activity in human duodenal enterocytes in iron deficiency anaemia and coeliac disease, Suppl.1.A80
Presentation and incidence of coeliac disease in South Glamorgan, Suppl.1.A10
- Colitis**, Classical cadherins as morphoregulators in human colitis: in vivo and in vitro, Suppl.1.A77
- Colitis activity index**, Further verification of the really useful simple colitis activity index, Suppl.1.A24
- Colon**
Inducible NOS is expressed in the normal human colon, Suppl.1.A27
Interstitial cells of Cajal in the human colon: regional density variations, Suppl.1.A43
Investigation of platelet-activating factor-induced secretion in human colon, Suppl.1.A26

- Nicardipine directly inhibits basolateral K⁺ channels involved in Cl secretion in human colon, Suppl.1.A79
- Randomized trial of oral sodium phosphate compared with oral sodium picosulphate preparation of the colon for colonoscopy, Suppl.1.A40
- Colonic cancer cells**, Vitamin D analogues are more potent activators of vitamin D response elements than the native hormone in colon cancer cells, Suppl.1.A78
- Colonic cell lines**
- Broad bean and wheat germ lectins increase cell adhesion and differentiation of colonic cancer cell lines, Suppl.1.A46
- Keratinocyte growth factor stimulates gut growth but is not a cytoprotective agent and does not stimulate migration of the human colonic carcinoma cell line HT29, Suppl.1.A79
- Synergism between mediators of Cl⁻ secretion in native rat colon: comparisons with colonic cell lines and implications for diarrhoea, Suppl.1.A81
- Colonic epithelial cells**
- CD10 expression on human neutrophils and colonic epithelial cells (Caco2) after short-term incubation with various chemokines and growth factors, Suppl.1.A74
- Cytotoxic effects of nitric oxide on HT29 colonic epithelial cells, Suppl.1.A75
- Human colonic epithelial cells down-regulate IL-8 expression in human microvascular endothelial cells: role of TGF- β , Suppl.1.A72
- Profound depression of carbachol stimulated secretion in colonic epithelial cells during invasion by *Campylobacter jejuni*, Suppl.1.A80
- Colonic epithelium**, Dietary calcium supplementation and apoptosis in murine colonic epithelium, Suppl.1.A46
- Colonic lamina propria**, Expression of $\alpha 5$ (CD49e) and $\alpha 6$ (CD49f) integrins on human colonic lamina propria T cells, Suppl.1.A73
- Colonic neoplasms**, Proliferative patterns of rectal mucosa as predictors of advanced colonic neoplasms in routinely processed rectal biopsies, Suppl.1.A48
- Colonic polyps**, Distribution and histology of diminutive colonic polyps removed by hot biopsy, Suppl.1.A47
- Colonoscopic argon plasma coagulation**, Colonoscopic argon plasma coagulation for benign and malignant rectal tumours, Suppl.1.A39
- Colonoscopy**
- Correlation between colonoscopy and CT-based virtual reality endoscopy in the detection of space-occupying lesions of the colon, Suppl.1.A83
- Dilemmas in colonoscopy. What would you do next? Suppl.1.A82
- Forces exerted by the endoscopist on the colonoscope during colonoscopy, Suppl.1.A40
- Coloproctology service**, 'One stop bottom shop' – a rapid access coloproctology service, Suppl.1.A53
- Colorectal adenomas**
- In acromegalics with colorectal adenomas or carcinomas, serum deoxycholic acid is increased, Suppl.1.A49
- p53 overexpression in polypoid versus "flat" colorectal adenomas, Suppl.1.A47
- Colorectal cancer (carcinoma)**
- An alternative method for the detection of genomic instability in colorectal cancers, Suppl.1.A78
- Colorectal cancer patients presenting with rectal bleeding have earlier stage tumours and longer pre-diagnosis history, Suppl.1.A50
- Detection of K-ras mutations in faecal samples from colorectal cancer patients by SSCP analysis, Suppl.1.A48
- Effective targeting of colorectal cancer *Kirsten ras* point mutations with antisense therapy *in vitro*, Suppl.1.A45
- Four audit cycles of the informational content of histopathological reports of resected colorectal carcinomas, Suppl.1.A65
- How many colorectal cancer patients might benefit from guidelines to improve the management of rectal bleeding? Suppl.1.A50
- Influence of microsomal epoxide hydrolase genetic polymorphisms in colorectal cancer susceptibility, Suppl.1.A78
- Kirsten ras mutations in 2,667 patients with colorectal cancer: results of the RASCAL (RAS Collaborative) project, Suppl.1.A49
- Laparoscopic surgery for colorectal cancer: awaiting the answers, Suppl.1.A50
- Lectins binding is a predictor of poor survival in patients with colorectal carcinoma, Suppl.1.A49
- 'One stop bottom shop' – a rapid access coloproctology service, Suppl.1.A53
- Results of the first 1,000 patients from the pilot study for "one-only" flexible sigmoidoscopy screening for colorectal cancers and polyps, Suppl.1.A57
- Colorectal nurse endoscopist**, The colorectal nurse endoscopist – initial results, Suppl.1.A38
- Colorectal out-patient clinic**, The value of a negative flexible sigmoidoscopy in the surgical colorectal out-patient clinic, Suppl.1.A66
- Colorectal surgery**, Randomized trial of oral sodium phosphate compared with oral sodium picosulphate for elective colorectal surgery, Suppl.1.A54
- Colorectal symptoms**, The frequency and severity of colorectal symptoms in patients during and after pelvic irradiation, Suppl.1.A51
- Colorectal tumours**, Determination of the clonality of colorectal tumours: clues to the origin of human cancer, Suppl.1.A45
- Colostrum**, Bovine colostrum is prophylactic against indomethacin-induced intestinal injury, Suppl.1.A72
- Columnar epithelium**, Prevalence of specialised columnar epithelium at the cardia of patients with gastro-oesophageal reflux without obvious Barrett's oesophagus: comparison with normal, Suppl.1.A36
- Common bile duct**, Laparoscopic exploration of the common bile duct, Suppl.1.A81
- Common bile duct exploration**, Prospective randomised trial of laparoscopic common bile duct exploration versus post-operative ERCP, Suppl.1.A68
- Computerized tomography**
- Comparison of endoanal magnetic resonance imaging and computerized tomography in the preoperative staging of low rectal cancer, Suppl.1.A50
- Correlation between colonoscopy and CT-based virtual reality endoscopy in the detection of space-occupying lesions of the colon, Suppl.1.A83
- Congenital neurological problems**, Under-investigation of folic acid deficiency: a cause of congenital neurological problems and ischaemic heart disease, Suppl.1.A64
- Constipation**
- Biofeedback provides long term benefit for patients with intractable slow and normal transit constipation, Suppl.1.A51
- Women with idiopathic constipation have marked psychological morbidity, altered female self perception, and increased somatization compared with healthy women and Crohn's disease, Suppl.1.A51
- Corpus mucosa**, Regulation of corpus mucosal function in *H. pylori* infected DU patients versus healthy volunteers, Suppl.1.A3
- COX-2 inhibitor**, Intestinal tolerability of the highly specific COX-2 inhibitor nimesulide in the rat, Suppl.1.A71
- Crohn's disease**
- Crohn's disease patients in clinical remission show evidence of ongoing mucosal inflammation, Suppl.1.A23
- Low bone mineral density is related to disease duration in Crohn's disease and to glucocorticoid treatment and male gender in ulcerative colitis, Suppl.1.A26
- Mesenteric marginal ulceration in Crohn's disease: correlation with vascular anatomy and critically-perfused sites, Suppl.1.A24
- Randomised double-blind trial of polymeric versus elemental diet in treatment of active Crohn's disease, Suppl.1.A19
- Social implications of childhood Crohn's disease, Suppl.1.A22
- Women with idiopathic constipation have marked psychological morbidity, altered female self perception, and increased somatization compared with healthy women and Crohn's disease, Suppl.1.A51
- Cyclin D1**, Amplification and overexpression of cyclin D1 in oesophageal carcinoma, Suppl.1.A37
- Cyclooxygenase**
- Immunohistochemical distribution of constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2) in benign and malignant gastric mucosa, Suppl.1.A79
- Role of uncoupling of oxidative phosphorylation and inhibition and cyclooxygenase in the pathogenesis of NSAID-enteropathy in the rat, Suppl.1.A70
- CYP2D6 antibodies**, Detection of anti conformational CYP2D6 antibodies in patients with autoimmune liver disease and HCV infection using a novel radioligand assay, Suppl.1.A15
- Cytokines**
- Cytokine expression and relapse of ulcerative colitis: a prospective study, Suppl.1.A28
- Differential effect of steroids on nitric oxide production by cytokine stimulated HT-29 cells, Suppl.1.A24
- Peripheral blood pro-inflammatory cytokine profile in active inflammatory bowel disease differ between smokers and non-smokers, Suppl.1.A24
- Cytotoxin**, *Clostridium difficile*-associated diarrhoea: antibiotic usage, delay in detection of cytotoxin and failure of protection by metronidazole, Suppl.1.A75
- Dental plaque**, Dental plaque as a reservoir for *Helicobacter pylori*: does immunochemistry answer the question? Suppl.1.A8

Deoxycholic acid

Bile acid metabolising intestinal bacterial enzyme activity: a novel factor in cholesterol gallstone pathogenesis, Suppl.1.A67

In acromegalics with colorectal adenomas or carcinomas, serum deoxycholic acid is increased, Suppl.1.A49

The pathogenesis of octreotide-induced gallbladder stones – prolonged large bowel transit increases deoxycholic acid input rate and pool size, Suppl.1.A66

Depression, Depression and life events in patients referred with gastro-oesophageal reflux symptoms, Suppl.1.A32

Desmoids, MRI appearances of desmoids in familial adenomatous polyposis, Suppl.1.A48

Diabetes, The recto-anal inhibitory reflex: abnormal response in diabetics suggests an intrinsic neuro-enteropathy, Suppl.1.A52

Diarrhoea

Clostridium difficile-associated diarrhoea: antibiotic usage, delay in detection of cytotoxin and failure of protection by metronidazole, Suppl.1.A75

Detection of intraluminal serotonin (5-HT) in patients with HIV-related diarrhoea, Suppl.1.A9

Synergism between mediators of Cl⁻ secretion in native rat colon: comparisons with colonic cell lines and implications for diarrhoea, Suppl.1.A81

Diet, Rapid colonic fermentation is associated with symptoms in IBS and corrected by exclusion diet, Suppl.1.A19

Digital examination, Accuracy of digital examination, endoanal ultrasound and concentric needle electromyography in detecting anal sphincter, Suppl.1.A54

Disaccharide, Small bowel juice disaccharide activity in the pre-term infant, Suppl.1.A20

Duodenal ulcer disease

Factors associated with *H. pylori* infection and duodenal ulcers in patients attending endoscopy, Suppl.1.A6

H. pylori eradication in duodenal ulcer disease: what determines cost effectiveness? Suppl.1.A58

H. pylori eradication therapy compared with ranitidine maintenance therapy in patients with chronic duodenal ulcer disease: a prospective pharmacoeconomic evaluation, Suppl.1.A5

Improving the long term management of bleeding duodenal ulcer, Suppl.1.A62

Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users—the OMNIUM study, journal 797

Regulation of corpus mucosal function in *H. pylori* infected DU patients versus healthy volunteers, Suppl.1.A3

Duodenogastro-oesophageal reflux, Simultaneous ambulatory oesophageal motility and duodenogastro-oesophageal reflux, Suppl.1.A32

Dyspepsia

Bacterial CagA status is unrelated to gastric function indexes or to the type either severity of symptoms in patients with *H. pylori*-positive non-ulcer dyspepsia, Suppl.1.A7

Differences in diagnostic yield of upper gastrointestinal endoscopy in dyspeptic patients on proton pump inhibitors and H2 receptor antagonists, Suppl.1.A60

Dyspepsia and irritable bowel syndrome in the community, Suppl.1.A61

Gastric arrhythmias in the functional bowel disorders, Suppl.1.A42

Is it possible to diagnose dyspepsia accurately in general practice? Suppl.1.A60

One year follow-up of a randomised trial of pre endoscopy screening for *H. pylori* in the management of dyspepsia, Suppl.1.A2

Primary care dyspepsia management in the *Helicobacter pylori* era, Suppl.1.A58

Ranitidine treatment induces dyspepsia in previously asymptomatic healthy volunteers, Suppl.1.A3

Value of the Helisal test in screening dyspeptic patients for *H. pylori* infection, Suppl.1.A2

Dysphagia, Does prior radio- and/or chemotherapy predispose to complications after intubation for malignant oesophago-gastric obstruction, Suppl.1.A38

Dysplasia, Altered cadherins and catenins expressed in the Barrett's oesophagus, dysplasia, adenocarcinoma sequence, Suppl.1.A76

E-selectin, Effects of nicotine on E-selectin expression in intestinal tissue biopsies in inflammatory bowel disease patients and controls, Suppl.1.A74

Echoendoscope, Introduction of the 8mm diameter echoendoscope in the staging of oesophageal cancer, Suppl.1.A57

Elderly, Use of self expandable stents in the treatment of benign peptic oesophageal strictures in the elderly, Suppl.1.A1

Electromyography, Accuracy of digital examination, endoanal ultrasound and concentric needle electromyography in detecting anal sphincter, Suppl.1.A54

Elemental diet, Randomised double-blind trial of polymeric versus elemental diet in treatment of active Crohn's disease, Suppl.1.A19

Endocytic pathways, Characterisation of endocytic pathways in human oesophagus, Suppl.1.A77

Endoscopic biopsy, Sensitive quantification of gut epithelial neutral endopeptidase expression using a flow cytometric double-staining technique and endoscopic biopsy, Suppl.1.A73

Endoscopic ligation, A prospective study of Speedband versus Steigmann-Goff in endoscopic ligation of oesophageal varices, Suppl.1.A15

Endoscopic mucosal resection, Tools, technique and pitfalls of endoscopic mucosal resection, Suppl.1.A83

Endoscopy, Suppl.1.A38-41, Suppl.1.A56-57

Ben's endoscopy, Suppl.1.A82

Factors associated with *H. pylori* infection and duodenal ulcers in patients attending endoscopy, Suppl.1.A6

Selection for endoscopy using *H. pylori* serology should not be restricted to under 45's, Suppl.1.A58

Endothelin levels, Low tissue endothelin levels in inflammatory bowel disease, despite enhanced ET-2 gene expression, Suppl.1.A26

Enteric dysmotility, The spectrum of enteric dysmotility revealed by prolonged small bowel manometry, Suppl.1.A41

Enterochromaffin, The proliferative status of enterochromaffin-like cells in the gastric mucosa: the plot thickens, Suppl.1.A2

Enterocyte suspensions, Manipulation of extracellular sodium, potassium and amiloride modulates iron uptake by human enterocyte suspensions *in vitro*, Suppl.1.A80

Epigastric pain, Gastric emptying and gastrointestinal regulatory peptides in children with recurrent epigastric pain, Suppl.1.A43

Epithelial cell-lines, Presence of a fMLP-receptor, stimulation of mucin synthesis and release of IL-8 by fMLP in human mucus-secreting gastrointestinal epithelial cell-lines, Suppl.1.A81

Epithelial regeneration, Mechanisms of carcinogenesis associated with intestinal epithelial regeneration, Suppl.1.A45

Epithelium, Dietary calcium supplementation and apoptosis in murine colonic epithelium, Suppl.1.A46

Epoxyde hydrolases, The influence of microsomal epoxyde hydrolase genetic polymorphisms in colorectal cancer susceptibility, Suppl.1.A78

ERCP, Prospective randomised trial of laparoscopic common bile duct exploration versus post-operative ERCP, Suppl.1.A68

Erosions, Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users—the OMNIUM study, journal 797

Escherichia coli, Absence of *E. coli*, *Listeria* and *Klebsiella pneumoniae* antigens within inflammatory bowel disease tissues, Suppl.1.A25

Essential fatty acid supplementation, Double-blind, placebo controlled trial to determine the efficacy of essential fatty acid supplementation in the treatment of ulcerative colitis, Suppl.1.A22

Essential fatty acids, A randomised controlled trial of essential fatty acids in acute ulcerative colitis, Suppl.1.A23

ET-2 gene expression, Low tissue endothelin levels in inflammatory bowel disease, despite enhanced ET-2 gene expression, Suppl.1.A26

Exclusion diet, Rapid colonic fermentation is associated with symptoms in IBS and corrected by exclusion diet, Suppl.1.A19

Faecal incontinence

Continent colonic conduit for faecal incontinence and rectal evacuatory disorders, Suppl.1.A55

GAX collagen injections: a novel treatment of faecal incontinence, Suppl.1.A52

Primary internal anal sphincter degeneration – a newly recognised cause of passive faecal incontinence, Suppl.1.A53

Randomized trial of faecal diversion in sphincter repair, Suppl.1.A55

Sacral nerve stimulation for faecal incontinence: evaluation of short term efficacy and effect on anorectal function, Suppl.1.A53

Faecal occult blood, High prevalence of undetected inflammatory bowel disease: data from the Nottingham Faecal Occult Blood screening trial, Suppl.1.A21

Faecal sulphide excretion, The contribution of dietary protein from meat to faecal sulphide excretion, Suppl.1.A27

Familial adenomatous polyposis

APC in the regulation of intestinal crypt fission, Suppl.1.A45

MRI appearances of desmoids in familial adenomatous polyposis, Suppl.1.A48

Fascin, Transforming growth factor- α increases E-cadherin and β -catenin binding to the actin-bundling protein fascin, Suppl.1.A76

- Fermentable carbohydrate**, Effects of fermentable carbohydrate on plasma PYY levels in human subjects, Suppl.1.A73
- Filament cytoskeleton**, Organization of the intermediate filament cytoskeleton in human intestinal M cells, Suppl.1.A72
- Flexible sigmoidoscopy**
Open-access flexible sigmoidoscopy for rectal bleeding, Suppl.1.A66
Results of the first 1,000 patients from the pilot study for “once-only” flexible sigmoidoscopy screening for colorectal cancers and polyps, Suppl.1.A57
The value of a negative flexible sigmoidoscopy in the surgical colorectal out-patient clinic, Suppl.1.A66
- Flow cytometry**
Clinical outcome and flow cytometric IgG crossmatch in liver transplantation, Suppl.1.A18
Sensitive quantification of gut epithelial neutral endopeptidase expression using a flow cytometric double-staining technique and endoscopic biopsy, Suppl.1.A73
- 5-Fluorouracil**, The importance of apoptosis in the gastrointestinal toxicity induced by 5-fluorouracil: rescue from toxicity in p53^{-/-} mice, Suppl.1.A79
- Folic acid deficiency**, Under-investigation of folic acid deficiency: a cause of congenital neurological problems and ischaemic heart disease, Suppl.1.A64
- Gallbladder**, “Routine” pathological examination of the gallbladder is a futile exercise, Suppl.1.A63
- Gallbladder smooth muscle**, ATP sensitive potassium channels in human gallbladder smooth muscle, Suppl.1.A66
- Gallbladder stones**
Bile acid metabolising intestinal bacterial enzyme activity: a novel factor in cholesterol gallstone pathogenesis, Suppl.1.A67
The pathogenesis of octreotide-induced gallbladder stones – prolonged large bowel transit increases deoxycholic acid input rate and pool size, Suppl.1.A66
- Gallstones**, Pathological gastroesophageal reflux in patients with a gallbladder *in situ* and small gallstones, Suppl.1.A33
- Gamma-irradiation**, Immunohistochemical localisation of p21WAF1/CIP1 in the small intestine of BDF1 and p53^{-/-} (null) mice following gamma-irradiation, Suppl.1.A78
- Gastric acid secretion**
Degree of suppression of gastric acid secretion by omeprazole is related to *H. pylori* status, Suppl.1.A1
The effects of N methylhistamine on gastric acid secretion in human volunteers, Suppl.1.A1
- Gastric adenocarcinoma**
Hypergastrinaemia is a strong predictor of distal gastric adenocarcinoma among *Helicobacter pylori* infected persons, Suppl.1.A46
Virulent *Helicobacter pylori* in patients with gastric and oesophageal adenocarcinoma, Suppl.1.A2
- Gastric arrhythmias**, Gastric arrhythmias in the functional bowel disorders, Suppl.1.A42
- Gastric atrophy**, CagA status is associated with serum IgA antibodies to 60kDa heat shock proteins in *H. pylori*-associated gastric atrophy, Suppl.1.A69
- Gastric cancer (carcinoma)**
Adenocarcinoma of the lower oesophagus and cardia are similar both epidemiologically and clinically: a population based study from 1974 to 1993, Suppl.1.A37
H. pylori induced hypochlorhydria is associated with increased risk of gastric cancer, Suppl.1.A83
Prospective randomised controlled study of the use of ranitidine in patients with gastric cancer, Suppl.1.A41
- Gastric emptying**
Gastric emptying and gastrointestinal regulatory peptides in children with recurrent epigastric pain, Suppl.1.A43
Gastric emptying in human immunodeficiency virus infected individuals: relationship to symptoms, autonomic function and gastrointestinal pathogens, Suppl.1.A44
- Gastric flora**, Postoperative septic morbidity is related to severity of illness at presentation and to preoperative colonisation of the proximal gastrointestinal tract, Suppl.1.A70
- Gastric leiomyomas**, A new minimally invasive surgical technique for gastric leiomyomas, Suppl.1.A8
- Gastric mucosa**
Immunohistochemical distribution of constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2) in benign and malignant gastric mucosa, Suppl.1.A79
Proliferative status of enterochromaffin-like cells in the gastric mucosa: the plot thickens, Suppl.1.A2
Semi-quantitative analysis of chemokine mRNA expression in gastric mucosa and its relation to the severity of gastritis, Suppl.1.A70
- Gastric tumours**, Prediction of resectability of gastric tumours using endoscopic ultrasound, Suppl.1.A41
- Gastric ulcer disease**
Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users—the OMNIUM study, journal 797
The natural history of non-NSAID gastric ulcer disease following *H. pylori* eradication: a one year follow-up study in the African setting, Suppl.1.A4
Ulcer development in long term NSAID users in the presence or absence of gastric neutrophils. A double-blind placebo-controlled study, Suppl.1.A4
- Gastrin**, Regulation of corpus mucosal function in *H. pylori* infected DU patients versus healthy volunteers, Suppl.1.A3
- Gastritis**, Semi-quantitative analysis of chemokine mRNA expression in gastric mucosa and its relation to the severity of gastritis, Suppl.1.A70
- Gastro-oesophageal reflux**
Depression and life events in patients referred with gastro-oesophageal reflux symptoms, Suppl.1.A32
Endoscopic gastroplasty for gastro-oesophageal reflux disease, Suppl.1.A34
Gastro-oesophageal reflux as a complication of achalasia therapy, Suppl.1.A34
Gastro-oesophageal reflux in patients fed by percutaneous endoscopic gastrostomy – scintigraphic detection, Suppl.1.A20
Impact of breast feeding, atopy and other factors on the prevalence of gastro-oesophageal reflux, Suppl.1.A33
Is *H. pylori* protective against gastro-oesophageal reflux disease? Suppl.1.A33
Long term objective follow up after laparoscopic fundoplication in patients with refractory gastro-oesophageal reflux disease, Suppl.1.A35
Loxiglumide inhibits post-prandial transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease, Suppl.1.A32
Pathological gastroesophageal reflux in patients with a gallbladder *in situ* and small gallstones, Suppl.1.A33
Prevalence of specialised columnar epithelium at the cardia of patients with gastro-oesophageal reflux without obvious Barrett’s oesophagus: a comparison with normal, Suppl.1.A36
Reflux symptoms in the long term follow up of patients after *Helicobacter pylori* eradication, Suppl.1.A3
- Gastrointestinal endoscopy**, Total intravenous anaesthesia in paediatric gastrointestinal endoscopy, Suppl.1.A41
- Gastrointestinal malignancies**, Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Suppl.1.A19
- Gastrointestinal regulatory peptides**, Gastric emptying and gastrointestinal regulatory peptides in children with recurrent epigastric pain, Suppl.1.A43
- Gastroscopy**
Effective use of video education in patients undergoing gastroscopy, Suppl.1.A56
Gastroscopy – a patient’s guide, Suppl.1.A82
- GAX collagen**, GAX collagen injections: a novel treatment for faecal incontinence, Suppl.1.A52
- Gender differences**, Gender differences and reproducibility of whole gut visceral sensitivity, Suppl.1.A43
- Gene mutations**, Gene mutations in the plasma of patients with pancreatic cancer, Suppl.1.A77
- General practice**
An audit of the use of long-term acid suppressants in general practice: potential for large savings, Suppl.1.A60
H2 receptor antagonists and proton pump inhibitors in general practice: prescribing trends in the UK from 1991 to 1996, Suppl.1.A60
Is it possible to diagnose dyspepsia accurately in general practice? Suppl.1.A60
- Genomic instability**, An alternative method for the detection of genomic instability in colorectal cancers, Suppl.1.A78
- GLP-1**, Effects of fermentable carbohydrate on plasma PYY levels in human subjects, Suppl.1.A73
- Glutathione-S-transferase**, Serum glutathione-S-transferase in acute liver allograft rejection, Suppl.1.A17
- Granulocyte apheresis**, Treatment of refractory inflammatory bowel disease with granulocyte apheresis, Suppl.1.A22
- Growth failure**, Growth failure in inflammatory bowel disease, Suppl.1.A27
- Gut visceral sensitivity**, Gender differences and reproducibility of whole gut visceral sensitivity, Suppl.1.A43
- H2 receptor antagonists**
Differences in diagnostic yield of upper gastrointestinal endoscopy in dyspeptic patients on proton pump inhibitors and H2 receptor antagonists, Suppl.1.A60

- H2 receptor antagonists and proton pump inhibitors in general practice: prescribing trends in the UK from 1991 to 1996, Suppl.1.A60
- Haemochromatosis**, Liver function tests and liver damage in haemochromatosis, Suppl.1.A13
- Haemophilia**, Outcome of orthotopic liver transplantation in haemophilia, Suppl.1.A17
- Heat shock protein antibodies**, IgG, IgM, IgA heat shock protein antibodies in primary biliary cirrhosis: effect of UDCA therapy, Suppl.1.A14
- Heat shock proteins**, CagA status is associated with serum IgA antibodies to 60kDa heat shock proteins in *H. pylori*-associated gastric atrophy, Suppl.1.A69
- Helicobacter pylori**
- Adult social class as an independent risk factor for *H. pylori*, Suppl.1.A69
- Bacterial CagA status is unrelated to gastric function indexes or to the type either severity of symptoms in patients with *H. pylori*-positive non-ulcer dyspepsia, Suppl.1.A7
- CagA status is associated with serum IgA antibodies to 60kDa heat shock proteins in *H. pylori*-associated gastric atrophy, Suppl.1.A69
- CLO-testing for *H. pylori*: are we missing positive results? Suppl.1.A59
- Culturing *H. pylori* from gastric aspirates: the effect of acid *in vivo* and *in vitro*, Suppl.1.A7
- Degree of suppression of gastric acid secretion by omeprazole is related to *H. pylori* status, Suppl.1.A1
- Dental plaque as a reservoir for *H. pylori*: does immunochemistry answer the question? Suppl.1.A8
- Detection of *H. pylori* from GI secretions using PCR, Suppl.1.A7
- Effect of *H. pylori*, aspirin and anoxia on antibiotic permeability in the rat stomach, Suppl.1.A6
- Factors associated with *H. pylori* infection and duodenal ulcers in patients attending endoscopy, Suppl.1.A6
- H. pylori*: a test and treat strategy in primary care, Suppl.1.A58
- H. pylori* eradication in duodenal ulcer disease: what determines cost effectiveness? Suppl.1.A58
- H. pylori* eradication therapy compared with ranitidine maintenance therapy in patients with chronic duodenal ulcer disease: a prospective pharmacoeconomic evaluation, Suppl.1.A5
- H. pylori*-induced hypergastrinaemia is related to bacterial CagA status, Suppl.1.A46
- H. pylori* induced hypochlorhydria is associated with increased risk of gastric cancer, Suppl.1.A83
- H. pylori* induction of IL-8 synthesis in gastric epithelial cells depends on genes throughout the *cag* pathogenicity island, Suppl.1.A69
- Hypergastrinaemia is a strong predictor of distal gastric adenocarcinoma among *H. pylori* infected persons, Suppl.1.A46
- Influence of siblings on risk of *H. pylori* infection, Suppl.1.A68
- Is *H. pylori* protective against gastro-oesophageal reflux disease? Suppl.1.A33
- Marked rebound acid hypersecretion following omeprazole therapy in *H. pylori* negative subjects, Suppl.1.A3
- Motilities of ulcer and non-ulcer associated strains of *H. pylori*, Suppl.1.A6
- Natural history of non-NSAID gastric ulcer disease following *H. pylori* eradication: a one year follow-up study in the African setting, Suppl.1.A4
- New, internationally applicable, polymerase chain reaction-based typing of *H. pylori vacA*, Suppl.1.A1
- Non-steroidal anti-inflammatory drugs and *H. pylori* as independent risk factors for peptic ulcer bleeding, Suppl.1.A4
- One year follow-up of a randomised trial of pre endoscopy screening for *H. pylori* in the management of dyspepsia, Suppl.1.A2
- Optimum 5 day therapy against *H. pylori*, Suppl.1.A5
- Primary care dyspepsia management in the *H. pylori* era, Suppl.1.A58
- Prolonged acid suppression therapy and proximal migration of *H. pylori*, Suppl.1.A7
- Ranitidine bismuth citrate plus clarithromycin and tetracycline: a seven-day *H. pylori* eradication regimen, Suppl.1.A5
- Reflux symptoms in the long term follow up of patients after *H. pylori* eradication, Suppl.1.A3
- Regulation of corpus mucosal function in *H. pylori* infected DU patients versus healthy volunteers, Suppl.1.A3
- Relationship between mucosal production of reactive oxygen metabolites and toxinogenicity of *H. pylori*, Suppl.1.A69
- Resistance of *H. pylori* to metronidazole: an imaginary problem? Suppl.1.A5
- Role of *H. pylori* in gastric adaptation to repeated aspirin administration in man, Suppl.1.A6
- Selection for endoscopy using *H. pylori* serology should not be restricted to under 45's, Suppl.1.A58
- Value of the Helisal test in screening dyspeptic patients for *H. pylori* infection, Suppl.1.A2
- Virulent *H. pylori* in patients with gastric and oesophageal adenocarcinoma, Suppl.1.A2
- Helisal test**, Value of the Helisal test in screening dyspeptic patients for *H. pylori* infection, Suppl.1.A2
- Hepatitis**, Interpretation of a hepatic biochemical picture, Suppl.1.A62
- Hepatitis C**
- Availability and usage of interferon alfa for treating chronic hepatitis C in the UK, Suppl.1.A63
- Beneficial *in vitro* effects of tucaresol on the immune response to hepatitis C virus, Suppl.1.A30
- Detection of anti conformational CYP2D6 antibodies in patients with autoimmune liver disease and HCV infection using a novel radioligand assay, Suppl.1.A15
- Findings on liver biopsy for abnormal liver function tests in the post hepatitis C testing era, Suppl.1.A13
- Impact of chronic hepatitis C infection on HIV disease and progression in intravenous drug abusers, Suppl.1.A16
- Interferon sparing effect of adjuvant tauro-ursodeoxycholic acid for treatment of chronic hepatitis C: results on liver histology, Suppl.1.A16
- Lower prevalence of markers of autoimmunity in chronic hepatitis C in north-east of England, Suppl.1.A16
- Plasma TIMP-1 levels increase with severity of liver disease in chronic hepatitis C, Suppl.1.A16
- Hepatocyte cell lines**, Proliferating hepatocyte cell lines condition their extracellular environment whilst developing three dimensional configuration in a hollow fibre cartridge, Suppl.1.A30
- Histamine-2 receptor antagonists**, Audit of the use of anti-secretory drugs, Suppl.1.A59
- HIV**, Gastric emptying in human immunodeficiency virus infected individuals: relationship to symptoms, autonomic function and gastrointestinal pathogens, Suppl.1.A44
- HIV-related diarrhoea**, Detection of intraluminal serotonin (5-HT) in patients with HIV-related diarrhoea, Suppl.1.A9
- Hormone replacement therapy**, The effect of hormone replacement therapy on serum and urinary markers of bone turnover in primary biliary cirrhosis, Suppl.1.A13
- Hot biopsy**, Distribution and histology of diminutive colonic polyps removed by hot biopsy, Suppl.1.A47
- HT-29 cells**
- Cytotoxic effects of nitric oxide on HT29 colonic epithelial cells, Suppl.1.A75
- Differential effect of steroids on nitric oxide production by cytokine stimulated HT-29 cells, Suppl.1.A24
- Hydrogen sulphide**, Mechanisms for detoxifying hydrogen sulphide in the gastrointestinal tract, Suppl.1.A27
- Hypergastrinaemia**
- H. pylori*-induced hypergastrinaemia is related to bacterial CagA status, Suppl.1.A46
- Hypergastrinaemia is a strong predictor of distal gastric adenocarcinoma among *Helicobacter pylori* infected persons, Suppl.1.A46
- Hypochlorhydria**, *H. pylori* induced hypochlorhydria is associated with increased risk of gastric cancer, Suppl.1.A83
- IgA antibodies**, CagA status is associated with serum IgA antibodies to 60kDa heat shock proteins in *H. pylori*-associated gastric atrophy, Suppl.1.A69
- Ileoanal pouches**, Whole gut lavage inflammatory parameters in recently constructed ileoanal pouches, Suppl.1.A55
- Immunochemistry**, Dental plaque as a reservoir for *Helicobacter pylori*: does immunochemistry answer the question? Suppl.1.A8
- Immunosuppressive therapy**, Immunosuppressive therapy for ulcerative colitis – a survey of the practice of British gastroenterologists, Suppl.1.A65
- 111 Indium white cells**, Faecal calprotectin: a suitable, sensitive, alternative to 111 indium labelled white cells for assessing intestinal inflammation in man, Suppl.1.A73
- Indomethacin-induced blood stasis**, Reversal of and protection against indomethacin-induced blood stasis and mucosal damage by a β -agonist in rat villi, Suppl.1.A71
- Indomethacin-induced histological changes**, Slowing of villous blood flow and focal microvascular distortion precede early indomethacin-induced histological changes, Suppl.1.A71
- Indomethacin-induced intestinal injury**, Bovine colostrum is prophylactic against indomethacin-induced intestinal injury, Suppl.1.A72
- Indomethacin-induced ulceration**, Critically-perfused sites in the rat jejunum are susceptible to indomethacin-induced ulceration: a role for ischaemia-reperfusion injury, Suppl.1.A71
- Inflammatory bowel disease**, Suppl.1.A21–28
- Effects of nicotine on E-selectin expression in intestinal tissue biopsies in inflammatory bowel disease patients and controls, Suppl.1.A74

- In inflammatory bowel disease IL-8 production and tissue expression is modulated by nicotine and crude tobacco extract, Suppl.1.A74
- Serum leptin in inflammatory bowel disease: implications for the pathogenesis of anorexia and weight loss, Suppl.1.A19
- Information**, Are we telling patients enough? Suppl.1.A57
- Insulin independence**, Insulin independence following combined total pancreatectomy and islet autotransplantation, Suppl.1.A11
- Integrins**
- Expression of $\alpha 5$ (CD49e) and $\alpha 6$ (CD49f) integrins on human colonic lamina propria T cells, Suppl.1.A73
- Expression of integrin $\alpha 4\beta 7$ on circulating lymphocytes in inflammatory bowel disease, Suppl.1.A25
- Interferon**, Interferon sparing effect of adjuvant tauro-ursodeoxycholic acid for treatment of chronic hepatitis C: results on liver histology, Suppl.1.A16
- Interferon alfa**, Availability and usage of interferon alfa for treating chronic hepatitis C in the UK, Suppl.1.A63
- Interleukin-8**
- Helicobacter pylori* induction of IL-8 synthesis in gastric epithelial cells depends on genes throughout the *cag* pathogenicity island, Suppl.1.A69
- Human colonic epithelial cells down-regulate IL-8 expression in human microvascular endothelial cells: role of TGF- β , Suppl.1.A72
- In inflammatory bowel disease IL-8 production and tissue expression is modulated by nicotine and crude tobacco extract, Suppl.1.A74
- Inhibition of isolated rabbit parietal cells by interleukin-8, Suppl.1.A70
- Presence of a fMLP-receptor, stimulation of mucin synthesis and release of IL-8 by fMLP in human mucus-secreting gastrointestinal epithelial cell-lines, Suppl.1.A81
- Interleukins**, IL-4, IL-10 and IL-13 reveal strong capacity to down-regulate MCP-1 and GM-CSF in activated intestinal epithelial cells, Suppl.1.A74
- Interlink**, The use of a connection device reduces the cost of cyclical parenteral nutrition, Suppl.1.A63
- Interstitial cells of Cajal**, Interstitial cells of Cajal in the human colon: regional density variations, Suppl.1.A43
- Intestinal crypt fission**, APC in the regulation of intestinal crypt fission, Suppl.1.A45
- Intestinal epithelial cells**, IL-4, IL-10 and IL-13 reveal strong capacity to down-regulate MCP-1 and GM-CSF in activated intestinal epithelial cells, Suppl.1.A74
- Intestinal inflammation**, Faecal calprotectin: a suitable, sensitive, alternative to ¹¹¹indium labelled white cells for assessing intestinal inflammation in man, Suppl.1.A73
- Intestinal mucosa**, CD4+ T cell downregulation in the intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens, Suppl.1.A75
- Intestinal obstruction**, Histological phenotyping of enteric smooth muscle disease causing functional intestinal obstruction in childhood, Suppl.1.A42
- Intestinal trefoil factor**, Intestinal trefoil factor regulates the expression of E-cadherin, catenins and the adenomatous polyposis coli tumour suppressor protein, Suppl.1.A48
- Intraluminal serotonin**, Detection of intraluminal serotonin (5-HT) in patients with HIV-related diarrhoea, Suppl.1.A9
- Intravenous drug abusers**, The impact of chronic hepatitis C infection on HIV disease and progression in intravenous drug abusers, Suppl.1.A16
- Iodised oil**
- In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers, Suppl.1.A47
- Quantification of uptake and retention of iodised oil (lipiodol) in primary and secondary hepatic malignancy, Suppl.1.A47
- Iron deficiency anaemia**, Elevated nitric oxide synthase activity in human duodenal enterocytes in iron deficiency anaemia and coeliac disease, Suppl.1.A80
- Iron uptake**, Manipulation of extracellular sodium, potassium and amiloride modulates iron uptake by human enterocyte suspensions *in vitro*, Suppl.1.A80
- Irritable bowel syndrome**
- Alosetron slows colonic transit in patients with irritable bowel syndrome, Suppl.1.A44
- Dosed relaxation in resistant irritable bowel syndrome using gut directed biofeedback, Suppl.1.A51
- Dyspepsia and irritable bowel syndrome in the community, Suppl.1.A61
- Gastric arrhythmias in the functional bowel disorders, Suppl.1.A42
- High prevalence of irritable bowel syndrome in patients attending urological outpatient departments, Suppl.1.A65
- Menstrual cycle affects rectal visceral sensitivity in patients with irritable bowel syndrome but not healthy volunteers, Suppl.1.A52
- Quality of life in irritable bowel syndrome: does it improve with resolution of symptoms? Suppl.1.A64
- Rapid colonic fermentation is associated with symptoms in IBS and corrected by exclusion diet, Suppl.1.A19
- Rate of spontaneous swallowing and improvement with exclusion diet in irritable bowel syndrome, Suppl.1.A64
- Ischaemia-reperfusion injury**
- Critically-perfused sites in the rat jejunum are susceptible to indomethacin-induced ulceration: a role for ischaemia-reperfusion injury, Suppl.1.A71
- Ischaemia-reperfusion injury following syngeneic small bowel transplantation induces apoptosis, Suppl.1.A10
- Ischaemic heart disease**, Under-investigation of folic acid deficiency: a cause of congenital neurological problems and ischaemic heart disease, Suppl.1.A64
- Islet autotransplantation**, Insulin independence following combined total pancreatectomy and islet autotransplantation, Suppl.1.A11
- Jaundice**, Jaundice associated with augmentin: the tip of the iceberg? Suppl.1.A13
- K-ras mutations**
- Detection of K-ras mutations in faecal samples from colorectal cancer patients by SSCP analysis, Suppl.1.A48
- Kirsten ras mutations in 2,667 patients with colorectal cancer: results of the RASCAL (RAS Collaborative) project, Suppl.1.A49
- Keratinocyte growth factor**, Keratinocyte growth factor stimulates gut growth but is not a cytoprotective agent and does not stimulate migration of the human colonic carcinoma cell line HT29, Suppl.1.A79
- Ki-67**, Aberrant expression of p53 and Ki-67 during acute and chronic rejection following orthotopic liver transplantation, Suppl.1.A17
- Kirsten ras point mutations**, Effective targeting of colorectal cancer *Kirsten ras* point mutations with antisense therapy *in vitro*, Suppl.1.A45
- Klebsiella pneumoniae**
- Absence of *E. coli*, *Listeria* and *Klebsiella pneumoniae* antigens within inflammatory bowel disease tissues, Suppl.1.A25
- The immune response to *Klebsiella pneumoniae* in inflammatory bowel disease and ankylosing spondylitis, Suppl.1.A25
- Lansoprazole**, Endoscopic stigmata, acid suppression, quality of life and death from upper gastrointestinal bleeding, Suppl.1.A61
- Laparoscopic anti-reflux surgery**, Another view on laparoscopic anti-reflux surgery, Suppl.1.A35
- Laparoscopic fundoplication**, Long term objective follow up after laparoscopic fundoplication in patients with refractory gastro-oesophageal reflux disease, Suppl.1.A35
- Laparoscopic surgery**, Laparoscopic surgery for colorectal cancer: awaiting the answers, Suppl.1.A50
- Laparoscopy**
- Laparoscopic exploration of the common bile duct, Suppl.1.A81
- Prospective randomised trial of laparoscopic common bile duct exploration versus post-operative ERCP, Suppl.1.A68
- Laser Doppler mucosal flowmetry**, Laser Doppler mucosal flowmetry – the first direct measure of the level of activation of extrinsic nerves to the gut, Suppl.1.A52
- Lectins**
- Broad bean and wheat germ lectins increase cell adhesion and differentiation of colonic cancer cell lines, Suppl.1.A46
- Lectins binding is a predictor of poor survival in patients with colorectal carcinoma, Suppl.1.A49
- Soybean lectin stimulates cholecystokinin release through calcium influx via L-type calcium channels, Suppl.1.A81
- Left colon**, Limited exposure of left colon to daily dosed oral formulation in active distal ulcerative colitis: explanation of poor response to treatment? Suppl.1.A28
- Leiomyomas**, A new minimally invasive surgical technique for gastric leiomyomas, Suppl.1.A8
- Leptin**, Serum leptin in inflammatory bowel disease: implications for the pathogenesis of anorexia and weight loss, Suppl.1.A19
- Lexipafant**, Lexipafant, a platelet activation factor antagonist, reduces mortality in a randomised placebo-controlled study in patients with severe acute pancreatitis, Suppl.1.A12
- Lipiodol**
- In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers, Suppl.1.A47
- Quantification of uptake and retention of iodised oil (lipiodol) in primary and secondary hepatic malignancy, Suppl.1.A47

- Lipopolysaccharide**, Bactericidal/permeability-increasing protein blocks lipopolysaccharide-induced procoagulant activity of endothelial cells, Suppl.1.A72
- Listeria**, Absence of *E. coli*, *Listeria* and *Klebsiella pneumoniae* antigens within inflammatory bowel disease tissues, Suppl.1.A25
- Liver allograft rejection**, Serum glutathione-S-transferase in acute liver allograft rejection, Suppl.1.A17
- Liver biopsy**, Findings on liver biopsy for abnormal liver function tests in the post hepatitis C testing era, Suppl.1.A13
- Liver cancers**, In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers, Suppl.1.A47
- Liver disease**, Suppl.1.A12-18, Suppl.1.A29-30
- Liver fibrosis**, Effect of abrupt alcohol withdrawal on liver transaminases and markers of liver fibrosis, Suppl.1.A18
- Liver function tests**
Are abnormal liver function tests properly investigated in general practice? Suppl.1.A62
Effect of abrupt alcohol withdrawal on liver transaminases and markers of liver fibrosis, Suppl.1.A18
Findings on liver biopsy for abnormal liver function tests in the post hepatitis C testing era, Suppl.1.A13
Liver function tests and liver damage in haemochromatosis, Suppl.1.A13
- Liver malignancy**, Quantification of uptake and retention of iodised oil (lipiodol) in primary and secondary hepatic malignancy, Suppl.1.A47
- Liver transplantation**
Aberrant expression of p53 and Ki-67 during acute and chronic rejection following orthotopic liver transplantation, Suppl.1.A17
Auxiliary liver transplantation for metabolic diseases, Suppl.1.A18
Clinical outcome and flow cytometric IgG crossmatch in liver transplantation, Suppl.1.A18
Graft dysfunction associated with autoimmunity in paediatric liver transplantation, Suppl.1.A17
Long-term survival and alcohol relapse after liver transplantation for alcoholic liver disease, Suppl.1.A18
Outcome of orthotopic liver transplantation in haemophilia, Suppl.1.A17
- Loop ileostomies**, Randomized controlled trial of stapled versus sutured closure of loop ileostomies, Suppl.1.A54
- Lower oesophageal sphincter relaxations**, Loxiglumide inhibits post-prandial transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease, Suppl.1.A32
- Loxiglumide**, Loxiglumide inhibits post-prandial transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease, Suppl.1.A32
- Luminal bacterial antigens**, CD4+ T cell downregulation in the intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens, Suppl.1.A75
- Lymphocytes**, Expression of integrin $\alpha 4\beta 7$ on circulating lymphocytes in inflammatory bowel disease, Suppl.1.A25
- M cells**, Organization of the intermediate filament cytoskeleton in human intestinal M cells, Suppl.1.A72
- Magnetic resonance cholangiography**, Magnetic resonance cholangiography in obstructive jaundice, Suppl.1.A67
- Magnetic resonance imaging**, Comparison of endoanal magnetic resonance imaging and computerized tomography in the pre-operative staging of low rectal cancer, Suppl.1.A50
- Male gender**, Low bone mineral density is related to disease duration in Crohn's disease and to glucocorticoid treatment and male gender in ulcerative colitis, Suppl.1.A26
- Manometry**
Biliary manometry in AIDS related cholangitis: relationship to symptoms and radiological findings, Suppl.1.A67
Novel method for 24 hour pancolonic ambulatory manometry, Suppl.1.A42
The spectrum of enteric dysmotility revealed by prolonged small bowel manometry, Suppl.1.A41
- Measles RNA**, Hybrid capture followed by RT-PCR does not detect measles RNA in intestinal tissue, Suppl.1.A28
- Meat**, The contribution of dietary protein from meat to faecal sulphide excretion, Suppl.1.A27
- Meloxicam**, Low gastrointestinal toxicity of meloxicam, a selective inhibitor of the inducible cyclooxygenase (COX-2) enzyme, Suppl.1.A4
- Menstrual cycle**, The menstrual cycle affects rectal visceral sensitivity in patients with irritable bowel syndrome but not healthy volunteers, Suppl.1.A52
- Mesenteric marginal ulceration**, Mesenteric marginal ulceration in Crohn's disease: correlation with vascular anatomy and critically-perfused sites, Suppl.1.A24
- Metabolic diseases**, Auxiliary liver transplantation for metabolic diseases, Suppl.1.A18
- Metronidazole**
Clostridium difficile-associated diarrhoea: antibiotic usage, delay in detection of cytotoxin and failure of protection by metronidazole, Suppl.1.A75
Resistance of *Helicobacter pylori* to metronidazole: an imaginary problem? Suppl.1.A5
- Misoprostol**, Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users—the OMNIUM study, journal 797
- Monocyte-hepatoma cell adhesion**, Production of angiogenic and chemoattractant chemokines during monocyte-hepatoma cell adhesion, Suppl.1.A29
- Mortality**, Mortality in inflammatory bowel disease: the case for a national confidential enquiry, Suppl.1.A21
- Motility**, Suppl.1.A41-44
Motilities of ulcer and non-ulcer associated strains of *Helicobacter pylori*, Suppl.1.A6
- Mucosal drug levels**, Mucosal aminosalicylate levels correlate with clinical activity in patients with ulcerative colitis, Suppl.1.A23
- Mucosal inflammation**, Crohn's disease patients in clinical remission show evidence of ongoing mucosal inflammation, Suppl.1.A23
- N α methylhistamine**, The effects of N α methylhistamine on gastric acid secretion in human volunteers, Suppl.1.A1
- Nerve autonomic activity**, Laser Doppler mucosal flowmetry – the first direct measure of the level of activation of extrinsic nerves to the gut, Suppl.1.A52
- Neutral endopeptidase**, Sensitive quantification of gut epithelial neutral endopeptidase expression using a flow cytometric double-staining technique and endoscopic biopsy, Suppl.1.A73
- Neutrophils**, CD10 expression on human neutrophils and colonic epithelial cells (Caco2) after short-term incubation with various chemokines and growth factors, Suppl.1.A74
- Nicardipine**, Nicardipine directly inhibits basolateral K+ channels involved in Cl secretion in human colon, Suppl.1.A79
- Nicotine**
Effects of nicotine on E-selectin expression in intestinal tissue biopsies in inflammatory bowel disease patients and controls, Suppl.1.A74
In inflammatory bowel disease IL-8 production and tissue expression is modulated by nicotine and crude tobacco extract, Suppl.1.A74
- Nimesulide**, Intestinal tolerability of the highly specific COX-2 inhibitor nimesulide in the rat, Suppl.1.A71
- Nitric oxide**
Cytotoxic effects of nitric oxide on HT29 colonic epithelial cells, Suppl.1.A75
Differential effect of steroids on nitric oxide production by cytokine stimulated HT-29 cells, Suppl.1.A24
Nitric oxide release in the splanchnic circulation of cirrhotic rats, Suppl.1.A14
- Nitric oxide synthase**
Elevated nitric oxide synthase activity in human duodenal enterocytes in iron deficiency anaemia and coeliac disease, Suppl.1.A80
Inducible NOS is expressed in the normal human colon, Suppl.1.A27
- Non-NSAID gastric ulcer disease**, The natural history of non-NSAID gastric ulcer disease following *H. pylori* eradication: a one year follow-up study in the African setting, Suppl.1.A4
- Non-smokers (non-smoking)**
Coeliac disease is associated with non-smoking and cessation of smoking, Suppl.1.A11
Peripheral blood pro-inflammatory cytokine profile in active inflammatory bowel disease differ between smokers and non-smokers, Suppl.1.A24
- Non-steroidal anti-inflammatory drugs**
Long-term survival, symptoms and drug use after peptic ulcer haemorrhage, Suppl.1.A8
Non-steroidal anti-inflammatory drugs and *Helicobacter pylori* as independent risk factors for peptic ulcer bleeding, Suppl.1.A4
Prophylaxis against NSAID related ulcers and their complications – current practice in gastroenterology centres in the United Kingdom, Suppl.1.A61
Role of uncoupling of oxidative phosphorylation and inhibition of cyclooxygenase in the pathogenesis of NSAID-enteropathy in the rat, Suppl.1.A70
Ulcer development in long term NSAID users in the presence or absence of gastric neutrophils. A double-blind placebo-controlled study, Suppl.1.A4
- Nurse endoscopy (endoscopist)**
Colorectal nurse endoscopist – initial results, Suppl.1.A38

- Community based open access nurse led flexible sigmoidoscopy for rectal bleeding, Suppl.1.A39
- Obstructive jaundice**
Magnetic resonance cholangiography in obstructive jaundice, Suppl.1.A67
Obstructive jaundice does not promote bacterial translocation in man, Suppl.1.A67
- Ocreotide-induced gallbladder stones**, The pathogenesis of ocreotide-induced gallbladder stones – prolonged large bowel transit increases deoxycholic acid input rate and pool size, Suppl.1.A66
- Oesophageal adenocarcinoma**
Rising incidence of oesophageal adenocarcinoma: a 20 year retrospective review from a single unit, Suppl.1.A37
Virulent *Helicobacter pylori* in patients with gastric and oesophageal adenocarcinoma, Suppl.1.A2
- Oesophageal cancer (carcinoma)**
Adenocarcinoma of the lower oesophagus and cardia are similar both epidemiologically and clinically: a population based study from 1974 to 1993, Suppl.1.A37
Amplification and overexpression of cyclin D1 in oesophageal carcinoma, Suppl.1.A37
Introduction of the 8mm diameter echoendoscope in the staging of oesophageal cancer, Suppl.1.A57
PET scanning for assessing resectability of oesophageal cancer – preliminary results, Suppl.1.A37
- Oesophageal cell function**, Alginate alter oesophageal cell function in an animal model, Suppl.1.A31
- Oesophageal dilatation**, Forces exerted during oesophageal dilatation, Suppl.1.A33
- Oesophageal motility**
Simultaneous ambulatory oesophageal motility and duodeno-gastro-oesophageal reflux, Suppl.1.A32
Sumatriptan at the therapeutic dose alters oesophageal motility, Suppl.1.A44
- Oesophageal motor dysfunction**, Oesophageal motor dysfunction in patients with the indeterminate form of Chagas' disease, Suppl.1.A31
- Oesophageal stenosis**, Quality of life following stent insertion in malignant oesophageal stenosis: a randomised trial comparing metal and plastic stents, Suppl.1.A38
- Oesophageal varices**, A prospective study of Speedband versus Steigmann-Goff in endoscopic ligation of oesophageal varices, Suppl.1.A15
- Oesophago-gastric cancer**, The changing pattern of oesophago-gastric cancer, Suppl.1.A8
- Oesophago-gastric junction**, Prolonged acid suppression therapy and proximal migration of *Helicobacter pylori*, Suppl.1.A7
- Oesophago-gastric obstruction**, Does prior radio- and/or chemotherapy predispose to complications after intubation for malignant oesophago-gastric obstruction, Suppl.1.A38
- Oesophagogastroduodenoscopy**, Differences in diagnostic yield of upper gastrointestinal endoscopy in dyspeptic patients on proton pump inhibitors and H2 receptor antagonists, Suppl.1.A60
- Oesophagus**, Suppl.1.A30-38
Characterisation of endocytic pathways in human oesophagus, Suppl.1.A77
- Omeprazole**
Degree of suppression of gastric acid secretion by omeprazole is related to *H. pylori* status, Suppl.1.A1
Marked rebound acid hypersecretion following omeprazole therapy in *H. pylori* negative subjects, Suppl.1.A3
Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users—the OMNIUM study, journal 797
- Ondansetron**, Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial, Suppl.1.A12
- Open-access flexible sigmoidoscopy**, Open-access flexible sigmoidoscopy for rectal bleeding, Suppl.1.A66
- Open access gastroscopy**, Open access gastroscopy: the first 10,000 cases, Suppl.1.A56
- Oral formulation**, Limited exposure of left colon to daily dosed oral formulation in active distal ulcerative colitis: explanation of poor response to treatment? Suppl.1.A28
- Osteoporosis**, The effect of hormone replacement therapy on serum and urinary markers of bone turnover in primary biliary cirrhosis, Suppl.1.A13
- Oxidative phosphorylation**, Role of uncoupling of oxidative phosphorylation and inhibition and cyclooxygenase in the pathogenesis of NSAID-enteropathy in the rat, Suppl.1.A70
- Oxygen metabolites**, Relationship between mucosal production of reactive oxygen metabolites and toxinogenicity of *Helicobacter pylori*, Suppl.1.A69
- p21WAF1/CIP1**, Immunohistochemical localisation of p21WAF1/CIP1 in the small intestine of BDF1 and p53^{-/-} (null) mice following gamma-irradiation, Suppl.1.A78
- p53**
Aberrant expression of p53 and Ki-67 during acute and chronic rejection following orthotopic liver transplantation, Suppl.1.A17
p53 overexpression in polypoid versus "flat" colorectal adenomas, Suppl.1.A47
- p53^{-/-} mice**, The importance of apoptosis in the gastrointestinal toxicity induced by 5-fluorouracil: rescue from toxicity in p53^{-/-} mice, Suppl.1.A79
- p53^{-/-} (null) mice**, Immunohistochemical localisation of p21WAF1/CIP1 in the small intestine of BDF1 and p53^{-/-} (null) mice following gamma-irradiation, Suppl.1.A78
- Paediatric gastrointestinal endoscopy**, Total intravenous anaesthesia in paediatric gastrointestinal endoscopy, Suppl.1.A41
- Pancolonic ambulatory manometry**, A novel method for 24 hour pancolonic ambulatory manometry, Suppl.1.A42
- Pancreatectomy**, Insulin independence following combined total pancreatectomy and islet autotransplantation, Suppl.1.A11
- Pancreatic cancer**
Differences in perception of quality of life issues between pancreatic cancer patients and health professionals, Suppl.1.A12
Gene mutations in the plasma of patients with pancreatic cancer, Suppl.1.A77
- Pancreatic surgery**, Is pancreatic surgery safe in a small district general hospital? Suppl.1.A11
- Pancreatin**, Intestinal transit and release characteristics of pancreatin enzyme microspheres, Suppl.1.A21
- Pancreatitis**
Audit of the management of acute pancreatitis in Wessex, Suppl.1.A11
Lexipafant, a platelet activation factor antagonist, reduces mortality in a randomised placebo-controlled study in patients with severe acute pancreatitis, Suppl.1.A12
The parotid glands are not vulnerable to factors responsible for chronic pancreatitis, Suppl.1.A12
- Parenteral nutrition**
Intestinal permeability and absorptive capacity in patients receiving parenteral nutrition, Suppl.1.A10
Optimising catheter survival in peripheral parenteral nutrition: a randomised control trial, Suppl.1.A20
Randomised double blind prospective study of long chain triglyceride (LCT), MCT/LCT and medium chain triglyceride (MCT) during parenteral nutrition, Suppl.1.A20
The use of a connection device reduces the cost of cyclical parenteral nutrition, Suppl.1.A63
- Parietal cells**
Inhibition of isolated rabbit parietal cells by interleukin-8, Suppl.1.A70
Novel stimulatory effect of pituitary adenylate cyclase activating polypeptide on an isolated rabbit parietal cell preparation, Suppl.1.A80
- Parotid glands**, The parotid glands are not vulnerable to factors responsible for chronic pancreatitis, Suppl.1.A12
- Paroxetine**, Paroxetine inhibits cholera toxin induced secretion by depleting neuronal but not enterochromaffin cell 5-HT, Suppl.1.A9
- Patients**, Are we telling patients enough? Suppl.1.A57
- Pelvic floor dysfunction**, Biofeedback in the treatment of pelvic floor dysfunction, Suppl.1.A65
- Pelvic irradiation**, The frequency and severity of colorectal symptoms in patients during and after pelvic irradiation, Suppl.1.A51
- Peptic oesophageal strictures**, Use of self expandable stents in the treatment of benign peptic oesophageal strictures in the elderly, Suppl.1.A1
- Peptic ulcer bleeding**, Non-steroidal anti-inflammatory drugs and *Helicobacter pylori* as independent risk factors for peptic ulcer bleeding, Suppl.1.A4
- Peptic ulcer disease**
An audit of the use of long-term acid suppressants in general practice: potential for large savings, Suppl.1.A60
Prophylaxis against NSAID related ulcers and their complications – current practice in gastroenterology centres in the United Kingdom, Suppl.1.A61
- Peptic ulcer haemorrhage**, Long-term survival, symptoms and drug use after peptic ulcer haemorrhage, Suppl.1.A8
- Percutaneous endoscopic gastrostomy**
Gastro-oesophageal reflux in patients fed by percutaneous endoscopic gastrostomy – scintigraphic detection, Suppl.1.A20
Is a single dose of prophylactic antibiotics effective in preventing stoma infections following PEG insertion, Suppl.1.A64
- PET scanning**, PET scanning for assessing resectability of oesophageal cancer – preliminary results, Suppl.1.A37
- Pituitary adenylate cyclase activating polypeptide**, Novel stimulatory effect of pituitary adenylate cyclase activating polypeptide on an isolated rabbit parietal cell preparation, Suppl.1.A80

- Platelet-activating factor**, Investigation of platelet-activating factor-induced secretion in human colon, Suppl.1.A26
- Platelet activation factor antagonist**, Lexipafant, a platelet activation factor antagonist, reduces mortality in a randomised placebo-controlled study in patients with severe acute pancreatitis, Suppl.1.A12
- Polymerase chain reaction**
Detection of *Helicobacter pylori* from GI secretions using PCR, Suppl.1.A7
New, internationally applicable, polymerase chain reaction-based typing of *Helicobacter pylori vacA*, Suppl.1.A1
- Polymeric diet**, Randomised double-blind trial of polymeric versus elemental diet in treatment of active Crohn's disease, Suppl.1.A19
- Polyps**, Results of the first 1,000 patients from the pilot study for "once-only" flexible sigmoidoscopy screening for colorectal cancers and polyps, Suppl.1.A57
- Posterior colporrhaphy**, A prospective randomised trial of posterior colporrhaphy vs transanal repair of rectocele: an interim analysis, Suppl.1.A54
- Postoperative septic morbidity**, Postoperative septic morbidity is related to severity of illness at presentation and to preoperative colonisation of the proximal gastrointestinal tract, Suppl.1.A70
- Pouchitis**, The supramucosal defence barrier is not altered in patients who have had recurrent pouchitis, Suppl.1.A56
- Pre-endoscopy screening**, One year follow-up of a randomised trial of pre endoscopy screening for *H. pylori* in the management of dyspepsia, Suppl.1.A2
- Pre-term infant**, Small bowel juice disaccharide activity in the pre-term infant, Suppl.1.A20
- Pregnancy-related liver disease**, Maternal and perinatal outcome in severe pregnancy-related liver disease, Suppl.1.A29
- Primary biliary cirrhosis**
Effect of hormone replacement therapy on serum and urinary markers of bone turnover in primary biliary cirrhosis, Suppl.1.A13
IgG, IgM, IgA heat shock protein antibodies in primary biliary cirrhosis: effect of UDCA therapy, Suppl.1.A14
Prescribing habits in primary biliary cirrhosis – a national survey, Suppl.1.A63
Ursodeoxycholic acid therapy for primary biliary cirrhosis: 10 years' population-based experience, Suppl.1.A14
- Primary care**, *Helicobacter pylori*: a test and treat strategy in primary care, Suppl.1.A58
- Primary sclerosing cholangitis**, High dose ursodeoxycholic acid in primary sclerosing cholangitis: results after two years of a randomised double-blind, placebo-controlled trial, Suppl.1.A29
- Procoagulant activity**, Bactericidal/permeability-increasing protein blocks lipopolysaccharide-induced procoagulant activity of endothelial cells, Suppl.1.A72
- Proton pump inhibitors**
Audit of proton pump inhibitor usage in a teaching hospital setting, Suppl.1.A59
Audit of the use of anti-secretory drugs, Suppl.1.A59
Differences in diagnostic yield of upper gastrointestinal endoscopy in dyspeptic patients on proton pump inhibitors and H2 receptor antagonists, Suppl.1.A60
H2 receptor antagonists and proton pump inhibitors in general practice: prescribing trends in the UK from 1991 to 1996, Suppl.1.A60
- Pruritus**, Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial, Suppl.1.A12
- Pseudomembranous oesophagitis**, Pseudomembranous oesophagitis, Suppl.1.A30
- Pudendal nerve stimulation**, Does human pudendal nerve stimulation display functional asymmetry in modulating cortico-anal pathways? Suppl.1.A53
- Pyloric stenosis**, Technique, and long term outcome of endoscopic balloon dilatation for pyloric stenosis, Suppl.1.A40
- PYY**, Effects of fermentable carbohydrate on plasma PYY levels in human subjects, Suppl.1.A73
- Quality of life**
Differences in perception of quality of life issues between pancreatic cancer patients and health professionals, Suppl.1.A12
Quality of life in irritable bowel syndrome: does it improve with resolution of symptoms? Suppl.1.A64
- Radioligand assay**, Detection of anti conformational CYP2D6 antibodies in patients with autoimmune liver disease and HCV infection using a novel radioligand assay, Suppl.1.A15
- Radiotransmitting capsules**, The use of radiotransmitting capsules to measure intestinal transit, Suppl.1.A44
- Ranitidine**
H. pylori eradication therapy compared with ranitidine maintenance therapy in patients with chronic duodenal ulcer disease: a prospective pharmaco-economic evaluation, Suppl.1.A5
Prospective randomised controlled study of the use of ranitidine in patients with gastric cancer, Suppl.1.A41
Ranitidine bismuth citrate plus clarithromycin and tetracycline: a seven-day *H. pylori* eradication regimen, Suppl.1.A5
Ranitidine treatment induces dyspepsia in previously asymptomatic healthy volunteers, Suppl.1.A3
- Rectal bleeding**
Colorectal cancer patients presenting with rectal bleeding have earlier stage tumours and longer pre-diagnosis history, Suppl.1.A50
Community based open access nurse led flexible sigmoidoscopy for rectal bleeding, Suppl.1.A39
How many colorectal cancer patients might benefit from guidelines to improve the management of rectal bleeding? Suppl.1.A50
Open-access flexible sigmoidoscopy for rectal bleeding, Suppl.1.A66
- Rectal cancer**, Comparison of endoanal magnetic resonance imaging and computerized tomography in the preoperative staging of low rectal cancer, Suppl.1.A50
- Rectal evacuatory disorders**, The continent colonic conduit for faecal incontinence and rectal evacuatory disorders, Suppl.1.A55
- Rectal mucosa**, Proliferative patterns of rectal mucosa as predictors of advanced colonic neoplasms in routinely processed rectal biopsies, Suppl.1.A48
- Rectal tumours**, Colonoscopic argon plasma coagulation for benign and malignant rectal tumours, Suppl.1.A39
- Rectal visceral sensitivity**, The menstrual cycle affects rectal visceral sensitivity in patients with irritable bowel syndrome but not healthy volunteers, Suppl.1.A52
- Recto-anal inhibitory reflex**, The recto-anal inhibitory reflex: abnormal response in diabetics suggests an intrinsic neuro-enteropathy, Suppl.1.A52
- Rectocele**, A prospective randomised trial of posterior colporrhaphy vs transanal repair of rectocele: an interim analysis, Suppl.1.A54
- Recurrent epigastric pain**, Gastric emptying and gastrointestinal regulatory peptides in children with recurrent epigastric pain, Suppl.1.A43
- Reflux esophagitis**, Natural history of reflux esophagitis: a 5-year follow up study, Suppl.1.A32
- Renal blood flow**, Effect of TIPSS on renal blood flow in cirrhotic patients, Suppl.1.A15
- Renal calcium oxalate calculi**, Stone inhibitor/promotor ratio. A risk factor for renal calcium oxalate calculi formation in inflammatory bowel disease, Suppl.1.A26
- Reverse transcriptase-PCR**, Multiple blood sampling increases the probability of identifying circulating tumour cells, Suppl.1.A49
- Salmonella typhimurium**, Effect of bromelain on *Salmonella typhimurium* invasion in cultured human intestinal cells, Suppl.1.A75
- Sapheno-peritoneal shunting**, Sapheno-peritoneal shunting for diuretic resistant ascites, Suppl.1.A29
- Scintigraphy**, Gastro-oesophageal reflux in patients fed by percutaneous endoscopic gastrostomy – scintigraphic detection, Suppl.1.A20
- Sepsis**, A rapid qualitative technique for the in situ diagnosis of catheter related sepsis, Suppl.1.A76
- Septic morbidity**, Postoperative septic morbidity is related to severity of illness at presentation and to preoperative colonisation of the proximal gastrointestinal tract, Suppl.1.A70
- Serological screening**, Serological screening before endoscopy: the value of HP serology, pepsinogen I and serum recognition of cag A, Suppl.1.A56
- Serotonin**
Detection of intraluminal serotonin (5-HT) in patients with HIV-related diarrhoea, Suppl.1.A9
Paroxetine inhibits cholera toxin induced secretion by depleting neuronal but not enterochromaffin cell 5-HT, Suppl.1.A9
- Sigmoidoscopy**, Sigmoidoscopy – a patient's guide, Suppl.1.A82
- Simple clinical colitis activity index**, Further verification of the really useful simple colitis activity index, Suppl.1.A24
- Small bowel endoscopy**, Therapeutic small bowel endoscopy, Suppl.1.A40
- Small bowel juice disaccharide activity**, Small bowel juice disaccharide activity in the pre-term infant, Suppl.1.A20
- Small bowel manometry**, The spectrum of enteric dysmotility revealed by prolonged small bowel manometry, Suppl.1.A41
- Small bowel transplantation**, Ischaemia-reperfusion injury following syngeneic small bowel transplantation induces apoptosis, Suppl.1.A10

- Small intestinal crypt hyperplasia**, Small intestinal crypt hyperplasia in African tropical enteropathy, Suppl.1.A9
- Small intestinal permeability**, Intestinal permeability and absorptive capacity in patients receiving parenteral nutrition, Suppl.1.A10
- Smokers (smoking)**
 Coeliac disease is associated with non-smoking and cessation of smoking, Suppl.1.A11
 Peripheral blood pro-inflammatory cytokine profile in active inflammatory bowel disease differ between smokers and non-smokers, Suppl.1.A24
 Smoking and appendicectomy in twins discordant for inflammatory bowel disease, Suppl.1.A25
- Sodium phosphate**
 Randomized trial of oral sodium phosphate compared with oral sodium picosulphate for elective colorectal surgery, Suppl.1.A54
 Randomized trial of oral sodium phosphate compared with oral sodium picosulphate preparation of the colon for colonoscopy, Suppl.1.A40
- Sodium picosulphate**
 Randomized trial of oral sodium phosphate compared with oral sodium picosulphate for elective colorectal surgery, Suppl.1.A54
 Randomized trial of oral sodium phosphate compared with oral sodium picosulphate preparation of the colon for colonoscopy, Suppl.1.A40
- South Glamorgan**, Presentation and incidence of coeliac disease in South Glamorgan, Suppl.1.A10
- Soybean lectin**, Soybean lectin stimulates cholecystokinin release through calcium influx via L-type calcium channels, Suppl.1.A81
- Speedband ligation**, A prospective study of Speedband versus Steigmann-Goff in endoscopic ligation of oesophageal varices, Suppl.1.A15
- Sphincter of Oddi dysfunction**, Tachyoddia independent from the duodenal migrating motor complex may be a part of sphincter of Oddi dysfunction, Suppl.1.A43
- Splanchnic circulation**, Nitric oxide release in the splanchnic circulation of cirrhotic rats, Suppl.1.A14
- Stapled versus sutured closure**, Randomized controlled trial of stapled versus sutured closure of loop ileostomies, Suppl.1.A54
- Steigmann-Goff ligation**, A prospective study of Speedband versus Steigmann-Goff in endoscopic ligation of oesophageal varices, Suppl.1.A15
- Stents**
 Quality of life following stent insertion in malignant oesophageal stenosis: a randomised trial comparing metal and plastic stents, Suppl.1.A38
 Use of self expandable stents in the treatment of benign peptic oesophageal strictures in the elderly, Suppl.1.A1
- Steroids**, Loss of bone mass in inflammatory bowel disease patients on long term steroids. Is there a safe limit? Suppl.1.A28
- Stoma infections**, Is a single dose of prophylactic antibiotics effective in preventing stoma infections following PEG insertion, Suppl.1.A64
- Stone inhibitor/promotor ratio**, Stone inhibitor/promotor ratio. A risk factor for renal calcium oxalate calculi formation in inflammatory bowel disease, Suppl.1.A26
- Substance P**, Inhibition of cholera toxin but not *E. coli* enterotoxin-induced secretion by substance P antagonist, Suppl.1.A9
- Sumatriptan**
 Further evidence that sumatriptan induced chest pain is oesophageal in origin: effect on oesophageal visceral sensation, Suppl.1.A31
 Sumatriptan at the therapeutic dose alters oesophageal motility, Suppl.1.A44
- Supramucosal defence barrier**, The supramucosal defence barrier is not altered in patients who have had recurrent pouchitis, Suppl.1.A56
- Swallowing**
 Rate of spontaneous swallowing and improvement with exclusion diet in irritable bowel syndrome, Suppl.1.A64
 Volitional swallowing modulates cortical swallowing pathways via brainstem mediated interactions, Suppl.1.A42
- T cells**, Expression of $\alpha 5$ (CD49e) and $\alpha 6$ (CD49f) integrins on human colonic lamina propria T cells, Suppl.1.A73
- Tachyoddia**, Tachyoddia independent from the duodenal migrating motor complex may be a part of sphincter of Oddi dysfunction, Suppl.1.A43
- Tauro-ursodeoxycholic acid**, Interferon sparing effect of adjuvant tauro-ursodeoxycholic acid for treatment of chronic hepatitis C: results on liver histology, Suppl.1.A16
- Terminal ileum**, Aphthous ulceration in the terminal ileum: what is the significance? Suppl.1.A39
- Tetracycline**, Ranitidine bismuth citrate plus clarithromycin and tetracycline: a seven-day *Helicobacter pylori* eradication regimen, Suppl.1.A5
- Thoracoscopic splanchnicectomy**
 Prospective audit of thoracoscopic splanchnicectomy in the management of intractable upper abdominal pain, Suppl.1.A39
 Thoracoscopic splanchnicectomy by minimally invasive technique, Suppl.1.A83
- Thorascopy**, Thorascopic assisted transhiatal oesophagectomy – new lamps for old? Suppl.1.A35
- Throat spray**, Patients' own perceptions of endoscopy under throat spray, Suppl.1.A38
- TIMP-1 levels**, Plasma TIMP-1 levels increase with severity of liver disease in chronic hepatitis C, Suppl.1.A16
- TIPSS**, Effect of TIPSS on renal blood flow in cirrhotic patients, Suppl.1.A15
- Tobacco extract**, In inflammatory bowel disease IL-8 production and tissue expression is modulated by nicotine and crude tobacco extract, Suppl.1.A74
- Toxin**
 Inhibition of cholera toxin but not *E. coli* enterotoxin-induced secretion by substance P antagonist, Suppl.1.A9
 Paroxetine inhibits cholera toxin induced secretion by depleting neuronal but not enterochromaffin cell 5-HT, Suppl.1.A9
- Tranexamic acid**, Endoscopic stigmata, acid suppression, quality of life and death from upper gastrointestinal bleeding, Suppl.1.A61
- Transanal repair**, A prospective randomised trial of posterior colporrhaphy vs transanal repair of rectocele: an interim analysis, Suppl.1.A54
- Transforming growth factor- α** , Transforming growth factor- α increases E-cadherin and β -catenin binding to the actin-bundling protein fascin, Suppl.1.A76
- Transforming growth factor- β** , Human colonic epithelial cells down-regulate IL-8 expression in human microvascular endothelial cells: role of TGF- β , Suppl.1.A72
- Transhiatal oesophagectomy**, Thorascopic assisted transhiatal oesophagectomy – new lamps for old? Suppl.1.A35
- Transit**, Intestinal transit and release characteristics of pancreatic enzyme microspheres, Suppl.1.A21
- Transjugular intrahepatic portosystemic stent-shunt**, Effect of TIPSS on renal blood flow in cirrhotic patients, Suppl.1.A15
- Triglycerides**, A randomised double blind prospective study of long chain triglyceride (LCT), MCT/LCT and medium chain triglyceride (MCT) during parenteral nutrition, Suppl.1.A20
- Tropical enteropathy**, Small intestinal crypt hyperplasia in African tropical enteropathy, Suppl.1.A9
- Tucarezol**, Beneficial *in vitro* effects of tucarezol on the immune response to hepatitis C virus, Suppl.1.A30
- Ulcerative colitis**
 Cytokine expression and relapse of ulcerative colitis: a prospective study, Suppl.1.A28
 Double-blind, placebo controlled trial to determine the efficacy of essential fatty acid supplementation in the treatment of ulcerative colitis, Suppl.1.A22
 Further verification of the really useful simple colitis activity index, Suppl.1.A24
 Immunosuppressive therapy for ulcerative colitis – a survey of the practice of British gastroenterologists, Suppl.1.A65
 Limited exposure of left colon to daily dosed oral formulation in active distal ulcerative colitis: explanation of poor response to treatment? Suppl.1.A28
 Low bone mineral density is related to disease duration in Crohn's disease and to glucocorticoid treatment and male gender in ulcerative colitis, Suppl.1.A26
 Macroscopic and histological inactivity in ulcerative colitis surveillance: a good prognostic sign? Suppl.1.A23
 Mucosal aminosalicylate levels correlate with clinical activity in patients with ulcerative colitis, Suppl.1.A23
 Randomised controlled trial of essential fatty acids in acute ulcerative colitis, Suppl.1.A23
- Ultrasound**
 Accuracy of digital examination, endoanal ultrasound and concentric needle electromyography in detecting anal sphincter, Suppl.1.A54
 Prediction of resectability of gastric tumours using endoscopic ultrasound, Suppl.1.A41
- Upper abdominal pain**, Prospective audit of thoracoscopic splanchnicectomy in the management of intractable upper abdominal pain, Suppl.1.A39
- Upper gastrointestinal bleeding**
 Completion of the audit cycle and its positive impact on the management of upper gastrointestinal bleeding in a Trust, Suppl.1.A62

- Endoscopic stigmata, acid suppression, quality of life and death from upper gastrointestinal bleeding, Suppl.1.A61
- How are patients presenting to Accident & Emergency with upper gastrointestinal bleeding managed? Suppl.1.A61
- Upper gastrointestinal endoscopy**, A randomized trial of a 5.5mm vs 9.5mm diameter videogastroscope in unsedated upper GI endoscopy, Suppl.1.A57
- Urological outpatient departments**, High prevalence of irritable bowel syndrome in patients attending urological outpatient departments, Suppl.1.A65
- Ursodeoxycholic acid**
 High dose ursodeoxycholic acid in primary sclerosing cholangitis: results after two years of a randomised double-blind, placebo-controlled trial, Suppl.1.A29
 IgG, IgM, IgA heat shock protein antibodies in primary biliary cirrhosis: effect of UDCA therapy, Suppl.1.A14
 Prescribing habits in primary biliary cirrhosis – a national survey, Suppl.1.A63
 Ursodeoxycholic acid therapy for primary biliary cirrhosis: 10 years' population-based experience, Suppl.1.A14
- Video education**, Effective use of video education in patients undergoing gastroscopy, Suppl.1.A56
- Videogastroscope**, A randomized trial of a 5.5mm vs 9.5mm diameter videogastroscope in unsedated upper GI endoscopy, Suppl.1.A57
- Villi**, Reversal of and protection against indomethacin-induced blood stasis and mucosal damage by a β 3-agonist in rat villi, Suppl.1.A71
- Villous blood flow**, Slowing of villous blood flow and focal microvascular distortion precede early indomethacin-induced histological changes, Suppl.1.A71
- Virtual reality**, Correlation between colonoscopy and CT-based virtual reality endoscopy in the detection of space-occupying lesions of the colon, Suppl.1.A83
- Vitamin B deficiencies**, B vitamin deficiencies may be common in the acute inpatient population, Suppl.1.A21
- Vitamin D analogues**, Vitamin D analogues are more potent activators of vitamin D response elements than the native hormone in colon cancer cells, Suppl.1.A78
- Volitional swallowing**, Volitional swallowing modulates cortical swallowing pathways via brainstem mediated interactions, Suppl.1.A42
- Waf protein**, Bcl-2 and waf protein expression in chronic liver disease, Suppl.1.A14
- Weight loss**
 Serum leptin in inflammatory bowel disease: implications for the pathogenesis of anorexia and weight loss, Suppl.1.A19
 Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Suppl.1.A19
- Wessex**, Audit of the management of acute pancreatitis in Wessex, Suppl.1.A11
- Whole gut lavage**, Whole gut lavage inflammatory parameters in recently constructed ileoanal pouches, Suppl.1.A55
- Whole-gut transit time**, The use of radiotransmitting capsules to measure intestinal transit, Suppl.1.A44

Gut

Journal of the British Society of Gastroenterology
which is a registered charity

VOLUME 40 · 1997

Editor: Michael J G Farthing

Associate Editors: Michael J P Arthur, John Calam, Roger Chapman, Ian Forgacs (reviews, editorials)
Michael A Kamm, Thomas T MacDonald

Managing Editor: Andrea Horgan

Editorial Assistants: Michelle Dimler
Julia Neary

EDITORIAL BOARD

D Adams (UK)

D Alderson (UK)

C Arvanitakis (Greece)

G Bianchi Porro (Italy)

I Booth (UK)

M Buchler (Switzerland)

E Butruk (Poland)

J Dent (Australia)

G Dockray (UK)

J Galmiche (France)

J Heathcote (Canada)

S Hubscher (UK)

P Jansen (The Netherlands)

J Jass (New Zealand)

G Krejs (Austria)

S K Lam (Hong Kong)

N Lemoine (UK)

M M Levine (USA)

O Lundgren (Sweden)

P Malfertheiner (Germany)

J Neoptolemos (UK)

D Rachmilewitz (Israel)

D S Rampton (UK)

J Rask-Madsen (Denmark)

P Rutgeerts (Belgium)

G Sandle (UK)

C Scarpignato (Italy)

E Schrumpf (Norway)

P Shorvon (UK)

D Thompson (UK)

G Tytgat (The Netherlands)

B J R Whittle (UK)

T Wright (UK)

Shu-Dong Xiao (China)

R G Newcombe
(*Statistical adviser*)

Editor
British Medical Journal

Page	Leading articles
1	Role of cytokines and their inhibitors in acute pancreatitis <i>Andrew Kingsnorth</i>
5	Regional expression of intestinal genes for nutrient absorption <i>Charles J Shaw-Smith, Julian R F Walters</i>
	Helicobacter pylori
9	Evaluation of <i>Helicobacter pylori</i> in reflux oesophagitis and Barrett's oesophagus <i>M Newton, R Bryan, W R Burnham, M A Kamm</i>
14	Effect of N ^o -methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for <i>Helicobacter pylori</i> associated gastritis and gastric physiology <i>I L P Beales, J Calam</i>
20	Role of <i>Helicobacter pylori</i> surface structures in bacterial interaction with macrophages <i>M Chmiela, E Czkwianianc, T Wadstrom, W Rudnicka</i>
25	Synthesis and activity of <i>Helicobacter pylori</i> urease and catalase at low pH <i>P Bauerfeind, R Garner, B E Dunn, H L T Mobley</i>
	Stomach
31	Studies on gastric mucosal microcirculation. 1. The nature of regional variations induced by ethanol injury <i>N Kalia, N J Brown, S Jacob, M W R Reed, K D Bardhan</i>
36	Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study <i>J Labenz, U Peitz, C Leusing, B Tillenburg, A L Blum, G Börsch</i>
42	Cytokine effects on pepsinogen secretion from human peptic cells <i>M T Serrano, A I Lanas, S Lorente, R Sáinz</i>
49	Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans <i>S Teysen, T Lenzing, G González-Calero, A Korn, R L Riepl, M V Singer</i>
	Small intestine
57	The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vitro <i>E E Wheeler, D N Challacombe</i>
61	Twenty years of childhood coeliac disease in The Netherlands: a rapidly increasing incidence? <i>E K George, M L Mearin, H C M Franken, R H J Houwen, R A Hirasig, J P Vandenbroucke</i>
67	Enteral supplementation with ornithine α ketoglutarate improves the early adaptive response to resection <i>B Czernichow, E Nsi-Emvo, M Galluser, F Gossé, F Raul</i>
	Pancreas
73	Increased expression of transforming growth factor β s after acute oedematous pancreatitis in rats suggests a role in pancreatic repair <i>E Riesle, H Friess, L Zhao, M Wagner, W Uhl, K Baczako, L I Gold, M Korc, M W Büchler</i>
80	Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis <i>H Messmann, W Vogt, A Holstege, G Lock, A Heinisch, A von Fürstenberg, H G Leser, H Zirngibl, J Schölmerich</i>
86	Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans <i>J W Konturek, K Hengst, E Kulesza, A Gabryelewicz, S J Konturek, W Domschke</i>
	Biliary tract
92	Fibrinolysis and the biliary tree <i>D M Scott-Coombes, S A Whawell, E G Havranek, J N Thompson</i>
	Inflammatory bowel disease
95	Gene expression of group II phospholipase A2 in intestine in ulcerative colitis <i>M M Haapamäki, J M Grönroos, H Nurmi, K Alanen, M Kallajoki, T J Nevalainen</i>
102	Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils <i>P Gionchetti, M Vecchi, F Rizzello, M Ferretti, C Calabresi, A Venturi, M B Bianchi, C Brignola, R A Sinico, R De Franchis, M Miglioli, M Campieri</i>
105	Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease <i>R S Walmsley, M H Zhao, M I Hamilton, A Brownlee, P Chapman, R E Pounder, A J Wakefield, C M Lockwood</i>
	Cancer
110	Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer <i>L M Hunt, P S Rooney, K Bostock, M H E Robinson, J D Hardcastle, N C Armitage</i>
113	T cell receptor- ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma <i>W M C Mulder, E Bloemena, M J Stukart, J A Kummer, J Wagstaff, R J Scheper</i>
120	DPC4 gene mutation in colitis associated neoplasia <i>A T M S Hoque, S A Hahn, M Schutte, S E Kern</i>
123	Endoscopic treatment of early oesophageal or gastric cancer <i>K Takeshita, M Tani, H Inoue, I Saeki, S Hayashi, T Honda, F Kando, N Saito, M Endo</i>
	Liver
128	Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population <i>G H Haydon, L M Jarvis, P Simmonds, D J Harrison, O J Garden, P C Hayes</i>
133	Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice <i>R Bruck, H Shirin, R Hershkoviz, O Lider, G Kenet, H Aeed, Z Matas, L Zaidel, Z Halpern</i>
139	Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis <i>E H Forrest, I A D Bouchier, P C Hayes</i>
145	Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver <i>A M Vollmar, G Paumgartner, A L Gerbes</i>
	Commentaries
151	Natriuretic peptides: are these new links in the hepatorenal connections? <i>Florence Wong, Laurence Blendis</i>
153	Signals from lymphocytes in colon cancer <i>Rolf Kiessling</i>
155	Letters to the editor Book review Note
158	Referees

Page	Leading articles
161	Antimicrobial peptides in the gastrointestinal tract <i>Y R Mahida, F Rose, W C Chan</i>
164	Central peptidergic control of gastric acid secretion <i>J G Geoghegan, T N Pappas</i>

- Oesophagus**
- 167 Multivariate analysis of pathophysiological factors in reflux oesophagitis *G Cadiot, A Bruhat, D Rigaud, T Coste, A Vuagnat, Y Benyedder, T Vallot, D Le Guludec, M Mignon*
- 175 Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits *M J Naya, D Pereboom, J Ortego, J O Alda, A Lanas*
- 182 The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease *R E K Marshall, A Anggiansah, W A Owen, W J Owen*
- 188 Oesophageal manometry in the evaluation of megacolon with onset in adult life *G Basileisco, P Velio, P A Bianchi*
- Stomach**
- 192 Open access gastroscopy: second survey of current practice in the United Kingdom *J G Silcock, M G Bramble*
- 196 Epithelium related deposition of activated complement in *Helicobacter pylori* associated gastritis *A E Berstad, P Brandtzaeg, R Stave, T S Halstensen*
- 204 Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration *M A Hull, A Knifton, B Filipowicz, J L Brough, G Vautier, C J Hawkey*
- 211 Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans *G M McKnight, L M Smith, R S Drummond, C W Duncan, M Golden, N Benjamin*
- Small intestine**
- 215 Is the sugar intestinal permeability test a reliable investigation for coeliac disease screening? *C Catassi, E Fabiani, I M Ratsch, A Bonucci, M Dotti, G V Coppa, P L Giorgi*
- 218 Assessing the quality of life of patients with intestinal failure on home parenteral nutrition *D M Richards, M H Irving*
- 223 Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors *A McIntyre, R M Vincent, A C Perkins, R C Spiller*
- Inflammatory bowel disease**
- 228 Reduced bone density in patients with inflammatory bowel disease *I Bjarnason, A Macpherson, C Mackintosh, M Buxton-Thomas, I Forgacs, C Moniz*
- 234 Altered expression of mucins throughout the colon in ulcerative colitis *J E Smithson, A Campbell, J M Andrews, J D Milton, R Pigott, D P Jewell*
- 241 Altered expression of $\alpha_4\beta_7$, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation *J Meenan, J Spaans, T A Grool, S T Pals, G N J Tytgat, S J H van Deventer*
- Cancer**
- 247 Relation between gastric cancer and previous peptic ulcer disease *R M Molloy, A Sonnenberg*
- 253 In vitro influence of *Phaseolus vulgaris*, *Griffonia simplicifolia*, concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth *R Kiss, I Camby, C Duckworth, R De Decker, I Salmon, J-L Pasteels, A Danguy, P Yeaton*
- Pancreas**
- 262 Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients *P Lévy, D Heresbach, E A Pariente, A Boruchowicz, R Delcenserie, B Millat, J Moreau, L Le Bodic, L de Calan, M Barthet, A Sauvanet, P Bernades*
- 267 Expression of peptide receptors in human endocrine tumours of the pancreas *C Tang, I Biemond, C B H W Lamers*
- Biliary tract and liver**
- 272 Endoscopic management of Mirizzi's syndrome *R E England, D F Martin*
- 277 T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function *D E Jones, J M Palmer, M P Leon, S J Yeaman, M F Bassendine, A G Diamond*
- Occasional viewpoint**
- 284 Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? *T Sahnoud, J Y Mary*
- Commentaries**
- 286 Recombinant peptides for gastrointestinal ulceration: still early days *R J Playford*
- 288 Dietary nitrate: poison or panacea? *P Vallance*
- 289 **Letters to the editor** **Book review** **Note**
- Leading articles**
- 291 Clinical relevance of hepatitis C virus genotypes *P Simmonds*
- 294 Hepatitis G virus: identification, prevalence and unanswered questions *P Karayiannis, H C Thomas*
- Helicobacter pylori**
- 297 Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection *J Parsonnet, G D Friedman, N Orentreich, H Vogelman*
- 302 The *Helicobacter pylori* breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients *K E L McColl, A El-Nujumi, L Murray, E El-Omar, D Gillen, A Dickson, A Kelman, T E Hilditch*
- Inflammatory bowel disease**
- 307 Colonic muscle enhances the production of interleukin-1 β messenger RNA in experimental colitis *I Khan, F M Al-Awadi*
- 313 Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study *J Jahnsen, J A Falch, E Aadland, P Mowinkel*
- 320 CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study *A Stronkhorst, S Radema, S-L Yong, H Bijl, I J M ten Berge, G N J Tytgat, S J H van Deventer*
- 328 Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway *B Moum, A Ekbom, M H Vatn, E Aadland, J Sauar, I Lygren, T Schulz, N Stray, O Fausa*
- Immunology**
- 333 Intestinal intraepithelial lymphocytes have a promiscuous interleukin-8 receptor *A I Roberts, M Bilenker, E C Ebert*
- 339 Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor- α *L Mahraoui, M Heyman, O Plique, M T Droy-Lefaix, J F Desjeux*
- Neoplasia**
- 344 Effects of sulindac on sporadic colorectal adenomatous polyps *N Matsushashi, A Nakajima, Y Fukushima, Y Yazaki, T Oka*

- 350 Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases *A Dorandeu, J-L Raoul, F Siriser, N Leclercq-Rioux, M Gosselin, E D Martin, M-P Ramée, B Launois*
- 356 Detection and monitoring of serum p53 antibodies in patients with colorectal cancer *P Hammel, B Boissier, M-T Chaumette, P Piedbois, N Rotman, J-C Kouyoumdjian, R Lubin, J-C Delchier, T Soussi*
- 362 Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study *I R Sargeant, J S Tobias, G Blackman, S Thorpe, J R Glover, S G Bown*
- Motility**
- 370 Characterisation of relaxation of the lower oesophageal sphincter in healthy premature infants *T I Omari, K Miki, G Davidson, R Fraser, R Haslam, W Goldsworthy, M Bakewell, J Dent*
- 376 Stimulation of β -adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans *M Thollander, T H Svensson, P M Hellström*
- 381 Outcome of laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis *R J Baigrie, D I Watson, J C Myers, G G Jamieson*
- Pancreas**
- 386 Pathophysiological role of type I and II phospholipase A₂ in acute pancreatitis: an experimental study in rats *W Uhl, H-J Schrag, N Schmitter, T J Nevalainen, J Aufenanger, A M Wheatley, M W Büchler*
- Nutrition**
- 393 Two phase randomised controlled clinical trial of postoperative oral dietary supplements in surgical patients *A M Keele, M J Bray, P W Emery, H D Duncan, D B A Silk*
- Colon**
- 400 Oxidation of short and medium chain C₂-C₈ fatty acids in Sprague-Dawley rat colonocytes *J R Jørgensen, M R Clausen, P B Mortensen*
- 406 Colonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls *H P Haber, N Benda, G Fitzke, A Lang, M Langenberg, J Riethmüller, M Stern*
- Liver**
- 412 Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis – a simultaneous sonographic study *M Acalovschi, D L Dumitraşcu, I Csakany*
- 418 Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavage in chronic portacaval shunted rats *S W M Olde Damink, C H C Dejong, N E P Deutz, P B Soeters*
- Case report**
- 425 Whipple's disease: comparison of histology with diagnosis based on polymerase chain reaction in four consecutive cases *C Müller, D Petermann, C Stain, H Riemer, H Vogelsang, P Schneider, K Zeiler, F Wrba*
- Occasional viewpoint**
- 428 'Tropical sprue': some early investigators favoured an infective cause, but was a coccidian protozoan involved? *G C Cook*
- Commentary**
- 430 Discouraging colonic polyps *C B Williams*
- 431 **Letters to the editor Book reviews Notes**
- Leading articles**
- 435 Regulation of intestinal non-haem iron absorption *Martin Lombard, Eddy Chua, Paul O'Toole*
- 440 Autoimmunocholangitis *Jenny Heathcote*
- Review**
- 443 Tumour necrosis factor and Crohn's disease *S J H van Deventer*
- Oesophagus**
- 449 Effect of intraduodenal fat on lower oesophageal sphincter function and gastro-oesophageal reflux *R H Holloway, E Lyrenas, A Ireland, J Dent*
- Helicobacter pylori**
- 454 Comparison of serum, salivary, and rapid whole blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy based tests *T G Reilly, V Poxon, D S A Sanders, T S J Elliott, R P Walt*
- 459 A citric acid solution is an optimal test drink in the ¹³C-urea breath test for the diagnosis of *Helicobacter pylori* infection *J E Dominguez-Muñoz, A Leodolter, T Sauerbruch, P Malfertheiner*
- 463 Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of *Helicobacter pylori* *P Ch Konturek, H Ernst, S J Konturek, A J Bobrzyński, G Faller, C Klingler, E G Hahn*
- Inflammatory bowel disease**
- 470 Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease *J Bauditz, J Haemling, M Ortner, H Lochs, A Raedler, S Schreiber*
- 475 In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease *J M Reimund, S Dumont, C D Muller, J S Kenney, M Kedinger, R Baumann, P Poindron, B Duclos*
- 481 Pancreatic autoantibodies in Crohn's disease: a family study *F Seibold, H Mörk, S Tanza, A Müller, C Holzhiuter, P Weber, M Scheurden*
- 485 Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial *R I Breuer, K H Soergel, B A Lashner, M L Christ, S B Hanauer, A Vanaganas, J M Harig, A Keshavarzian, M Robinson, J H Sellin, D Weinberg, D E Vidican, K L Flemal, A W Rademaker*
- Coeliac disease**
- 492 Down's syndrome is strongly associated with coeliac disease *L Gale, H Wimalaratna, A Brotodiharjo, J M Duggan*
- Infection**
- 497 Increasing the intestinal resistance of rats to the invasive pathogen *Salmonella enteritidis*: additive effects of dietary lactulose and calcium *I M J Bovee-Oudenhoven, D S M L Termont, P J Heidi, R Van der Meer*
- 505 Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo *A Fasano, F R Noriega, F M Liao, W Wang, M M Levine*
- Cancer**
- 512 Micrometastases: marker of metastatic potential or evidence of residual disease? *G C O'Sullivan, J K Collins, J Kelly, J Morgan, M Madden, F Shanahan*

516 Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer
S Singh, R Poulson, N A Wright, M C Sheppard, M J S Langman

521 APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis *F M Giardiello, G M Petersen, S Piantadosi, S B Gruber, E I Traboulsi, G J A Offerhaus, K Muro, A J Krush, S V Booker, M C Luce, S J Laken, K W Kinzler, B Vogelstein, S R Hamilton*

Pancreas

526 Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis *Th Foitzik, H G Hotz, M Kinzig, F Sörgel, H J Buhr*

531 Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis *H Yamaguchi, H Weidenbach, H Lührs, M M Lerch, G Dickneite, G Adler*

536 Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster *M Chu, E Kullman, J F Rehfeld, K Borch*

541 Topical glyceryl trinitrate relaxes the sphincter of Oddi *W Luman, A Pryde, R C Heading, K R Palmer*

Liver

544 Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality *C Homann, K Varming, K Høgåsen, T E Mollnes, N Graudal, A C Thomsen, P Garred*

Case report

550 Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies *B Temmesfeld-Wollbrueck, C Heinrichs, A Szalay, W Seeger*

Occasional viewpoint

554 Video education and evidence in endoscopy *Andrew Hart, Margaret Mayberry, John Mayberry*

Commentaries

555 Micrometastases: are they clinically significant disease? *H J N Andreyev, D Cunningham*

557 Antibody 'markers' in Crohn's disease: opportunity or overstatement? *Fergus Shanahan*

559 Oxpentifylline, tumour necrosis factor- α and Crohn's disease *Thomas T MacDonald*

560 **Letters to the editor Book reviews Notes**

No 5 MAY 1997

Editorial

563 Reporting of clinical trials in *Gut*: the CONSORT statement *M J G Farthing, R G Newcombe*

Leading articles

565 Laparoscopic surgery for gastro-oesophageal reflux disease *D Alderson, C R B Welbourn*

568 Hepatitis B Virus infection and liver transplantation *N A Terrault, T L Wright*

572 The genetics of inflammatory bowel disease *J Satsangi, D P Jewell, J I Bell*

Oesophagus

575 Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans
J Boulant, S Mathieu, M D'Amato, A Abergel, M Dapoigny, G Bommelaer

582 Reappraisal of bicarbonate secretion by the human oesophagus *A Mertz-Nielsen, J Hillingsø, K Bukhave, J Rask-Madsen*

587 Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the "sensitive oesophagus" *R G P Watson, T C K Tham, B T Johnston, N I McDougall*

Stomach

591 Treatment of *Helicobacter pylori* infection favourably affects gastric mucosal superoxide dismutases *J M Götz, J L Thio, H W Verspaget, G J A Offerhaus, I Biemond, C B H W Lamers, R A Veenendaal*

597 The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in humans depends on an intact vagal innervation *A Wettergren, M Wøjdemann, S Meisner, F Stadil, J J Holst*

Small bowel

602 L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions *R A Wapnir, M A Wingertzahn, S Teichberg*

608 Intestinal tolerability of nitroxybutyl-flurbiprofen in rats *S Somasundaram, S Rafi, M Jacob, G Sighthorsson, T Mahmud, R Sherwood, A B Price, A Macpherson, D Scott, J M Wrigglesworth, I Bjarnason*

614 Daytime and night time motor activity of the small bowel after solid meals of different caloric value in humans
J v Schönfeld, D F Evans, D L Wingate

Inflammatory bowel disease

619 Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease *J M M Evans, A D McMahon, F E Murray, D G McDevitt, T M MacDonald*

623 Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis
U T Hacker, M Gomolka, E Keller, A Eigler, C Folwaczny, H Fricke, E Albert, K Loeschke, S Endres

628 Treatment of ulcerative colitis in the cotton-top tamarin using antibody to tumour necrosis factor alpha
P E Watkins, B F Warren, S Stephens, P Ward, R Foulkes

634 Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells *C T Taylor, A Murphy, D Kelleher, A W Baird*

Motility

641 Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus *M Samsom, L M A Akkermans, R J A Jebbink, H van Isselt, G P vanBerge-Henegouwen, A J P M Smout*

Cancer

647 Clinical significance of serum p53 antigen in patients with pancreatic carcinomas *H Suwa, G Ohshio, N Okada, Z Wang, M Fukumoto, T Imamura, M Imamura*

654 Allele loss, replication errors and loss of expression of E-cadherin in colorectal cancers *M Ilyas, I P M Tomlinson, A Hanby, I C Talbot, W F Bodmer*

660 High frequency of K-ras mutations in human colorectal hyperplastic polyps *K Otori, Y Oda, K Sugiyama, T Hasebe, K Mukai, T Fujii, H Tajiri, S Yoshida, S Fukushima, H Esumi*

Liver and biliary tract

664 Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? *R Jalan, E H Forrest, D N Redhead, J F Dillon, P C Hayes*

671 A prospective evaluation of cytology from biliary strictures *J C Mansfield, S M Griffin, V Wadehra, K Matthewson*

- 678 Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study *R Jakobs, H E Adamek, M Maier, M Krömer, C Benz, W R Martin, J F Riemann*
- Case reports**
- 683 Molecular analysis of T cell receptor β variability in a patient with orofacial granulomatosis *S H Lim, P Stephens, Q-X Cao, S Coleman, D W Thomas*
- 687 "Golf ball liver": agent orange hepatitis *C Leonard, C M Burke, C O'Keane, J S Doyle*
- 689 Familial hyperamylasaemia *P M Cuckow, A Y Foo, A Jamal, M D Stringer*
- Commentaries**
- 691 Metaplastic (hyperplastic) polyps of the large bowel: benign neoplasms after all? *G T Williams*
- 693 Human oesophageal bicarbonate secretion: a phenomenon waiting for a role *C M Brown, W D W Rees*
- 695 **Letters to the editor** **Book reviews**
- Leading articles**
- 697 Endoscopic sphincterotomy in the young patient: is there cause for concern? *T C K Tham, C L Carr-Locke, J S A Collins*
- 701 The clinical relevance of strain types of *Helicobacter pylori* *J C Atherton*
- Review**
- 704 Trauma and the gut: interactions between stressful experience and intestinal function *R Stam, L M A Akkermans, V M Wiegant*
- Oesophagus**
- 710 Short segment Barrett's oesophagus: prevalence, diagnosis and associations *S Nandurkar, N J Talley, C J Martin, T H K Ng, S Adams*
- Stomach and duodenum**
- 716 Decision analysis in the management of duodenal adenomatosis in familial adenomatosis polyposis *H F A Vasen, S Bülow, T Myrholm, L Mathus-Vliegen, G Griffioen, E Buskens, B G Taal, F Nagengast, J F M Slors, P de Ruiter*
- 720 Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide *J M Scheiman, A Tiller, T Pohl, A Oldenburg, S Angermüller, E Görlach, G Engel, K H Usadel, K Kusterer*
- Helicobacter pylori**
- 726 Effects of *Helicobacter pylori* eradication therapy on hyperammonaemia in patients with liver cirrhosis *H Miyaji, S Ito, T Azuma, Y Ito, Y Yamazaki, Y Ohtaki, F Sato, M Hirai, M Kuriyama, Y Kohli*
- 731 In vitro evaluation of the role of antibodies against *Helicobacter pylori* in inhibiting adherence of the organism to gastric cells *M Clyne, J Thomas, L Weaver, B Drumm*
- Immunology**
- 739 Gastric mucosal secretion of interleukin-10: relations to histopathology, *Helicobacter pylori* status and tumour necrosis factor- α secretion *K Bodger, J I Wyatt, R V Heatley*
- 745 Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy *S C Bischoff, J Mayer, J Wedemeyer, P N Meier, G Zeck-Knapp, B Wedi, A Knapp, Y Cetin, M Gebel, M P Manns*
- Inflammatory bowel disease**
- 754 Pre-illness dietary factors in inflammatory bowel disease *S Reif, I Klein, F Lubin, M Farbstein, A Hallak, T Gilat*
- 761 Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicilate *S Schreiber, J Hämling, E Zehnter, S Howaldt, W Daerr, A Raedler, W Kruis*
- 767 Neurochemical coding in the small intestine of patients with Crohn's disease *A Belai, P B Boulos, T Robson, G Burnstock*
- 775 Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis *J K Marshall, E J Irvine*
- Colon**
- 782 Histochemistry of the surface mucous gel layer of the human colon *K Matsuo, H Ota, T Akamatsu, A Sugiyama, T Katsuyama*
- Motility**
- 790 Contribution of gastrointestinal transit and pouch characteristics in determining pouch function *P A Goldberg, M A Kamm, R J Nicholls, G Morris, K E Britton*
- Pancreas**
- 794 Activation of cellular immune response in acute pancreatitis *A Mora, M Pérez-Mateo, J A Viedma, F Carballo, J Sánchez-Payá, G Liras*
- 797 Erratum
- Liver**
- 798 Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis *A E A Mahmoud, E Elias, N Beauchamp, J T Wilde*
- Case report**
- 801 Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder *A N J Tutt, M Brada, S A Sampson*
- Commentaries**
- 804 Short answer in short segment Barrett's oesophagus *A Ireland, T R deMeester*
- 805 *Helicobacter pylori*, ammonia and the brain *S D Taylor-Robinson, N Jackson, C Buckley*
- 807 Colonic mucus and ulcerative colitis *J M Rhodes*
- 809 **Book reviews** **Notes**
- 811 **Volume 40: Author Index – Main Headings**
- 814 **Volume 40: Subject Index – Main Headings**
- 824 **Volume 40: Author Index – Supplement**
- 827 **Volume 40: Subject Index – Supplement**
- Volume 40: Contents**

Gut

Journal of the British Society of Gastroenterology
which is a registered charity

Gut publishes original papers, short rapid communications, leading articles, and reviews concerned with all aspects of the scientific basis of diseases of the alimentary tract, liver, and pancreas. Case reports will only be accepted if of exceptional merit. Letters related to articles published in *Gut* or with topics of general professional interest are welcomed. Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.

COMMUNICATIONS Three copies of the manuscript and figures should be addressed to the Editor, *Gut*, BMA House, Tavistock Square, London WC1H 9JR, UK (tel: 0171 383 6157; fax: 0171 383 6787 Email: 101317.465@compuserve.com). Manuscripts should follow the Vancouver conventions (see *BMJ* 1979; i: 532-5. *Gut* 1979; 20: 651-2). They should be in double spaced typewriting on one side of the paper only. The title page should include the name of the author with initials or distinguishing first name only, and the name and address of the hospital or laboratory where the work was performed. The paper must include a precise summary of the work of less than 200 words, which should be divided into six sections headed background, aims, patients (or subjects), methods, results, and conclusions. Keywords (maximum six) should be included. Use of abbreviation is discouraged. A separate covering letter signed by all authors must state that the data have not been published elsewhere in whole or in part and that all authors agree to publication in *Gut*. Previous publication in abstract form must be disclosed in footnote. Papers must not be published elsewhere without prior permission of the Editorial Committee. If requested, authors shall produce the data upon which the manuscript is based for examination by the editor.

ACKNOWLEDGEMENT OF MANUSCRIPTS Manuscripts will only be acknowledged if an addressed postcard is enclosed.

ILLUSTRATIONS *Photographs* Unmounted photographs on glossy paper should be provided. Illustrations should not be inserted in the text but marked on the back with the figure numbers, title of paper and name of author. All photographs, graphs, diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet.

ETHICS Ethical aspects will be considered in the assessment of papers (see the Medical Research Council's publications on the ethics of human experimentation, and the World Medical Association's code of ethics, known as the Declaration of Helsinki (see *BMJ* 1964; ii: 177)).

SI UNITS All measurements except blood pressure are expressed in SI units. In tables and illustrations values are given in SI units. For general guidance on the International System of Units and some useful conversion factors, see *The SI for Health Professions* (WHO,

1977). NB: Such conversion is the responsibility of the author.

REFERENCES These follow the Vancouver system - that is, references numbered consecutively in the text and listed numerically with journal titles abbreviated in the style of *Index Medicus*, *Standard journal article*. List up to six authors, then add *et al*.

CORRECTIONS other than printers' errors may be charged to the author.

REPRINTS Reprints will be available on payment of the necessary costs; the number of reprints required should be sent to the Publishing Manager on the form provided with the proof.

NOTICE TO ADVERTISERS All applications for advertisement space and rates should be addressed to the Advertisement Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR.

NOTICE TO SUBSCRIBERS *Gut* is published monthly. The annual subscription rates are £226 (USA \$339). Reduced subscriptions of £88 available to trainees for one year (direct only). Orders should be sent to the Subscription Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, can be sent to: BMJ Publishing Group, PO Box 590A, Kennebunkport, ME 04046, USA. All enquiries, however, must be addressed to the Publisher in London.) Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and the expiry date of the card. All overseas copies of the journal are sent by accelerated surface post. If required, full air mail rates and enquiries for single copies already published should be addressed to the Publisher in London.

COPYRIGHT © 1997 *Gut*. This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Apart from any relaxations permitted under national copyright laws, no part of the publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the copyright owners. Permission is not, however, required to copy abstracts of papers or articles on condition that a full reference to the source is shown. Multiple copying of the contents of the publication without permission is always illegal.

Periodicals postage paid, Rahway NJ. Postmaster: send address changes to: *Gut*, c/o Mercury Airfreight International Ltd Inc, 2323 Randolph Avenue, Avenel, NJ 07001, USA. ISSN 0017-5749.

Contents lists and Instructions to Authors are now available on the Internet:
<http://www.bmj.com/bmj/>

Published by British Medical Association, Tavistock Square, London WC1H 9JR. Typeset and printed on Acid-Free paper by Stott Brothers Ltd, Halifax